var title_f34_58_35744="Doppler derived AV gradient";
var content_f34_58_35744=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Continuous wave Doppler in aortic stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The peak velocity, recorded by continuous wave Doppler obtained from the right upper sternal border, is 4.3 m/sec. By the Bernoulli equation, this represents a peak pressure across the valve of 74 mmHg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_58_35744=[""].join("\n");
var outline_f34_58_35744=null;
var title_f34_58_35745="Calculator: Kt/V Dialysis Dose Daugirdas Formula";
var content_f34_58_35745=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"Kt_V_Daugirdas_form\" name=\"Kt_V_Daugirdas_form\" onkeydown=\"clrResults();\" onkeyup=\"Kt_V_Daugirdas_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Kt/V Dialysis Dose Daugirdas Formula",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         Kt/VDaugirdas = -ln((BUNPost / BUNPre) - (0.008 * Hours)) + ((4 - (3.5 * BUNPost / BUNPre)) * UFVol / WeightPost)",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"      <tr>",
"       <td align=\"right\" width=\"50%\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Input:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             BUN Pre",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"BUN_Pre_param\" onblur=\"Kt_V_Daugirdas_fx(); minMaxCheck();\" onchange=\"Kt_V_Daugirdas_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"BUN_Pre_unit\" onchange=\"Kt_V_Daugirdas_fx();\" style=\"width:105px;\">",
"             <option value=\"100|0|gm/L\">",
"              gm/L",
"             </option>",
"             <option value=\"1000|0|gm/dL\">",
"              gm/dL",
"             </option>",
"             <option value=\"1|0|mg%\">",
"              mg%",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|mg/dL\">",
"              mg/dL",
"             </option>",
"             <option value=\"100|0|mg/mL\">",
"              mg/mL",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             BUN Post",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"BUN_Post_param\" onblur=\"Kt_V_Daugirdas_fx(); minMaxCheck();\" onchange=\"Kt_V_Daugirdas_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"BUN_Post_unit\" onchange=\"Kt_V_Daugirdas_fx();\" style=\"width:105px;\">",
"             <option value=\"100|0|gm/L\">",
"              gm/L",
"             </option>",
"             <option value=\"1000|0|gm/dL\">",
"              gm/dL",
"             </option>",
"             <option value=\"1|0|mg%\">",
"              mg%",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|mg/dL\">",
"              mg/dL",
"             </option>",
"             <option value=\"100|0|mg/mL\">",
"              mg/mL",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Hours",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Hours_param\" onblur=\"Kt_V_Daugirdas_fx(); minMaxCheck();\" onchange=\"Kt_V_Daugirdas_fx();\" size=\"6\" type=\"text\" value=\"0\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Hours_unit\" onchange=\"Kt_V_Daugirdas_fx();\" style=\"width:105px;\">",
"             <option value=\"24|0|day\">",
"              day",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|hr\">",
"              hr",
"             </option>",
"             <option value=\"0.0166666666666667|0|min\">",
"              min",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             UF Vol",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"UF_Vol_param\" onblur=\"Kt_V_Daugirdas_fx(); minMaxCheck();\" onchange=\"Kt_V_Daugirdas_fx();\" size=\"6\" type=\"text\" value=\"0\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"UF_Vol_unit\" onchange=\"Kt_V_Daugirdas_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|L\">",
"              L",
"             </option>",
"             <option value=\"0.001|0|mL\">",
"              mL",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Weight Post",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Weight_Post_param\" onblur=\"Kt_V_Daugirdas_fx(); minMaxCheck();\" onchange=\"Kt_V_Daugirdas_fx();\" size=\"6\" type=\"text\" value=\"0\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Weight_Post_unit\" onchange=\"Kt_V_Daugirdas_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|kg\">",
"              kg",
"             </option>",
"             <option value=\"0.45359237|0|lb\">",
"              lb",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Result:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Kt/V Daugirdas",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"KtV_Daugirdas_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td align=\"left\">",
"            &nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            &nbsp;",
"            <br/>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"center\" colspan=\"3\">",
"            <span class=\"medCalcFontOneBold\">",
"             Decimal Precision:",
"            </span>",
"            <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"Kt_V_Daugirdas_fx();\">",
"             <option>",
"              0",
"             </option>",
"             <option>",
"              1",
"             </option>",
"             <option selected=\"selected\">",
"              2",
"             </option>",
"             <option>",
"              3",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontRef\">",
"     <b>",
"      References",
"     </b>",
"    </span>",
"    <ol>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       Kovacic V, Roguljic L, Jukic I, Kovacic V. Comparison of Methods for Hemodialysis Dose Calculation.",
"       <i>",
"        Dialysis &amp; Transplantation",
"       </i>",
"       . Vol 32:4 April 2003, p.170-175.",
"      </span>",
"     </li>",
"    </ol>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_58_35745=[" /* <![CDATA[ */",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function Kt_V_Daugirdas_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.Kt_V_Daugirdas_form){",
"",
"",
"doCalc = true;",
"if (BUN_Pre_param.value.indexOf(',') >= 0){ BUN_Pre_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(BUN_Pre_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = BUN_Pre_unit.options[BUN_Pre_unit.selectedIndex].value.split('|');",
"BUN_Pre = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (BUN_Post_param.value.indexOf(',') >= 0){ BUN_Post_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(BUN_Post_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = BUN_Post_unit.options[BUN_Post_unit.selectedIndex].value.split('|');",
"BUN_Post = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Hours_param.value.indexOf(',') >= 0){ Hours_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Hours_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Hours_unit.options[Hours_unit.selectedIndex].value.split('|');",
"Hours = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (UF_Vol_param.value.indexOf(',') >= 0){ UF_Vol_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(UF_Vol_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = UF_Vol_unit.options[UF_Vol_unit.selectedIndex].value.split('|');",
"UF_Vol = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Weight_Post_param.value.indexOf(',') >= 0){ Weight_Post_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Weight_Post_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Weight_Post_unit.options[Weight_Post_unit.selectedIndex].value.split('|');",
"Weight_Post = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"KtV_Daugirdas =  -ln((BUN_Post / BUN_Pre) - (0.008 * Hours)) + ((4 - (3.5 * BUN_Post / BUN_Pre)) * UF_Vol / Weight_Post);",
"",
"if (doCalc) KtV_Daugirdas_param.value = fixDP(KtV_Daugirdas, dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.Kt_V_Daugirdas_form){",
"",
"if (BUN_Pre_param.value && BUN_Pre < 0) {",
"BUN_Pre = 0;",
"BUN_Pre_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for BUN Pre is 0 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (BUN_Pre_param.value && BUN_Pre > 300) {",
"BUN_Pre_param.value = \"\";",
"clrResults();",
"BUN_Pre = 0;",
"doCalc = false;",
"alert(\"The maximum value for BUN Pre is 300 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (BUN_Post_param.value && BUN_Post < 0) {",
"BUN_Post = 0;",
"BUN_Post_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for BUN Post is 0 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (BUN_Post_param.value && BUN_Post > 300) {",
"BUN_Post_param.value = \"\";",
"clrResults();",
"BUN_Post = 0;",
"doCalc = false;",
"alert(\"The maximum value for BUN Post is 300 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.Kt_V_Daugirdas_form){",
"",
"KtV_Daugirdas_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"/* ]]> */"].join("\n");
var outline_f34_58_35745=null;
var title_f34_58_35746="Patient information: Osteoporosis (The Basics)";
var content_f34_58_35746=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15482\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/13/18647\">",
"         Foods and drinks with calcium and vitamin D",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/58/29611\">",
"          Foods and drinks with calcium",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/12/36034\">",
"         Patient information: Calcium and vitamin D for bone health (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/34/30243\">",
"         Patient information: Fractures (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?14/33/14867\">",
"         Patient information: Hip fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/41/6803\">",
"         Patient information: Medicines for osteoporosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?26/63/27635\">",
"         Patient information: Vertebral compression fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/29/1491\">",
"         Patient information: Bone density testing (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?22/60/23491\">",
"         Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/49/25366\">",
"         Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?28/52/29507\">",
"         Patient information: Primary hyperparathyroidism (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?14/62/15331\">",
"         Patient information: Vitamin D deficiency (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Osteoporosis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/osteoporosis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H483055778\">",
"      <span class=\"h1\">",
"       What is osteoporosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Osteoporosis is a disease that makes your bones weak. People with the disease can break their bones too easily. For instance, people with osteoporosis sometimes break a bone after falling down at home.",
"     </p>",
"     <p>",
"      Breaking a bone can be serious, especially if the bone is in the hip. People who break a hip sometimes lose the ability to walk on their own. Many of them end up in a nursing home. That&rsquo;s why it is so important to avoid breaking a bone in the first place.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H483055785\">",
"      <span class=\"h1\">",
"       How do I know if I have osteoporosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Osteoporosis does not cause symptoms until you break a bone. But your doctor or nurse can have you tested for it. The best test is a bone density test called the &ldquo;DXA test.&rdquo; It is a special kind of X-ray.",
"     </p>",
"     <p>",
"      Experts recommend bone density testing for women older than 65. That is because women in this age group have the highest risk of osteoporosis. Still, other people should sometimes be tested, too. Ask your doctor or nurse if you should be tested.",
"     </p>",
"     <p>",
"      Some people learn that they have osteoporosis because they break a bone during a fall or a mild impact. This is called a &ldquo;fragility fracture,&rdquo; because people with healthy bones should not break a bone that easily. People who have fragility fractures are at high risk of having other bones break.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H483055792\">",
"      <span class=\"h1\">",
"       What can I do to keep my bones as healthy as possible?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Eat foods with a lot of calcium, such as milk, yogurt, and green leafy vegetables (",
"        <a class=\"graphic graphic_table graphicRef67824 \" href=\"mobipreview.htm?28/58/29611\">",
"         table 1",
"        </a>",
"        and",
"        <a class=\"graphic graphic_figure graphicRef79375 \" href=\"mobipreview.htm?18/13/18647\">",
"         figure 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Eat foods with a lot of vitamin D, such as milk that has vitamin D added, and fish from the ocean",
"       </li>",
"       <li>",
"        Take calcium and vitamin D pills",
"       </li>",
"       <li>",
"        Be active for at least 30 minutes, most days of the week",
"       </li>",
"       <li>",
"        Avoid smoking",
"       </li>",
"       <li>",
"        Limit the amount of alcohol you drink to 1 to 2 drinks a day at most",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H483055799\">",
"      <span class=\"h1\">",
"       Do your best to keep from falling, too",
"      </span>",
"      &nbsp;&mdash;&nbsp;It sounds simple, but you can prevent a lot of fractures by reducing the chances of a fall. To do that:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Make sure all your rugs have a no-slip backing to keep them in place",
"       </li>",
"       <li>",
"        Tuck away any electrical cords, so they are not in your way",
"       </li>",
"       <li>",
"        Light all walkways well",
"       </li>",
"       <li>",
"        Watch out for slippery floors",
"       </li>",
"       <li>",
"        Wear sturdy, comfortable shoes with rubber soles",
"       </li>",
"       <li>",
"        Have your eyes checked",
"       </li>",
"       <li>",
"        Ask your doctor or nurse to check whether any of your medicines might make you dizzy or increase your risk of falling",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H483055806\">",
"      <span class=\"h1\">",
"       Can osteoporosis be treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, there are a few medicines to treat osteoporosis. These medicines can reduce the chances that you will break a bone.",
"     </p>",
"     <p>",
"      Doctors and nurses usually suggest trying medicines called bisphosphonates first. If those medicines do not do enough or if they cause side effects that you cannot stand, there are other medicines to try.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H483055813\">",
"      <span class=\"h1\">",
"       How will I know the treatment is working?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors and nurses often order bone density tests to check if osteoporosis medicines are working. These are the same tests they use to find osteoporosis in the first place. Sometimes a blood or urine test is also needed.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H483055820\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/12/36034?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/34/30243?source=see_link\">",
"       Patient information: Fractures (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/33/14867?source=see_link\">",
"       Patient information: Hip fracture (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/63/27635?source=see_link\">",
"       Patient information: Vertebral compression fracture (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/41/6803?source=see_link\">",
"       Patient information: Medicines for osteoporosis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=see_link\">",
"       Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/29/1491?source=see_link\">",
"       Patient information: Bone density testing (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/60/23491?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/52/29507?source=see_link\">",
"       Patient information: Primary hyperparathyroidism (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/62/15331?source=see_link\">",
"       Patient information: Vitamin D deficiency (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/58/35746?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15482 Version 5.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-FA3CAE7412-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_58_35746=[""].join("\n");
var outline_f34_58_35746=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H483055778\">",
"      What is osteoporosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H483055785\">",
"      How do I know if I have osteoporosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H483055792\">",
"      What can I do to keep my bones as healthy as possible?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H483055799\">",
"      Do your best to keep from falling, too",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H483055806\">",
"      Can osteoporosis be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H483055813\">",
"      How will I know the treatment is working?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H483055820\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15482\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/13/18647\">",
"      Foods and drinks with calcium and vitamin D",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/58/29611\">",
"       Foods and drinks with calcium",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/29/1491?source=related_link\">",
"      Patient information: Bone density testing (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/60/23491?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/12/36034?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/34/30243?source=related_link\">",
"      Patient information: Fractures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/33/14867?source=related_link\">",
"      Patient information: Hip fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/41/6803?source=related_link\">",
"      Patient information: Medicines for osteoporosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=related_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/52/29507?source=related_link\">",
"      Patient information: Primary hyperparathyroidism (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/63/27635?source=related_link\">",
"      Patient information: Vertebral compression fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/62/15331?source=related_link\">",
"      Patient information: Vitamin D deficiency (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_58_35747="Positive and negative remodel";
var content_f34_58_35747=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Positive and negative arterial remodeling extremes of the remodeling response",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Longitudinal sections through vessel segments show positively and negatively remodeled lesions. The lumen diameter is maintained with positive remodeling, while there is significant luminal narrowing with negative remodeling.",
"    <div class=\"footnotes\">",
"     EEM: external elastic membrane; RR: remodeling ratio (EEM area lesion/EEM area proximal reference).",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from Schoenhagen P, Ziada KM, Vince DC, et al. J Am Coll Cardiol 2001; 38:297. Copyright &copy; 2001 American College of Cardiology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_58_35747=[""].join("\n");
var outline_f34_58_35747=null;
var title_f34_58_35748="Repaglinide: Patient drug information";
var content_f34_58_35748=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Repaglinide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/25/4503?source=see_link\">",
"     see \"Repaglinide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F217610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Prandin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F217611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CO-Repaglinide;",
"     </li>",
"     <li>",
"      GlucoNorm&reg;;",
"     </li>",
"     <li>",
"      PMS-Repaglinide;",
"     </li>",
"     <li>",
"      Sandoz-Repaglinide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702861",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to repaglinide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Acidic blood problem or type 1 diabetes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697009",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are 80 or older, use this drug with care. You could be more sensitive to low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695823",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 15 to 30 minutes before meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695103",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If a meal is skipped, skip the dose. If a meal is added, add a dose for that meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it, with a meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11024 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-FE8AB3007C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_58_35748=[""].join("\n");
var outline_f34_58_35748=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217610\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217611\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018746\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018748\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018747\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018752\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018753\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018755\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018750\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018751\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018756\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018757\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/25/4503?source=related_link\">",
"      Repaglinide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_58_35749="Poliovirus vaccine (inactivated): Drug information";
var content_f34_58_35749=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Poliovirus vaccine (inactivated): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/17/11537?source=see_link\">",
"    see \"Poliovirus vaccine (inactivated): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/57/33684?source=see_link\">",
"    see \"Poliovirus vaccine (inactivated): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      IPOL&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F211025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Imovax&reg; Polio",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F211033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vaccine, Inactivated (Viral)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F211026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Immunization:",
"     </b>",
"     I.M., SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Previously unvaccinated: Two 0.5 mL doses administered at 1- to 2-month intervals, followed by a third dose 6-12 months later. If &lt;3 months, but at least 2 months are available before protection is needed, 3 doses may be administered at least 1 month apart. If administration must be completed within 1-2 months, give 2 doses at least 1 month apart. If &lt;1 month is available, give 1 dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Incompletely vaccinated: Adults with at least 1 previous dose of OPV, &lt;3 doses of IPV, or a combination of OPV and IPV equaling &lt;3 doses, administer at least one 0.5 mL dose of IPV. Additional doses to complete the series may be given if time permits.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Completely vaccinated and at increased risk of exposure: One 0.5 mL dose",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F211029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/57/33684?source=see_link\">",
"      see \"Poliovirus vaccine (inactivated): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Immunization:",
"     </b>",
"     I.M., SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Primary immunization:",
"     </i>",
"     Administer three 0.5 mL doses, at 2, 4, and 6-18 months of age; do not administer more frequently than 4 weeks apart (preferably given more than 8 weeks apart).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Booster dose:",
"     </i>",
"     0.5 mL at 4-6 years of age; Minimum interval between booster and previous dose is 6 months. The final (booster) dose should be given at &ge;4 years of age, regardless of the number of previous doses. If the final dose is not given at 4-6 years of age, it should be given as soon as feasible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Use of the minimum age and minimum intervals during the first 6 months of life should only be done when the vaccine recipient is at risk for imminent exposure to circulating poliovirus (shorter intervals and earlier start dates may lead to lower seroconversion).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F211027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F211013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     IPOL&reg;: Type 1 poliovirus 40 D-antigen units, type 2 poliovirus 8 D-antigen units, and type 3 poliovirus 32 D-antigen units per 0.5 mL (0.5 mL, 5 mL) [contains 2-phenoxyethanol, formaldehyde, calf serum protein, neomycin (may have trace amounts), streptomycin (may have trace amounts), and polymyxin B (may have trace amounts)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F211001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F211016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not administer I.V.; for I.M. or SubQ administration. Administer to midlateral aspect of the thigh in infants and small children. Administer in the deltoid area to adults or older children.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Simultaneous administration of vaccines helps ensure the patients will be fully vaccinated by the appropriate age. Simultaneous administration of vaccines is defined as administering &gt;1 vaccine on the same day at different anatomic sites. The use of licensed combination vaccines is generally preferred over separate injections of the equivalent components. Separate vaccines should not be combined in the same syringe unless indicated by product specific labeling. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible. Adolescents and adults should be vaccinated while seated or lying down. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F211014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Active immunization against poliomyelitis caused by poliovirus types 1, 2 and 3.",
"     <b>",
"      Note:",
"     </b>",
"     Combination products containing polio vaccine are also available and may be preferred in certain age groups if recipients are likely to be susceptible to the agents contained within each vaccine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     &bull; All children (first dose given at 2 months of age)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Routine immunization of adults in the United States is generally not recommended. Adults with previous wild poliovirus disease, who have never been immunized, or those who are incompletely immunized may receive inactivated poliovirus vaccine if they fall into one of the following categories:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Travelers to regions or countries where poliomyelitis is endemic or epidemic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Healthcare workers in close contact with patients who may be excreting poliovirus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory workers handling specimens that may contain poliovirus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Members of communities or specific population groups with diseases caused by wild poliovirus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Incompletely vaccinated or unvaccinated adults in a household or with other close contact with children receiving oral poliovirus (may be at increased risk of vaccine associated paralytic poliomyelitis)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F12705163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Poliovirus vaccine (inactivated) may be confused with tuberculin products. Medication errors have occurred when poliovirus vaccine (IPV) has been inadvertently administered instead of tuberculin skin tests (PPD). These products are refrigerated and often stored in close proximity to each other.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F211031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Percentages noted with concomitant administration of DTP or DTaP vaccine and observed within 48 hours of injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Irritability (7% to 65%; most common in infants 2 months of age), tiredness (4% to 61%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia (1% to 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection Site: Tenderness (&le;29%), swelling (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever &gt;39&deg;C (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site: Erythema (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Persistent crying (&le;1% reported within 72 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports (Limited to important or life-threatening): Allergic reaction, anaphylactic shock, anaphylaxis, febrile seizures, hypersensitivity reactions, lymphadenopathy, seizures; Guillain-Barr&eacute; syndrome has been temporally related to another inactivated poliovirus vaccine",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F211018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the vaccine",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F211004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syncope: Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute illness: May consider deferring administration in patients with moderate or severe acute illness (with or without fever); may administer to patients with mild acute illness (with or without fever).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polio infection: Patients with prior clinical poliomyelitis or incomplete immunization with oral poliovirus vaccine (OPV) may receive inactivated poliovirus vaccine (IPV).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune globulin: Immune response may be decreased in patients receiving immune globulin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and adverse events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered immunocompetence: Use with caution in severely immunocompromised patients; patients with HIV infection, severe combined immunodeficiency, hypogammaglobulinemia,  agammaglobulinemia, or altered immunity (due to corticosteroids, alkylating agents, antimetabolites or radiation) may receive inactivated poliovirus vaccine (IPV). In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use of the minimum age and minimum intervals during the first 6 months of life should only be done when the vaccine recipient is at risk for imminent exposure to circulating poliovirus (shorter intervals and earlier start dates may lead to lower seroconversion).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; 2-phenoxyethanol: Products may contain 2-phenoxyethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calf serum protein: Products may contain calf serum protein.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Formaldehyde: Products may contain formaldehyde.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neomycin: Products may contain neomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polymyxin B: Products may contain polymyxin B.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Streptomycin: Products may contain streptomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F211008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F211010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2983218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Animal reproduction studies have not been conducted. Although adverse effects of IPV have not been documented in pregnant women or their fetuses, vaccination of pregnant women should be avoided on theoretical grounds. Pregnant women at increased risk for infection and requiring immediate protection against polio may be administered the vaccine.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2984174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excretion into breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12674687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inactivated virus vaccines do not affect the safety of breast-feeding for the mother or the infant. Breast-feeding infants should be vaccinated according to the recommended schedules (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7676664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Imovax Polio (AR, BE, BG, CZ, EE, FI, HK, HN, IL, IT, KP, NO, PE, PK, PY, TW, UY);",
"     </li>",
"     <li>",
"      Ipol (NZ);",
"     </li>",
"     <li>",
"      Opvero (TH);",
"     </li>",
"     <li>",
"      Polio Salk \"Sero\" (AT)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control  and Prevention (CDC), &ldquo;Imported Vaccine-Associated Paralytic Poliomyelitis -- United States,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2005, 55(4):97-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/58/35749/abstract-text/16456525/pubmed\" id=\"16456525\" target=\"_blank\">",
"        16456525",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Poliomyelitis Prevention in the United States: Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2000, 49(RR-5):14.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/58/35749/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC),&ldquo;Syncope After Vaccination -- United States, January 2005-July 2007,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/58/35749/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP) Regarding Routine Poliovirus Vaccination,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2009, 58(30):829-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/58/35749/abstract-text/19661857/pubmed\" id=\"19661857\" target=\"_blank\">",
"        19661857",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gardner P and Schaffner W, &ldquo;Immunization of Adults,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 328(17):1252-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/58/35749/abstract-text/8464436/pubmed\" id=\"8464436\" target=\"_blank\">",
"        8464436",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/58/35749/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, &ldquo;Febrile seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008,  121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/58/35749/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9787 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-4E1BBEB838-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_58_35749=[""].join("\n");
var outline_f34_58_35749=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211024\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211025\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211033\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211026\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211029\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211027\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211013\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211001\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211016\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211014\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12705163\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211031\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211018\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211004\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299896\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211008\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211010\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983218\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984174\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12674687\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7676664\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038772\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9787\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9787|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/17/11537?source=related_link\">",
"      Poliovirus vaccine (inactivated): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/57/33684?source=related_link\">",
"      Poliovirus vaccine (inactivated): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_58_35750="Pathophysiology of the sideroblastic anemias";
var content_f34_58_35750=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology of the sideroblastic anemias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/58/35750/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/58/35750/contributors\">",
"     Sylvia S Bottomley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/58/35750/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/58/35750/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/58/35750/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/58/35750/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/58/35750/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sideroblastic anemias feature congenital or acquired defects affecting the biosynthesis of heme, iron-sulfur (Fe-S) cluster generation, or mitochondrial protein synthesis within red cell precursors. The diverse circumstances under which these disorders are encountered, and the continuing discovery of molecular defects associated with the phenotype, underscore a broad spectrum of causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Yet, in a large proportion of patients the underlying mechanism remains undefined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/1,4-6\">",
"     1,4-6",
"    </a>",
"    ]. A conventional classification of the sideroblastic anemias provides an inclusive reference for their discussion and diagnosis (",
"    <a class=\"graphic graphic_table graphicRef79712 \" href=\"mobipreview.htm?9/3/9276\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In order to maintain a continual replacement of senescent red cells, approximately 85 percent of body heme is generated within the erythron. Heme synthesis is directly impaired in the two common forms of congenital sideroblastic anemia: the X-linked form because of deficient erythroid 5-aminolevulinate synthase (ALAS2), and the autosomal recessive disorder because of defects in the erythroid mitochondrial transporter SLC25A38. In the other congenital and most acquired forms, the production of heme is impaired secondarily (eg, when defects disrupt Fe-S cluster biogenesis), or the pathogenesis of the ring sideroblast abnormality is not defined. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/37/36441?source=see_link\">",
"     \"Causes of congenital and acquired sideroblastic anemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Deranged heme synthesis in the developing red cell leads to decreased hemoglobin production with the formation of hypochromic and microcytic red cells and other misshaped erythrocytes (",
"    <a class=\"graphic graphic_picture graphicRef66705 \" href=\"mobipreview.htm?28/4/28742\">",
"     picture 1",
"    </a>",
"    ). These red cells are the progeny of the ring sideroblasts that constitute the diagnostic hallmark of any sideroblastic anemia and are detected in the Prussian blue stained smear of the marrow aspirate, as shown in the upper panel (",
"    <a class=\"graphic graphic_picture graphicRef62536 \" href=\"mobipreview.htm?37/56/38788\">",
"     picture 2",
"    </a>",
"    ). The ultrastructure of the iron-positive cytoplasmic granules of ring sideroblasts is indicated by electron dense deposits within mitochondria, as shown in the lower panel (",
"    <a class=\"graphic graphic_picture graphicRef62536 \" href=\"mobipreview.htm?37/56/38788\">",
"     picture 2",
"    </a>",
"    ), reflecting accumulated iron, in a unique mitochondrial ferritin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], that has been delivered to the developing erythroblast normally, but cannot be utilized. In those sideroblastic anemias in which cellular hemoglobin production does not appear to be affected, the red cell morphology is normocytic or macrocytic.",
"   </p>",
"   <p>",
"    This topic review will address the physiologic consequences of defective heme production, namely the ineffective erythropoiesis and the associated iron overload. The molecular pathology of recognized genetic defects leading to impaired heme synthesis and other abnormalities in the sideroblastic anemias are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/37/36441?source=see_link\">",
"     \"Causes of congenital and acquired sideroblastic anemias\"",
"    </a>",
"    .) The clinical manifestations, diagnosis, and treatment of these disorders are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6138?source=see_link\">",
"     \"Clinical aspects, diagnosis, and treatment of the sideroblastic anemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INEFFECTIVE ERYTHROPOIESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of ineffective erythropoiesis is suspected on morphologic grounds when anemia is associated with erythroid hyperplasia in the bone marrow in the absence of a reticulocyte response in the peripheral blood. In this situation, erythroid progenitor cells are intact, and erythropoietin production in response to anemic hypoxia is appropriately increased. However, cellular maturation involving either nuclear (DNA synthesis) or cytoplasmic (hemoglobin production) processes is disrupted, giving rise to faulty erythroblasts, many of which are destroyed within the bone marrow (ie, intramedullary hemolysis) via mechanisms that include apoptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In clonal sideroblastic anemia (the refractory anemia with ring sideroblasts [RARS] category of myelodysplastic syndromes), it was observed that erythroid apoptosis is initiated at the stem cell level with mitochondrial release of cytochrome c and activation of caspases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/10\">",
"     10",
"    </a>",
"    ], as is accumulation of the aberrant mitochondrial ferritin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/11\">",
"     11",
"    </a>",
"    ]. These events appear to be inhibited by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], which often potentiates a beneficial effect of administered erythropoietin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=see_link&amp;anchor=H7196544#H7196544\">",
"     \"Management of the complications of the myelodysplastic syndromes\", section on 'Combination therapy (EPO + G-CSF)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ineffective erythropoiesis is demonstrated kinetically through the presence of an increased plasma iron turnover rate in association with a reduced incorporation of iron into circulating red cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/14\">",
"     14",
"    </a>",
"    ]. The presence of mild degrees of hyperbilirubinemia and increased urobilinogen excretion reflect an increased component of the \"early label\" bilirubin peak that arises from destruction of nonviable erythroid precursors within the marrow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Heme synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In sideroblastic anemias, as in iron deficiency, diminished heme synthesis leads to reduced hemoglobin production and delayed cytoplasmic maturation within the developing erythroblast. Generally, the magnitude of the ineffective erythropoiesis correlates with severity of the anemia. The molecular pathology of the abnormalities leading to altered heme synthesis in the sideroblastic anemias is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/37/36441?source=see_link\">",
"     \"Causes of congenital and acquired sideroblastic anemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1850935\">",
"    <span class=\"h3\">",
"     Role of pyridoxine in heme synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the biosynthesis of heme is the enzymatic condensation of glycine and succinyl-coenzyme A to form 5-aminolevulinic acid. In the erythroid cell, this reaction is catalyzed by the mitochondrial enzyme ALAS2, and requires pyridoxal 5'-phosphate as a co-factor. Normally, in coordination with the availability of iron, this step is rate limiting for the production of heme. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28984?source=see_link&amp;anchor=H4#H4\">",
"     \"Porphyrias: An overview\", section on 'Regulation of heme synthesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Deficiency of pyridoxine (vitamin B6) because of diet is not seen in humans, but ingestion of agents that reduce its biologic availability can impair the activity of ALAS2 and lead to sideroblastic changes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/37/36441?source=see_link&amp;anchor=H17#H17\">",
"     \"Causes of congenital and acquired sideroblastic anemias\", section on 'Acquired metabolic sideroblastic anemias'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pyridoxal 5'-phosphate, the active cofactor form of vitamin B6, facilitates the function of only some mutant forms of ALAS2 when given in pharmacologic doses. Hence, the salutary effect of pyridoxine supplementation is often partial and is rarely complete [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/1,16\">",
"     1,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/37/36441?source=see_link&amp;anchor=H6#H6\">",
"     \"Causes of congenital and acquired sideroblastic anemias\", section on 'Molecular basis for pyridoxine responsiveness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Globin synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced globin chain production, that underlies the reduced hemoglobin production in the thalassemias, has been demonstrated in vitro in selected cases of sideroblastic anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/17\">",
"     17",
"    </a>",
"    ]. This finding is considered to be a secondary defect, as it is corrected by the addition of heme. In vivo, the role of the heme regulated kinase (HRI) likely comes into play, as excess globin chains usually do not accumulate in erythroblasts in the sideroblastic disorders, unlike the situation in the thalassemias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Iron metabolism in erythroblasts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of iron delivery to the erythroid cell does not appear to be altered in the face of impaired heme synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Iron also continues to be transported normally to mitochondria, where it accumulates in the matrix compartment in mitochondrial ferritin (seen in the lower panel of the picture) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_picture graphicRef62536 \" href=\"mobipreview.htm?37/56/38788\">",
"     picture 2",
"    </a>",
"    ), resulting in the production of ring sideroblasts (seen in the upper panel of the picture) (",
"    <a class=\"graphic graphic_picture graphicRef62536 \" href=\"mobipreview.htm?37/56/38788\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1732725\">",
"    <span class=\"h3\">",
"     Biogenesis of Fe-S clusters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited defects causing impaired production of Fe-S clusters disrupt mitochondrial and cytosolic iron homeostasis and secondarily lead to reduced heme synthesis and mitochondrial iron overload [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. When Fe-S clusters are lacking, the IRP1-IRE regulatory system becomes activated, inhibiting ALAS2 translation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, integrity of ferrochelatase, the terminal enzyme in the heme synthesis pathway, is diminished as it requires an Fe-S cluster [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/22\">",
"     22",
"    </a>",
"    ]. Data implicate a role of cytosolic Fe-S cluster generation also in the pathogenesis of the common clonal disorder refractory anemia with ring sideroblasts (RARS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     IRON OVERLOAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic iron overload is a nearly constant feature of sideroblastic anemias resulting from impaired heme synthesis, and it is referred to as erythropoietic hemochromatosis; it is not found in erythropoietic protoporphyria, the syndromic congenital and the transient, metabolic or reversible forms (",
"    <a class=\"graphic graphic_table graphicRef79712 \" href=\"mobipreview.htm?9/3/9276\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/24\">",
"     24",
"    </a>",
"    ]. Its magnitude is not always related to the severity of anemia, and cirrhosis secondary to increased deposition of iron within the liver may be encountered in asymptomatic patients who have milder anemia or have responded well to pyridoxine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. However, it is more closely related to the degree of marrow erythroid hyperplasia, the patient's age, and the duration of the abnormality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/25,29\">",
"     25,29",
"    </a>",
"    ]. Thus, the iron overload is usually more severe in congenital sideroblastic anemia than in the acquired forms. Inappropriate therapy with iron",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    multiple red cell transfusions predictably add to the iron overload.",
"   </p>",
"   <p>",
"    Occasional co-inheritance of a C282Y hemochromatosis allele(s) in the HFE gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/24,30-32\">",
"     24,30-32",
"    </a>",
"    ], or perhaps of mutant allele(s) in other genes causing hemochromatosis may contribute to this process. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38856?source=see_link&amp;anchor=H2#H2\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Anemia due to ineffective erythropoiesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Increased intestinal absorption of iron",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ineffective erythropoiesis in the sideroblastic anemias mediates increased intestinal absorption of iron [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/33\">",
"     33",
"    </a>",
"    ]. As in the thalassemias and congenital dyserythropoietic anemias, the markedly expanded but ineffective erythropoiesis suppresses production of hepcidin, the key regulator of iron absorption and homeostasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. Two signal molecules released from erythroblasts that inhibit generation of hepcidin are growth differentiation factor 15 (GDF15) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/38,39\">",
"     38,39",
"    </a>",
"    ] and twisted gastrulation homolog 1 (TWSG1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/40\">",
"     40",
"    </a>",
"    ]; both are highly expressed in ineffective erythropoiesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/36\">",
"     36",
"    </a>",
"    ]. A primary role of the HFE gene mutations of genetic hemochromatosis per se has been excluded in the pathogenesis of the iron overload [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/24,41,42\">",
"     24,41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pattern of iron overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to genetic hemochromatosis, progressive iron deposition occurs in bone marrow macrophages secondary to the ineffective erythropoiesis. However, there is also prominent deposition of iron in parenchymal tissues, presumably due to redistribution of iron in concert with the increased rate of plasma iron turnover [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/1\">",
"     1",
"    </a>",
"    ], as well as an increased influx of iron into plasma due to hepcidin deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/37\">",
"     37",
"    </a>",
"    ], saturating transferrin with iron and generating non-transferrin-bound iron (NTBI). NTBI is rapidly taken up by hepatocytes, cardiac myocytes and endocrine cells, causing tissue damage and organ failure. The clinical and pathologic features and course are indistinguishable from those of genetic hemochromatosis. Morbidity from the iron overload increases with time, and is high once symptoms have occurred, often reflecting irreversible organ damage (eg, cirrhosis (",
"    <a class=\"graphic graphic_picture graphicRef62989 \" href=\"mobipreview.htm?14/58/15274\">",
"     picture 3",
"    </a>",
"    ), cardiomyopathy (",
"    <a class=\"graphic graphic_picture graphicRef81850 \" href=\"mobipreview.htm?24/37/25177\">",
"     picture 4",
"    </a>",
"    ), and endocrine deficits).",
"   </p>",
"   <p>",
"    To what extent the iron overload accentuates the anemia is difficult to assess. Observations in instances where iron depletion reduced the severity of anemia in patients with erythropoietic hemochromatosis (eg, sideroblastic anemia, congenital dyserythropoietic anemia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/43-45\">",
"     43-45",
"    </a>",
"    ], suggest that erythroblast mitochondrial function is improved, ineffective erythropoiesis is diminished, and a component of hypersplenism may be relieved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/1\">",
"     1",
"    </a>",
"    ]. Pyridoxine responsiveness may also be enhanced upon iron depletion in some cases of X-linked sideroblastic anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35750/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3446841\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sideroblastic anemias are due to congenital or acquired defects diminishing the biosynthesis of heme directly or through disrupted production of Fe-S clusters within red cell precursors, and uncommonly due to genetic defects involving mitochondrial proteins (",
"    <a class=\"graphic graphic_table graphicRef79712 \" href=\"mobipreview.htm?9/3/9276\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/37/36441?source=see_link\">",
"     \"Causes of congenital and acquired sideroblastic anemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Ring sideroblasts",
"      </strong>",
"      &mdash; Iron delivery to the developing erythroid cell is not down-regulated in the face of impaired heme synthesis or other mitochondrial defects, leading to accumulation of mitochondrial iron and formation of ring sideroblasts (",
"      <a class=\"graphic graphic_picture graphicRef62536 \" href=\"mobipreview.htm?37/56/38788\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Iron metabolism in erythroblasts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Ineffective erythropoiesis",
"      </strong>",
"      &mdash; Maturation of affected erythroid cells is disrupted, giving rise to faulty erythroblasts, many of which are destroyed within the bone marrow (ie, intramedullary hemolysis) via mechanisms that include apoptosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Ineffective erythropoiesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Abnormal circulating red cells",
"      </strong>",
"      &mdash; Deranged heme synthesis in marrow erythroblasts leads to impaired hemoglobin production with the formation of hypochromic and microcytic red cells and other misshaped erythrocytes (",
"      <a class=\"graphic graphic_picture graphicRef66705 \" href=\"mobipreview.htm?28/4/28742\">",
"       picture 1",
"      </a>",
"      ). However, when mitochondrial protein synthesis is faulty, erythrocytes are normocytic or macrocytic, and the pathogenesis of the anemia is not understood.",
"     </li>",
"     <li>",
"      <strong>",
"       Iron overload",
"      </strong>",
"      &mdash; Iron overload, a common feature of many sideroblastic anemias, is due to suppressed production of hepcidin by the ineffective erythropoiesis and is related to the degree of marrow erythroid hyperplasia, the patient's age, and the duration of the abnormality. The clinical and pathologic features are indistinguishable from those of genetic hemochromatosis and may include irreversible organ damage (eg, cirrhosis (",
"      <a class=\"graphic graphic_picture graphicRef62989 \" href=\"mobipreview.htm?14/58/15274\">",
"       picture 3",
"      </a>",
"      ), cardiomyopathy (",
"      <a class=\"graphic graphic_picture graphicRef81850 \" href=\"mobipreview.htm?24/37/25177\">",
"       picture 4",
"      </a>",
"      ), and endocrine deficits). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Iron overload'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Bottomley SS. Sideroblastic anemias. In: Wintrobe's Clinical Hematology, 12th ed, Greer JP, Foerster J, Rodgers GM, et al. (Eds), Lippincott, Williams and Wilkins, Philadelphia 2008. p.835.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/2\">",
"      Fleming MD. Congenital sideroblastic anemias: iron and heme lost in mitochondrial translation. Hematology Am Soc Hematol Educ Program 2011; 2011:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/3\">",
"      Camaschella C. Recent advances in the understanding of inherited sideroblastic anaemia. Br J Haematol 2008; 143:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/4\">",
"      Cazzola M, Invernizzi R. Ring sideroblasts and sideroblastic anemias. Haematologica 2011; 96:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/5\">",
"      Bergmann AK, Campagna DR, McLoughlin EM, et al. Systematic molecular genetic analysis of congenital sideroblastic anemia: evidence for genetic heterogeneity and identification of novel mutations. Pediatr Blood Cancer 2010; 54:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/6\">",
"      Ducamp S, Kannengiesser C, Touati M, et al. Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations. Hum Mutat 2011; 32:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/7\">",
"      Levi S, Corsi B, Bosisio M, et al. A human mitochondrial ferritin encoded by an intronless gene. J Biol Chem 2001; 276:24437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/8\">",
"      Cazzola M, Invernizzi R, Bergamaschi G, et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood 2003; 101:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/9\">",
"      Matthes TW, Meyer G, Samii K, Beris P. Increased apoptosis in acquired sideroblastic anaemia. Br J Haematol 2000; 111:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/10\">",
"      Hellstr&ouml;m-Lindberg E, Schmidt-Mende J, Forsblom AM, et al. Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. Br J Haematol 2001; 112:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/11\">",
"      Tehranchi R, Invernizzi R, Grandien A, et al. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood 2005; 106:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/12\">",
"      Schmidt-Mende J, Tehranchi R, Forsblom AM, et al. Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed sideroblasts. Leukemia 2001; 15:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/13\">",
"      Tehranchi R, Fadeel B, Forsblom AM, et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 2003; 101:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/14\">",
"      Finch CA, Deubelbeiss K, Cook JD, et al. Ferrokinetics in man. Medicine (Baltimore) 1970; 49:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/15\">",
"      Barrett PV, Cline MJ, Berlin NI. The association of the urobilin \"early peak\" and erythropoiesis in man. J Clin Invest 1966; 45:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/16\">",
"      Cotter PD, May A, Fitzsimons EJ, et al. Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts. J Clin Invest 1995; 96:2090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/17\">",
"      White JM, Ali MA. Globin synthesis in sideroblastic anaemia. II. The effect of pyridoxine, -aminolaevulinic acid and haem, in vitro. Br J Haematol 1973; 24:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/18\">",
"      Chen JJ. Regulation of protein synthesis by the heme-regulated eIF2alpha kinase: relevance to anemias. Blood 2007; 109:2693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/19\">",
"      Bottomley SS. The spectrum and role of iron overload in sideroblastic anemia. Ann N Y Acad Sci 1988; 526:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/20\">",
"      May A, de Souza P, Barnes K, et al. Erythroblast iron metabolism in sideroblastic marrows. Br J Haematol 1982; 52:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/21\">",
"      Ye H, Rouault TA. Erythropoiesis and iron sulfur cluster biogenesis. Adv Hematol 2010; 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/22\">",
"      Ye H, Jeong SY, Ghosh MC, et al. Glutaredoxin 5 deficiency causes sideroblastic anemia by specifically impairing heme biosynthesis and depleting cytosolic iron in human erythroblasts. J Clin Invest 2010; 120:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/23\">",
"      Nikpour M, Scharenberg C, Liu A, et al. The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts. Leukemia 2012.",
"     </a>",
"    </li>",
"    <li>",
"     Bottomley SS. Iron overload in sideroblastic and other non-thalassemic anemias. In: Hemochromatosis. Genetics, Pathophysiology, Diagnosis and Treatment, Barton JC, Edwards CQ (Eds), Cambridge University Press, Cambridge 2000. p.442.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/25\">",
"      Peto TE, Pippard MJ, Weatherall DJ. Iron overload in mild sideroblastic anaemias. Lancet 1983; 1:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/26\">",
"      Marcus RE. Iron overload in mild sideroblastic anaemia. Lancet 1983; 1:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/27\">",
"      Bottomley SS. Sideroblastic anemia: Death from iron overload. Hosp Pract 1991; 26(suppl 3):55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/28\">",
"      Heller T, H&ouml;chstetter V, Basler M, Borck V. [Vitamin B6-sensitive hereditary sideroblastic anemia]. Dtsch Med Wochenschr 2004; 129:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/29\">",
"      Cazzola M, Barosi G, Bergamaschi G, et al. Iron loading in congenital dyserythropoietic anaemias and congenital sideroblastic anaemias. Br J Haematol 1983; 54:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/30\">",
"      Yaouanq J, Grosbois B, Jouanolle AM, et al. Haemochromatosis Cys282Tyr mutation in pyridoxine-responsive sideroblastic anaemia. Lancet 1997; 349:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/31\">",
"      Cotter PD, May A, Li L, et al. Four new mutations in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causing X-linked sideroblastic anemia: increased pyridoxine responsiveness after removal of iron overload by phlebotomy and coinheritance of hereditary hemochromatosis. Blood 1999; 93:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/32\">",
"      Nearman ZP, Szpurka H, Serio B, et al. Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts. Am J Hematol 2007; 82:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/33\">",
"      Pootrakul P, Kitcharoen K, Yansukon P, et al. The effect of erythroid hyperplasia on iron balance. Blood 1988; 71:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/34\">",
"      Papanikolaou G, Tzilianos M, Christakis JI, et al. Hepcidin in iron overload disorders. Blood 2005; 105:4103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/35\">",
"      Nemeth E. Iron regulation and erythropoiesis. Curr Opin Hematol 2008; 15:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/36\">",
"      Tanno T, Miller JL. Iron Loading and Overloading due to Ineffective Erythropoiesis. Adv Hematol 2010; 2010:358283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/37\">",
"      Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med 2011; 62:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/38\">",
"      Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nature Med 2007; 13:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/39\">",
"      Tanno T, Noel P, Miller JL. Growth differentiation factor 15 in erythroid health and disease. Curr Opin Hematol 2010; 17:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/40\">",
"      Tanno T, Porayette P, Sripichai O, et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 2009; 114:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/41\">",
"      Bottomley SS, Wasson EG, Wise PD. Role of the hemochromatosis HFE gene mutation(s) in the iron overload of hereditary sideroblastic anemia (abstract). Blood 1997; 90:11b.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/42\">",
"      Beris P, Samii K, Darbellay R, et al. Iron overload in patients with sideroblastic anaemia is not related to the presence of the haemochromatosis Cys282Tyr and His63Asp mutations. Br J Haematol 1999; 104:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/43\">",
"      French TJ, Jacobs P. Sideroblastic anaemia associated with iron overload treated by repeated phlebotomy. S Afr Med J 1976; 50:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/44\">",
"      Jensen PD, Heickendorff L, Pedersen B, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996; 94:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35750/abstract/45\">",
"      Hofmann WK, Kaltwasser JP, Hoelzer D, et al. Successful treatment of iron overload by phlebotomies in a patient with severe congenital dyserythropoietic anemia type II. Blood 1997; 89:3068.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7122 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-6BDFF69EB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_58_35750=[""].join("\n");
var outline_f34_58_35750=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3446841\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INEFFECTIVE ERYTHROPOIESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Heme synthesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1850935\">",
"      - Role of pyridoxine in heme synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Globin synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Iron metabolism in erythroblasts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1732725\">",
"      - Biogenesis of Fe-S clusters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      IRON OVERLOAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Increased intestinal absorption of iron",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pattern of iron overload",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3446841\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7122\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7122|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/4/28742\" title=\"picture 1\">",
"      RBC in sideroblastic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/56/38788\" title=\"picture 2\">",
"      Bone marrow sideroblasts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/58/15274\" title=\"picture 3\">",
"      Severe cirrhosis iron overload",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/37/25177\" title=\"picture 4\">",
"      Myocardial siderosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7122|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/3/9276\" title=\"table 1\">",
"      Causes of sideroblastic anemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/37/36441?source=related_link\">",
"      Causes of congenital and acquired sideroblastic anemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6138?source=related_link\">",
"      Clinical aspects, diagnosis, and treatment of the sideroblastic anemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38856?source=related_link\">",
"      Iron overload syndromes other than hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=related_link\">",
"      Management of the complications of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28984?source=related_link\">",
"      Porphyrias: An overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_58_35751="Calcitriol: Pediatric drug information";
var content_f34_58_35751=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Calcitriol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?39/13/40152?source=see_link\">",
"    see \"Calcitriol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/11/10421?source=see_link\">",
"    see \"Calcitriol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Calcijex&reg; [DSC];",
"     </li>",
"     <li>",
"      Rocaltrol&reg;;",
"     </li>",
"     <li>",
"      Vectical&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F144220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Calcijex&reg;;",
"     </li>",
"     <li>",
"      Rocaltrol&reg;;",
"     </li>",
"     <li>",
"      Silkis&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Rickets, Treatment Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vitamin D Analog",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vitamin, Fat Soluble",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hypocalcemia secondary to hypoparathyroidism: Oral: 1 mcg once daily for the first 5 days of life",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alternate regimen: Oral: 0.02-0.06 mcg/kg/day; similar dosage has also been described in neonates with DiGeorge syndrome (Miller, 1983)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hypocalcemic tetany:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 0.05 mcg/kg once daily for 5-12 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Initial: 0.25 mcg/dose once daily, followed by 0.01-0.10 mcg/kg/day divided in 2 doses (maximum daily dose: 2 mcg)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/13/40152?source=see_link\">",
"      see \"Calcitriol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Management of hypocalcemia in patients with chronic kidney disease (CKD):",
"     </b>",
"     Indicated for therapy when serum levels of 25(OH)D are &gt;30 ng/mL (75 nmol/L) and serum levels of intact parathyroid hormone (iPTH) are above the target range for the stage of CKD; serum levels of corrected total calcium are &lt;9.5-10 mg/dL (2.37 mmol/L) and serum levels of phosphorus in children are less than age-appropriate upper limits of normal or in adults &lt;4.6 mg/dL (1.49 mmol/L) (K/DOQI Guidelines, 2005):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adolescents: CKD Stages 2-4: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;10 kg: 0.05 mcg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     10-20 kg: 0.1-0.15 mcg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;20 kg: 0.25 mcg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dosage adjustment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     If  iPTH decrease is &lt;30% after 3 months of therapy and serum levels of calcium and phosphorus are within the target ranges based upon the CKD Stage, increase dosage by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     If iPTH decrease &lt; target range for CKD stage hold calcitriol therapy until iPTH increases to above target range; resume therapy at half the previous dosage (if dosage &lt;0.25 mcg capsule or 0.05 mcg liquid, use every other day therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     If serum levels of total corrected calcium exceed 10.2 mg/dL (2.37 mmol/L) hold calcitriol therapy until serum calcium decreased to &lt;9.8 mg/dL (2.37 mmol/L); resume therapy at half the previous dosage (if dosage &lt;0.25 mcg capsule or 0.05 mcg liquid, use every other day therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     If serum levels of phosphorus increase to &gt; age-appropriate upper limits, hold calcitriol therapy (initiate or increase phosphate binders until the levels of serum phosphorus decrease to age-appropriate limits); resume therapy at half the previous dosage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adolescents: CKD Stage 5: Oral, I.V.: Serum calcium times phosphorus product (Ca x P) should not exceed 65 mg",
"     <sup>",
"      2",
"     </sup>",
"     /dL",
"     <sup>",
"      2",
"     </sup>",
"     for infants and children &lt;12 years of age and 55 mg",
"     <sup>",
"      2",
"     </sup>",
"     /dL",
"     <sup>",
"      2",
"     </sup>",
"     for adolescents, serum phosphorus should be within target, serum calcium &lt;10 mg/dL (2.37 mmol/L):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     iPTH 300-500 pg/mL: 0.0075 mcg/kg per dialysis session (3 times/week); not to exceed 0.25 mcg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     iPTH &gt;500-1000 pg/mL: 0.015 mcg/kg per dialysis session (3 times/week); not to exceed 0.5 mcg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     iPTH &gt;1000 pg/mL: 0.025 mcg/kg per dialysis session (3 times/week); not to exceed 1 mcg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dosage adjustment: If  iPTH decrease is &lt;30% after 3 months of therapy and serum levels of calcium and phosphorus are within the target ranges based upon the CKD Stage 5, increase dosage by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adult CKD Stages 3 or 4: Serum calcium &lt;9.5 mg/dL (2.37 mmol/L), serum phosphorus &lt;5.5 mg/dL (1.77 mmol/L), serum calcium times phosphorus product (Ca x P) &lt;55 mg",
"     <sup>",
"      2",
"     </sup>",
"     /dL",
"     <sup>",
"      2",
"     </sup>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     iPTH 300-600 pg/mL: Oral, I.V.: 0.5-1.5 mcg per dialysis session (3 times/week)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     iPTH 600-1000 pg/mL: I.V.: 1-3 mcg per dialysis session (3 times/week); Oral: 1-4 mcg per dialysis session (3 times/week)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     iPTH &gt;1000 pg/mL: I.V. 3-5 mcg per dialysis session (3 times/week); Oral: 3-7 mcg per dialysis session (3 times/week)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dosage adjustment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     If iPTH decrease &lt; target range for CKD stage 5 hold calcitriol therapy until iPTH increases to above target range; resume therapy at half the previous dosage (if dosage &lt;0.25 mcg capsule or 0.05 mcg liquid, use every other day therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     If serum levels of total corrected calcium exceed 9.5 mg/dL (2.37 mmol/L) hold calcitriol therapy until serum calcium decreased to &lt;9.5 mg/dL (2.37 mmol/L); resume therapy at half the previous dosage (if dosage &lt;0.25 mcg capsule or 0.05 mcg liquid, use every other day therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     If serum levels of phosphorus increase to &gt;4.6 mg/dL (1.49 mmol/L), hold calcitriol therapy (initiate or increase phosphate binders until the levels of serum phosphorus decrease to 4.6 mg/dL (1.49 mmol/L); resume therapy at prior dosage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note: Intermittent administration of calcitriol by I.V. or oral routes is more effective than daily oral calcitriol in lowering iPTH levels.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypoparathyroidism/pseudohypoparathyroidism:",
"     </b>",
"     Oral (evaluate dosage at 2- to 4-week intervals):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &lt;1 year: 0.04-0.08 mcg/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1-5 years: 0.25-0.75 mcg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;6 years and Adults: 0.5-2 mcg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vitamin D-dependent rickets:",
"     </b>",
"     Children and Adults: Oral: 1 mcg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vitamin D-resistant rickets (familial hypophosphatemia):",
"     </b>",
"     Children and Adults: Oral: Initial: 0.015-0.02 mcg/kg once daily; maintenance: 0.03-0.06 mcg/kg once daily; maximum dose: 2 mcg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Psoriasis:",
"     </b>",
"     Adults: Topical: Apply twice daily to affected areas (maximum: 200 g/week)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F144194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral: 0.25 mcg, 0.5 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rocaltrol&reg;: 0.25 mcg, 0.5 mcg [contains coconut oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 1 mcg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Calcijex&reg;: 1 mcg/mL (1 mL [DSC]) [contains aluminum]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vectical&reg;: 3 mcg/g (100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 1 mcg/mL (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rocaltrol&reg;: 1 mcg/mL (15 mL) [contains palm oil]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes ointment",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May be administered with or without meals; when administering small doses from the liquid-filled capsules, consider the following concentration for Rocaltrol&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mcg capsule = 0.25 mcg per 0.17 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mcg capsule = 0.5 mcg per 0.17 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: May be administered undiluted as a bolus dose I.V. through the catheter at the end of hemodialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Apply externally; not for ophthalmic, oral, or intravaginal use",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F144272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, sterile water for injection.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1057094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; protect oral and I.V. formulations from light and heat. Do not refrigerate or freeze topical ointment.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral/Injection: Management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate-to-severe chronic renal failure not yet on dialysis (FDA approved in ages &ge;3 years and adults); management of hypocalcemia and resultant metabolic bone disease in patients on chronic renal dialysis (FDA approved in ages &ge;18 years); management of hypocalcemia in patients with hypoparathyroidism (FDA approved in ages &ge;1 year and adults) and pseudohypoparathyroidism (FDA approved in ages &ge;6 years and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical: Management of mild-to-moderate plaque psoriasis (FDA approved in ages &ge;18 years)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F144274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Calcitriol may be confused with alfacalcidol, Calciferol&trade;, calcitonin, calcium carbonate, captopril, colestipol, paricalcitol, ropinirole",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Dosage is expressed in mcg (micrograms),",
"       <b>",
"        not",
"       </b>",
"       mg (milligrams); rare cases of acute overdose have been reported",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F144271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oral, I.V.:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrhythmia, hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Apathy, headache, hyperthermia, psychosis, sensory disturbances, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Erythema multiforme, erythematous skin disorders, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration, growth suppression, hypercalcemia, hypercholesterolemia, libido decreased, polydipsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, metallic taste, nausea, pancreatitis, stomach ache, vomiting, weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Nocturia, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site pain (mild)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bone pain, myalgia, dystrophy, soft tissue calcification, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis, photophobia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Albuminuria, BUN increased, creatinine increased, hypercalciuria, nephrocalcinosis, polyuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, hypersensitivity reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Topical:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Pruritus, psoriasis, skin discomfort",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Endocrine: Hypercalcemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: Urine abnormality",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Renal: Hypercalciuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Rare but important or life-threatening: Kidney stones",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to calcitriol or any component; hypercalcemia; vitamin D toxicity; abnormal sensitivity to the effects of vitamin D",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F4589575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypercalcemia potentiates digoxin toxicity; use concomitantly with caution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical: For external use only; not for ophthalmic, oral, or intravaginal use. Do not apply to facial skin, eyes, or lips. Absorption may be increased with occlusive dressings. Avoid or limit excessive exposure to natural or artificial sunlight or phototherapy. The safety and effectiveness have not been evaluated in patients with erythrodermic, exfoliative, or pustular psoriasis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     The parenteral product contains aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4-5 mcg/kg/day is associated with CNS and bone toxicity and tissue loading may occur at lower doses.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1057090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excessive administration may lead to over suppression of PTH, hypercalcemia, hypercalciuria, hyperphosphatemia, and adynamic bone disease. Acute hypercalcemia may increase risk of cardiac arrhythmias and seizures. Chronic hypercalcemia may lead to generalized vascular and other soft-tissue calcification. Phosphate and vitamin D (and its derivatives) should be withheld during therapy to avoid hypercalcemia. Monitor serum calcium levels closely; the calcitriol dosage should be adjusted accordingly; serum calcium times phosphorus product (Ca x P) should not exceed 65 mg",
"     <sup>",
"      2",
"     </sup>",
"     /dL",
"     <sup>",
"      2",
"     </sup>",
"     for infants and children &lt;12 years of age and 55 mg",
"     <sup>",
"      2",
"     </sup>",
"     /dL",
"     <sup>",
"      2",
"     </sup>",
"     for adolescents and adults. Not indicated for use in patients with rapidly worsening kidney function or those who are noncompliant with medications or follow-up (K/DOQI Guidelines, 2003).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical: May cause hypercalcemia; if alterations in calcium occur, discontinue treatment until levels return to normal.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F144260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F144187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the therapeutic effect of Calcitriol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcitriol may increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May decrease the serum concentration of Vitamin D Analogs. More specifically, orlistat may impair absorption of Vitamin D Analogs. Management: Monitor clinical response (including serum calcium) to oral vitamin D analogs closely if used with orlistat.  If this combination must be used, consider giving the vitamin D analog at least 2 hrs before or after orlistat.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sevelamer: May decrease the serum concentration of Calcitriol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F144190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5078799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in some animal reproduction studies. Mild hypercalcemia has been reported in a newborn following maternal use of calcitriol during pregnancy. Adverse effects on fetal development were not observed with use of calcitriol during pregnancy in women (N=9) with pseudovitamin D-dependent rickets. Doses were adjusted every 4 weeks to keep calcium concentrations within normal limits (Edouard, 2011). If calcitriol is used for the management of hypoparathyroidism in pregnancy, dose adjustments may be needed as pregnancy progresses and again following delivery. Vitamin D and calcium levels should be monitored closely and kept in the lower normal range.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1057097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of vitamin D intoxication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum calcium and phosphorus:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: Twice weekly during initial phase, then at least monthly once dose established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: At least every 2 weeks for 3 months or following dose adjustment, then monthly for 3 months, then every 3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum or plasma intact parathyroid hormone (iPTH): At least every 2 weeks for 3 months or following dose adjustment, then monthly for 3 months, then as per K/DOQI Guidelines below.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Per Kidney Disease Outcome Quality Initiative Practice Guidelines: Children (K/DOQI, 2005):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Stage 3 CKD: iPTH every 6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Stage 4 CKD: iPTH every 3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Stage 5 CKD: iPTH every 3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Per Kidney Disease Outcome Quality Initiative Practice Guidelines: Adults (K/DOQI, 2003):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Stage 3 CKD: iPTH every 12 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Stage 4 CKD: iPTH every 3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Stage 5 CKD: iPTH every 3 months",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F4589576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chronic kidney disease (CKD) is defined either as kidney damage or GFR &lt;60 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     for &ge;3 months); stages of CKD are described below:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CKD Stage 1: Kidney damage with normal or increased GFR; GFR &gt;90 mL/minute/1.73m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CKD Stage 2: Kidney damage with mild decrease in GFR; GFR 60-89 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CKD Stage 3: Moderate decrease in GFR; GFR 30-59 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CKD Stage 4: Severe decrease in GFR; GFR 15-29 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CKD Stage 5: Kidney failure; GFR &lt;15 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     or dialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Target range for iPTH:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Stage 2 CKD: Children: 35-70 pg/mL (3.85-7.7 pmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Stage 3 CKD: Children and Adults: 35-70 pg/mL (3.85-7.7 pmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Stage 4 CKD: Children and Adults: 70-110 pg/mL (7.7-12.1 pmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Stage 5 CKD:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children: 200-300 pg/mL (22-33 pmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: 150-300 pg/mL (16.5-33 pmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum phosphorous:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Stages 1-4 CKD: Children: At or above the age-appropriate lower limits and no higher than age-appropriate upper limits",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Stage 3 and 4 CKD: Adults: &ge;2.7 to &lt;4.6 mg/dL (&ge;0.87 to &lt;1.49 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Stage 5 CKD:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 1-12 years: 4-6 mg/dL (1.29-1.94 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &gt;12 years and Adults: 3.5-5.5 mg/dL (1.13-1.78 mmol/L)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcitriol, the active form of vitamin D (1,25 hydroxyvitamin D",
"     <sub>",
"      3",
"     </sub>",
"     ), binds to and activates the vitamin D receptor in kidney, parathyroid gland, intestine, and bone, stimulating intestinal calcium transport and absorption. It reduces PTH levels and improves calcium and phosphate homeostasis by stimulating bone resorption of calcium and increasing renal tubular reabsorption of calcium. Decreased renal conversion of vitamin D to its primary active metabolite (1,25 hydroxyvitamin D) in chronic renal failure leads to reduced activation of vitamin D receptor, which subsequently removes inhibitory suppression of parathyroid hormone (PTH) release; increased serum PTH (secondary hyperparathyroidism) reduces calcium excretion and enhances bone resorption. The mechanism by which calcitriol is beneficial in the treatment of psoriasis has not been established.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1057103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 3-5 days",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1057104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Breast milk: Very low (levels 2.2 &plusmn; 0.1 pg/mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99.9%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily to 1,24,25-trihydroxycholecalciferol and 1,24,25-trihydroxy ergocalciferol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1.8-16 years undergoing peritoneal dialysis: 27.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults without renal dysfunction: 5-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults with CRF: 16.2-21.9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Feces 27% and urine 7% excreted unchanged in 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Children 1.8-16 years undergoing peritoneal dialysis: 15.3 mL/hour/kg",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1057096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/11/10421?source=see_link\">",
"      see \"Calcitriol: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take as directed; do not increase dosage without consulting healthcare provider. Adhere to diet as recommended (do not take any other phosphate or vitamin D-related compounds while taking calcitriol). You may experience nausea, vomiting, dry mouth (small frequent meals, frequent mouth care, chewing gums, or sucking lozenges may help).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Department Health and Human Services, Food Drug Administration, \"Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition,\"",
"      <i>",
"       Federal Register",
"      </i>",
"      , 2000, 65(17):4103-11.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Children With Chronic Kidney Disease,\"",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2005, 46(4 Suppl 1):S1-121.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Guideline 1. Evaluation of Calcium and Phosphorus Metabolism,\"",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2003, 42(4 Suppl 3):52-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/58/35751/abstract-text/14520607 /pubmed\" id=\"14520607 \" target=\"_blank\">",
"        14520607",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Guideline 3. Evaluation of Serum Phosphorus Levels,\"",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2003, 42(4 Suppl 3):62-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/58/35751/abstract-text/14520607 /pubmed\" id=\"14520607 \" target=\"_blank\">",
"        14520607",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification, Part 4. Definition and Classification of Stages of Chronic Kidney Disease,\"",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2002, 39(2 Suppl 1):46-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/58/35751/abstract-text/ 11904577 /pubmed\" id=\" 11904577 \" target=\"_blank\">",
"        11904577",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanchez CP, &ldquo;Secondary Hyperparathyroidism in Children With Chronic Renal Failure: Pathogenesis and Treatment,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2003, 5(11): 763-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/58/35751/abstract-text/14580225/pubmed\" id=\"14580225\" target=\"_blank\">",
"        14580225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ziolkowska H, &ldquo;Minimizing Bone Abnormalities in Children With Renal Failure,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2006, 8(4):205-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/58/35751/abstract-text/16898852/pubmed\" id=\"16898852\" target=\"_blank\">",
"        16898852",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13107 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-2345798AF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_58_35751=[""].join("\n");
var outline_f34_58_35751=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144219\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144220\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057098\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442161\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057091\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144194\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144178\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057101\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144272\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057094\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057100\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144274\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144271\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057105\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4589575\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057090\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144260\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144187\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144190\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5078799\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057097\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4589576\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057089\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057103\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057104\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057096\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13107\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13107|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/13/40152?source=related_link\">",
"      Calcitriol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/11/10421?source=related_link\">",
"      Calcitriol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_58_35752="Mohs surgery 1";
var content_f34_58_35752=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Mohs surgery of squamous cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 517px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Biopsy proven squamous cell carcinoma of the left preauricular area.",
"    <br>",
"     (B) After delineation of the clinical lesion, a curette is used to debulk the lesion.",
"     <br>",
"      (C) Using a blade angled at 45 degrees, a saucerized excision is performed with reference nicks at 12 and 6 o'clock.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_58_35752=[""].join("\n");
var outline_f34_58_35752=null;
var title_f34_58_35753="Overview of phenylketonuria";
var content_f34_58_35753=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of phenylketonuria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/58/35753/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/58/35753/contributors\">",
"     Olaf A Bodamer, MD, FACMG, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/58/35753/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/58/35753/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/58/35753/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/58/35753/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/58/35753/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phenylketonuria (PKU, MIM#261600) is a disorder affecting the aromatic amino acid phenylalanine. It results from a deficiency of phenylalanine hydroxylase and if untreated is characterized by intellectual disability (mental retardation).",
"   </p>",
"   <p>",
"    An overview of PKU will be presented here; a general discussion of amino acid disorders is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27047?source=see_link\">",
"     \"Inborn errors of metabolism: Classification\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of PKU is one in 13,500 to 19,000 births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/1\">",
"     1",
"    </a>",
"    ]. It is less common in the Afro-American population with an incidence of about 1 in 50,000 based on newborn screening data from the state of Maryland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hepatic enzyme phenylalanine hydroxylase (PAH) catalyzes the conversion of the essential amino acid phenylalanine to tyrosine (",
"    <a class=\"graphic graphic_figure graphicRef59603 \" href=\"mobipreview.htm?33/35/34366\">",
"     figure 1",
"    </a>",
"    ). Tetrahydrobiopterin (BH4) is a cofactor required for PAH activity. This pathway accounts for most of the catabolism and is responsible for the disposal of approximately 75 percent of dietary phenylalanine, with the remainder used for protein synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/3\">",
"     3",
"    </a>",
"    ]. PKU in most cases is caused by deficiency of PAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. This results in elevated blood and urine concentrations of phenylalanine and its metabolites, phenylacetate and phenyllactate. Tyrosine concentration is normal or low normal. Occasionally tyrosine concentrations are low. Defects in BH4 metabolism account for approximately 2 percent of patients with elevated phenylalanine levels. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Tetrahydrobiopterin (BH4) deficiency'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Complete enzyme deficiency results in classic PKU, in which serum phenylalanine concentration exceeds 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1200",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    Residual enzyme activity causes mild PKU (phenylalanine concentration 10 to 20",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    600 to 1200",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and hyperphenylalaninemia (HPA, phenylalanine concentration 2.5 to 10",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    150 to 600",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mechanism of intellectual disability",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism by which the elevated concentration of phenylalanine causes intellectual disability (mental retardation) is unknown. Excessive phenylalanine is thought to interfere with brain growth, myelination, and neurotransmitter synthesis. Potential mechanisms have been proposed based upon the following studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal development of neurons, glia, and extracellular matrix of the brain in postnatal rats exposed to high phenylalanine levels was suggested by changes in molecular markers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/6\">",
"       6",
"      </a>",
"      ]. These included increased hyaluronate-binding activity in extracellular matrix formation, alteration in the content of neural cell adhesion molecule, and increased glial fibrillary acidic protein during cerebellar development.",
"     </li>",
"     <li>",
"      High phenylalanine concentrations may disrupt brain development through oxidative stress. In brains of hyperphenylalaninemic rats, total radical-trapping antioxidant potential was reduced and chemiluminescence was increased [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/7\">",
"       7",
"      </a>",
"      ]. Phenylalanine inhibited both catalase and glutathione peroxidase in vivo. However, catalase was inhibited only in vitro, and superoxide dismutase was not affected in either condition.",
"     </li>",
"     <li>",
"      The phenylalanine metabolites phenylacetate and phenylpyruvate may inhibit synthesis of alpha-tocopherolquinone, an essential cofactor for the synthesis of brain arachidonic and docosahexaenoic acid, polyunsaturated fatty acids required for normal brain development [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In cultured rat hippocampal cells, phenylalanine specifically inhibited N-methyl-D-aspartate (NMDA) receptors, thought to be involved in the regulation of memory and learning [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The transport of large neutral amino acids (LNAA) into the brain was inhibited by increased concentration of phenylalanine. Decreased LNAA is thought to inhibit synthesis of protein and neurotransmitters, resulting in deficient concentrations of dopamine and serotonin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHENYLALANINE HYDROXYLASE (PAH) DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of PKU are caused by PAH deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mode of inheritance for PKU is autosomal recessive. Nearly all cases are caused by mutations in the gene encoding PAH, which has been mapped to human chromosome 12q24.1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/3\">",
"     3",
"    </a>",
"    ]. More than 400 mutations, including deletions, insertions, splicing defects, and missense and nonsense mutations, have been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/1\">",
"     1",
"    </a>",
"    ]. No single mutation predominates in white populations, although certain mutations are more common in specific ethnic groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/10\">",
"     10",
"    </a>",
"    ]. Most affected patients are compound heterozygotes for two different mutations.",
"   </p>",
"   <p>",
"    Mutations affect the structure of PAH. PAH is a tetramer, with each monomer consisting of a catalytic and tetramerization domain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/11\">",
"     11",
"    </a>",
"    ]. Most of the mutations that result in PKU are located in the catalytic domain. However, some occur at the interface of the two domains, where they can affect the stability of the enzyme.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of widespread neonatal screening, overt clinical manifestations of PKU are rare. Newborn infants are asymptomatic prior to the initiation of feeds containing phenylalanine (eg, breast milk or standard infant formula). If undetected by metabolic screening, the onset of PKU is insidious and may not cause symptoms until early infancy.",
"   </p>",
"   <p>",
"    In untreated patients, the hallmark of the disease is intellectual disability (mental retardation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/5\">",
"     5",
"    </a>",
"    ]. Mental impairment worsens during myelination in early childhood with increasing dietary exposure, but stabilizes when brain maturation is complete. In a series of 51 untreated patients evaluated at 28.8 to 71.8 years of age, the extent of retardation was approximately evenly divided between severe (IQ &lt;35) and mildly to moderately impaired (IQ 36 to 67) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/12\">",
"     12",
"    </a>",
"    ]. Two had IQ &gt;68. Epilepsy occurs frequently, with 12 (23 percent) adult patients affected. Although some patients had loss of motor function over time, 41 (80 percent) had no further deterioration.",
"   </p>",
"   <p>",
"    Other findings include abnormalities of gait, sitting posture, and stance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/12\">",
"     12",
"    </a>",
"    ]. Hyperactivity may occur. Light pigmentation is common, and patients may have an eczematous rash. The body and urine may have a \"mousy\" odor due to the increased concentration of the metabolite phenylacetic acid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Brain imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;White matter injury is apparent on magnetic resonance imaging in the majority of patients with PKU, including those who were detected by newborn screening and received early dietary treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/13-18\">",
"     13-18",
"    </a>",
"    ]. A common finding is a symmetrical increase of T2-weighted signal in the periventricular white matter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/14\">",
"     14",
"    </a>",
"    ]. The changes are thought to represent increased turnover of myelin caused by increased phenylalanine concentration, and may be reversible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The severity of the abnormalities appears to be related to dietary status. This was demonstrated by a series of 34 PKU patients, aged 8 to 33 years, of whom 25 were detected by newborn screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/16\">",
"     16",
"    </a>",
"    ]. In the early diagnosed group, the severity of MRI changes was significantly associated with serum phenylalanine concentration at the time of the study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of PKU is based upon the finding of an elevated serum concentration of phenylalanine. Blood elevations typically are very high (&gt;20",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    1200",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in patients with complete deficiency of PAH.",
"   </p>",
"   <p>",
"    The most useful laboratory method for newborn screening is tandem mass spectrometry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/1\">",
"     1",
"    </a>",
"    ]. This method also can measure additional amino acids including tyrosine and acylcarnitine ester. A high concentration of phenylalanine together with low to low-normal tyrosine concentration may assist in making the diagnosis of PKU. In addition, tandem mass spectrometry can identify many other inborn errors of metabolism in a single sample. Other methods are the Guthrie bacterial inhibition assay and fluorometric analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because PAH activity is expressed only in the liver, enzyme analysis is not usually performed to confirm the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/10\">",
"     10",
"    </a>",
"    ]. Molecular analysis can be used to demonstrate mutations at the PAH locus in peripheral blood leukocytes or for carrier detection or prenatal diagnosis in families in whom the mutation is known. In some cases, it may be possible to predict enzyme activity from the PAH genotype, although the relationship may be inconsistent. The NIH Consensus Development Conference on PKU recommended mutation analysis and genotype determination on all affected patients for initial diagnosis, genetic counseling, follow-up, and long-term prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11759633\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of patients with HPA or PKU should be provided by an experienced interdisciplinary team of nutritionists, psychologists, social workers, metabolic specialists, and pediatricians (or internists for adult patients). Ideally, adult patients should be seen in an adult clinic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Dietary restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of therapy in PKU is dietary restriction of phenylalanine (",
"    <a class=\"graphic graphic_table graphicRef71966 \" href=\"mobipreview.htm?10/6/10348\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/1,20-24\">",
"     1,20-24",
"    </a>",
"    ]. This requires the use of medical foods including phenylalanine-free protein substitutes (amino acid mixtures or protein hydrolysates) that supply approximately 75 percent of protein requirements (except phenylalanine) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/25\">",
"     25",
"    </a>",
"    ]. The table shows the current treatment guidelines for the United States and selected European countries (",
"    <a class=\"graphic graphic_table graphicRef77915 \" href=\"mobipreview.htm?4/29/4572\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The optimal intake of protein substitute needed to meet requirements, including optimal growth and development, is uncertain. Uncontrolled studies have conflicting results regarding the benefit of high versus low intake of protein substitute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]. Two weeks of therapy with low (1.2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day) and high (2.0",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day) protein substitute intake were compared in a randomized crossover study in 25 children with well-controlled PKU whose usual median protein intake was 2.2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/31\">",
"     31",
"    </a>",
"    ]. During low protein substitute intake, median phenylalanine levels increased compared to the control period. During high protein substitute intake, median phenylalanine levels were unchanged from the control period. However, there was wide variability between subjects, which appeared to be related to the carbohydrate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fat content of the protein substitute.",
"   </p>",
"   <p>",
"    The poor palatability of protein substitutes adversely affects compliance with the diet, especially in older children. The required amount of phenylalanine is provided with small amounts of natural protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/1\">",
"     1",
"    </a>",
"    ]. Rare patients may need tyrosine supplementation.",
"   </p>",
"   <p>",
"    Treatment should be initiated as soon as possible, usually before one week of age, in infants with PKU and blood phenylalanine concentration &gt;10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (600",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/1\">",
"     1",
"    </a>",
"    ]. Treatment for elevated, but slightly lower levels of phenylalanine is controversial. We recommend treating newborns with persistent phenylalanine levels of 7 to 10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (420 to 600",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    BH4 deficiency should be excluded prior to treatment.",
"   </p>",
"   <p>",
"    Continuation of dietary restriction throughout life appears to be necessary for optimal outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/1,32,33\">",
"     1,32,33",
"    </a>",
"    ]. This was supported by findings in a long-term follow-up study of newborns with PKU who participated in a trial of dietary management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/32\">",
"     32",
"    </a>",
"    ]. In the initial trial, infants were treated with a phenylalanine-restricted diet until they reached six years of age and then were randomly assigned to continue or discontinue the diet. At approximately 25 years of age, 70 of the initial 211 infants were reevaluated. Children who continued the diet had a decreased rate of eczema (11 versus 28 percent), asthma (0 versus 12 percent), headache (0 versus 31 percent), mental disorders (22 versus 41 percent), hyperactivity (0 versus 14 percent), and hypoactivity (0 versus 19 percent), compared to those who discontinued the diet. Continuation of the diet was associated with better intellectual and achievement test scores and lower blood phenylalanine concentration. MRI abnormalities were associated with higher brain phenylalanine concentrations as assessed by MR spectroscopy.",
"   </p>",
"   <p>",
"    In nonrandomized studies, IQ scores remained stable in older children and adults with PKU who were not on a restricted diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/1,34-37\">",
"     1,34-37",
"    </a>",
"    ]. However, subtle deficits in measures of attention and speed of processing were noted when compared to baseline, continuously treated patients,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. High phenylalanine levels were shown to affect mood and sustained attention in adults in a randomized crossover trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/38\">",
"     38",
"    </a>",
"    ]. Nine adults were given a supplement containing phenylalanine or placebo for four weeks while on a restricted diet. Scores on the Profile of Mood States (POMS) questionnaire filled out by both the patients and their friend or relative were significantly lower on phenylalanine supplementation compared with placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic doses of tetrahydrobiopterin (BH4), a cofactor for PAH, may be an alternative treatment in patients with mild HPA phenotypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. The response to BH4 among children with PKU (but not BH4 deficiency) has been evaluated in several studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In one of the larger studies, blood phenylalanine levels were measured in 557 newborns and children with PKU after administration of BH4 (20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/42\">",
"     42",
"    </a>",
"    ]. With responsiveness defined by a 30 percent reduction in phenylalanine level, 38 percent of patients responded when phenylalanine was measured eight hours after administration and 46 percent responded when phenylalanine was measured 24 hours after administration. The prevalence of responsiveness was 79 to 83 percent in patients with mild HPA (phenylalanine &lt;10",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    600",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    49 to 60 percent in patients with mild PKU (phenylalanine 10 to 20",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    600 to 1200",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and 7 to 10 percent in patients with classic PKU (phenylalanine &gt;20",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    1200",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    In a smaller study, responsiveness to BH4 was not consistently predicted by genotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/9/31892?source=see_link\">",
"     Sapropterin",
"    </a>",
"    (6R-BH4, Kuvan), a biologically active synthetic form of BH4, was approved by the US Food and Drug Administration in December 2007 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. Sapropterin may be used as an adjunct to dietary restriction in PKU patients who are responsive to BH4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/43,46-50\">",
"     43,46-50",
"    </a>",
"    ]. Responsiveness to BH4 should be shown using an appropriate BH4 load protocol with an observational period of at least 24 hours (48 hours is better), followed by a one- to four-week trial of sapropterin with subsequent adjustment of sapropterin dose and phenylalanine intake to optimize phenylalanine levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The suggested starting dose is 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    once daily for up to one month; in patients who do not respond, the dose may be increased to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    once daily for up to one month [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/44\">",
"     44",
"    </a>",
"    ]. The final dose can be adjusted within a range of 5 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, titrated to blood phenylalanine level.",
"   </p>",
"   <p>",
"    In a multicenter trial, 89 patients with PKU were randomly assigned to treatment with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/9/31892?source=see_link\">",
"     sapropterin",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    or placebo for six weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/52\">",
"     52",
"    </a>",
"    ]. Sapropterin therapy was associated with a decrease in mean blood phenylalanine concentration of 3.9",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (236",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    compared with a 0.05",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    increase in the placebo group; 44 percent of patients in the treatment group had a reduction of blood phenylalanine concentration from baseline of at least 30 percent, compared to 9 percent of controls. Long-term neurologic function in patients with PKU treated with sapropterin has not been assessed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a follow-up study, 46 patients (aged 4 to 12 years) who responded to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/9/31892?source=see_link\">",
"     sapropterin",
"    </a>",
"    were randomly assigned (3:1) to sapropterin (20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) or placebo for 10 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/49\">",
"     49",
"    </a>",
"    ]. Subjects continued on a phenylalanine-restricted diet, but after three weeks, dietary phenylalanine supplements were added or removed every two weeks depending upon phenylalanine control. Phenylalanine tolerance was increased in the sapropterin-treated patients (adjusted mean difference 17.7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, 95% CI 9-27",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day).",
"   </p>",
"   <p>",
"    Additional studies are needed to evaluate the effects associated with long-term use. Because there are no long-term safety data, supplementation of BH4 should be considered very carefully.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Other therapies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Long chain polyunsaturated fats &mdash; Because it is low in animal protein, a phenylalanine-restricted diet results in low blood concentrations of long chain polyunsaturated fatty acids (LCPUFA) and docosahexanoic acid (DHA), which may compromise neurodevelopment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/53\">",
"       53",
"      </a>",
"      ]. In a randomized trial in children with well-controlled HPA, supplementation for 12 months with LCPUFA including DHA increased blood DHA concentration and improved visual function compared to placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/54\">",
"       54",
"      </a>",
"      ]. However, these values returned to baseline after three years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/55\">",
"       55",
"      </a>",
"      ]. In a nonrandomized trial, supplementation with fish oil (omega-3 LCPUFA) for three months improved the motor skills of children with well-controlled PKU compared to age-matched controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/56\">",
"       56",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      It is unclear if there is a conditional requirement for dietary DHA to achieve optimal neural and cognitive development. In the absence of dietary recommendations, the provision of 300",
"      <span class=\"nowrap\">",
"       mg/100",
"      </span>",
"      kcal or 2.7 percent of dietary energy as alpha-linolenic acid, a precursor of DHA, is adequate to prevent essential fatty acid deficiency and supports, in part, the metabolic needs of the body for DHA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/57,58\">",
"       57,58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Large neutral amino acids (LNAAs)",
"      <strong>",
"       &nbsp;",
"      </strong>",
"      LNAAs (arginine, histidine, isoleucine, leucine, lysine, methionine, threonine, tryptophan, tyrosine and valine) compete with phenylalanine for the same amino transporter at the blood brain barrier. Supplementation with LNAAs may therefore significantly reduce the influx of phenylalanine into the brain in patients with PKU [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/59\">",
"       59",
"      </a>",
"      ]. In addition, LNAA supplementation",
"      <span class=\"nowrap\">",
"       (250-500mg/kg/day)",
"      </span>",
"      may significantly reduce phenylalanine concentrations in plasma due to competitive inhibition of phenylalanine absorption in the small intestine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/60\">",
"       60",
"      </a>",
"      ]. LNAA should not be substituted for amino acid mixtures, but rather should be used in selected patients to improve metabolic control.",
"     </li>",
"     <li>",
"      Glycomacropeptide &nbsp;Another potential approach to dietary treatment in PKU is glycomacropeptide (GMP). GMP is a natural protein found in sweet cheese whey that contains no phenylalanine, but is rich in LNAA. Studies have demonstrated the efficacy and palatability of a GMP diet in patients with PKU [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/21,61\">",
"       21,61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3596819\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood concentrations of phenylalanine should be monitored frequently, especially during infancy. The intervals can be extended with increasing age. The NIH Consensus Development Conference on PKU recommended testing at weekly intervals during the first year, twice monthly from 1 to 12 years of age, and monthly after 12 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The blood phenylalanine concentration associated with optimal neurodevelopmental outcome is uncertain. No consensus exists among treatment centers in the United States or other countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/1\">",
"     1",
"    </a>",
"    ]. The NIH Consensus Development Conference on PKU recommended maintaining a blood concentration of 2 to 6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (120 to 360",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    for affected children through 12 years of age and 2 to 15",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (120 to 900",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    after 12 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/1\">",
"     1",
"    </a>",
"    ]. However, although data are limited, higher blood phenylalanine concentrations appear to adversely affect brain function, even in adults. Thus, maintenance of lower levels (2 to 10",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    120 to 600",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    is strongly encouraged during adolescence or even beyond. Elevated phenylalanine concentration may be associated with intercurrent illnesses, trauma, high phenylalanine intake, or inadequate intake of amino acid mixture, total energy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    protein in relation to metabolic needs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tyrosine is an essential amino acid in patients with PKU, because of their inability to convert phenylalanine to tyrosine. Consequently, tyrosine concentrations may be low, which may have a negative effect on thyroxine, catecholamine, and melanin synthesis. Patients with PKU need to take particular care that their amino acid mixture is shaken sufficiently before they drink it due to its insolubility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Phenylalanine and tyrosine concentrations and intake of phenylalanine, amino acids, vitamins, minerals, and essential fatty acids (by a three-day record of food intake) should be monitored regularly in patients with PKU, particularly in those individuals who receive insufficient amounts of amino acid mixture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11759930\">",
"    <span class=\"h2\">",
"     Osteopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 40 percent or more of young adults with PKU have a low peak bone mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. The etiology remains unclear, although there is some indication that increased phenylalanine concentrations may affect normal bone development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary treatment appears to reverse all signs of PKU except cognitive impairment that has already occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Cognitive outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Affected children who are treated by dietary restriction tend to have IQ scores in the average range. However, their IQ scores are, on the average, approximately one-half of a standard deviation lower than unaffected controls. They also score slightly lower than their unaffected parents or siblings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cognitive outcome appears to be correlated with the extent of control of blood phenylalanine concentration, especially during early childhood. In a review of longitudinal studies of patients with early treatment for PKU, IQ decreased by approximately one-half of a standard deviation for each 300",
"    <span class=\"nowrap\">",
"     micromol/L",
"    </span>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    increase in blood phenylalanine concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/67\">",
"     67",
"    </a>",
"    ]. Outcomes were nearly normal when phenylalanine concentration was less than 400",
"    <span class=\"nowrap\">",
"     micromol/L",
"    </span>",
"    (6.7",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    during early and middle childhood. Another study showed that there was a 1.3 to 3.9 point decline in IQ score for each 100",
"    <span class=\"nowrap\">",
"     micromol/L",
"    </span>",
"    increase in phenylalanine concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Behavior problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some affected patients have learning disabilities and behavior problems, although evidence is inconsistent. This was examined in a systematic review of four studies that each included more than 20 subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/69\">",
"     69",
"    </a>",
"    ]. Taken together, patients with early treated PKU appear to have a higher prevalence of behavior problems and psychological disturbance than controls. The range of problems reported included excessive sadness, fear, and anxiety; a sense of isolation and poor self-image; and lack of autonomy and drive. Whether children with PKU are at higher risk for attention deficit hyperactivity disorder is controversial.",
"   </p>",
"   <p>",
"    Both neurobiologic impairment and the stressful nature of the restrictive diet may contribute to disturbances in behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/69\">",
"     69",
"    </a>",
"    ]. Adequate studies comparing blood phenylalanine levels and behavior disorders are unavailable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Visual abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;High phenylalanine concentrations appear to cause subclinical visual impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. This was illustrated by a study of pattern reversal visual evoked potentials (VEPs) in patients with PKU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/70\">",
"     70",
"    </a>",
"    ]. VEPs were abnormal in only one of nine children younger than 14 years old who were on a restricted diet, compared to more than 80 percent of older patients, whether or not they were still on a low-phenylalanine diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Resources",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"external\" href=\"file://depts.washington.edu/pku/\">",
"     Cristine M. Trahms Program for Phenylketonuria",
"    </a>",
"    provides resources for families of children with PKU and professionals who work with children with PKU, including educational material about the PKU diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TETRAHYDROBIOPTERIN (BH4) DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetrahydrobiopterin (BH4) is an essential cofactor for PAH, tyrosine hydroxylase, and tryptophan hydroxylase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/10,72\">",
"     10,72",
"    </a>",
"    ]. BH4 deficiency can result from decreased regeneration by dihydropteridine reductase (DHPR) and pterin-4-carbinolamine dehydratase (PCD) or from impaired BH4 synthesis. BH4 is synthesized from guanosine triphosphate by GTP cyclohydrolase 1 (GTPCH), 6-pyruvoyl-tetrahydrobiopterin synthase (PTPS), and sepiapterin reductase (SR).",
"   </p>",
"   <p>",
"    Defects in BH4 metabolism account for approximately 2 percent of patients with elevated phenylalanine levels. However, some variants of these defects, such as GTPCH deficiency, may present with symptoms of neurotransmitter deficiency (eg, dopa-responsive dystonia) rather than HPA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Inheritance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mode of inheritance of these disorders is autosomal recessive, with the exception of dominantly inherited GTPCH deficiency. Mutations have been detected in the genes encoding DHPR, PCD, GTPCH, PTPS, and SR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Affected patients typically have hyperphenylalaninemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progressive neurologic deterioration during infancy due to decreased production of the neurotransmitters dopamine, epinephrine, norepinephrine, and serotonin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/73\">",
"     73",
"    </a>",
"    ]. Untreated patients typically die before reaching one year of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Diagnosis of BH4 deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is made by measurement of elevated concentrations of biopterin or neopterin in blood, urine, or cerebrospinal fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/5\">",
"     5",
"    </a>",
"    ]. Neurotransmitter metabolites also are measured in cerebrospinal fluid. Decreased dihydropteridine reductase (DHPR) activity can be demonstrated in blood. It is essential to investigate every infant with elevated phenylalanine concentrations for BH4 deficiency using an appropriate BH4 loading test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Treatment of BH4 deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;BH4 deficiency is treated with a diet low in phenylalanine and supplementation with BH4 (2 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/73\">",
"     73",
"    </a>",
"    ]. This will lower phenylalanine concentrations but will not improve neurologic status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/10\">",
"     10",
"    </a>",
"    ]. The neurotransmitter precursors L-dopa, carbidopa, and serotonin also are provided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/73\">",
"     73",
"    </a>",
"    ]. Folinic acid supplementation is given in DHPR deficiency. It is essential that the treatment is initiated as early as possible in the course of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PHENYLALANINE EMBRYOPATHY (MATERNAL PKU)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated serum phenylalanine concentration during early pregnancy in a mother with PKU or hyperphenylalaninemia (HPA) can result in phenylalanine embryopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. The risk results from the mother's metabolic status and is independent of whether the fetus has PKU. Women with PKU should be encouraged to receive family planning and preconception services [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concentration of phenylalanine is higher in fetal than maternal plasma. In one report, concentrations in fetal blood obtained by cordocentesis were compared to simultaneous maternal venous samples in 14 pregnancies from 19 weeks to term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/77\">",
"     77",
"    </a>",
"    ]. The overall fetal-maternal concentration ratio was 1.35 &plusmn; 0.42 (SD) and decreased gradually over the period of measurement. Because of the concentration gradient, even if maternal phenylalanine levels are in a reasonable range, fetal levels may reach a level that is teratogenic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Clinical effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The embryopathic effects of maternal PKU include intrauterine growth restriction, intellectual disability (mental retardation), microcephaly, and cardiac malformations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. The clinical picture is similar to that of alcohol embryopathy.",
"   </p>",
"   <p>",
"    The risk of abnormalities depends upon the maternal blood phenylalanine concentration and is independent from the fetal genotype (eg, heterozygosity or homozygosity for PKU) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/74\">",
"     74",
"    </a>",
"    ]. In untreated pregnancies in which the maternal blood phenylalanine concentration was &ge;20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1200",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    microcephaly and intellectual disability occurred in 73 to 92 percent of the offspring, and 12 percent had congenital heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outcome is improved substantially when treatment results in low maternal phenylalanine concentrations ideally before conception or less optimally before 10 weeks gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/74,75,80-83\">",
"     74,75,80-83",
"    </a>",
"    ]. This was illustrated by the Maternal PKU Study, an international collaboration that prospectively evaluated 572 pregnancies in women with PKU and 99 controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/80\">",
"     80",
"    </a>",
"    ]. Among the affected mothers who delivered live offspring, metabolic control was achieved before conception or by 10 weeks in 16 and 18 percent, respectively. In these groups, the rates of microcephaly were 3.6 and 5 percent, respectively, substantially lower than rates in untreated pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of congenital heart disease in offspring depends upon maternal blood phenylalanine levels at baseline and during the period of cardiogenesis (4 to 10 weeks gestation). In another report from the Maternal PKU Study cited above, offspring were compared from affected and control pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/81\">",
"     81",
"    </a>",
"    ]. Congenital heart disease occurred in 34 of 235 offspring (14 percent) of mothers with a basal phenylalanine level &ge;15",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&ge;900",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and a persistent level &ge;10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&ge;600",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    by the eighth week of gestation, compared with 1 of 99 controls (1 percent). The rate of coarctation of the aorta (20 percent) and hypoplastic left heart syndrome (11 percent) were greater than would be expected in the general population.",
"   </p>",
"   <p>",
"    Another report from the Maternal PKU Study examined the effect of microcephaly and congenital heart disease in the offspring on developmental outcome measured by the McCarthy General Cognitive Index at four years of age and the Wechsler Intelligence Scale for Children Revised at six years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/82\">",
"     82",
"    </a>",
"    ]. The overall rates of congenital heart disease and microcephaly were 7.7 and 33 percent, respectively. Infants with both anomalies had higher maternal phenylalanine levels than those with only heart disease. All of the infants with heart disease had maternal phenylalanine levels above 6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (360",
"    <span class=\"nowrap\">",
"     micromol/L",
"    </span>",
"    during the first 8 to 10 weeks of gestation). Compared to children without either anomaly, IQ was lower with either microcephaly or congenital heart disease, and even lower with both. Decreasing IQ was associated with increasing phenylalanine exposure.",
"   </p>",
"   <p>",
"    Findings similar to those of the Maternal PKU Study were described in a retrospective report from the United Kingdom PKU registry between 1978 and 1997 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/83\">",
"     83",
"    </a>",
"    ]. In this report, infants born to mothers who initiated a phenylalanine restricted diet before conception had the following outcomes compared to those whose mothers started the diet during pregnancy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Greater mean birth weight (3160 versus 2818 grams)",
"     </li>",
"     <li>",
"      Greater mean birth head circumference (33.6 versus 32.7 cm)",
"     </li>",
"     <li>",
"      Greater mean developmental quotient (DQ) at four years (108.9 versus 96.8)",
"     </li>",
"     <li>",
"      Greater mean DQ at eight years (103.4 versus 86.5)",
"     </li>",
"     <li>",
"      Lower rates of congenital heart disease (2.4 percent versus 17 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phenylalanine embryopathy can be prevented by dietary restriction of phenylalanine intake in women with PKU or HPA before and during pregnancy. The NIH Consensus Development statement recommended that plasma phenylalanine levels should be reduced to levels &lt;6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (360",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    at least three months before conception and remain at 2 to 6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (120 to 360",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/1\">",
"     1",
"    </a>",
"    ]. Mothers who conceive while blood levels are greater than recommended should achieve metabolic control as soon as possible. Plasma phenylalanine concentration should be monitored twice weekly, or a minimum of once weekly. The amount of phenylalanine tolerated increases during pregnancy. The diet should be adjusted according to plasma levels.",
"   </p>",
"   <p>",
"    Maternal plasma tyrosine levels should be maintained between 0.9 and 1.8",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Tyrosine supplementation may be needed to maintain this range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     MILD MATERNAL HYPERPHENYLALANINEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Offspring do not appear to be affected by mild maternal hyperphenylalaninemia (MHPA), a condition distinct from PKU. Blood concentrations of phenylalanine in MHPA are lower than in PKU. In an international survey that included 219 untreated pregnancies in 86 mothers with MHPA (blood phenylalanine concentration 167 to 715",
"    <span class=\"nowrap\">",
"     micromol/L,",
"    </span>",
"    2.8 to 11.9",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    rates of spontaneous fetal loss (13 percent), congenital heart disease (2.3 percent), and severe noncardiac anomalies (2.9 percent) were similar to those expected for the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, length and head circumference at birth were lower in offspring of mothers with phenylalanine concentration &gt;400",
"    <span class=\"nowrap\">",
"     micromol/L",
"    </span>",
"    (6.6",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    compared to those with lower levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/58/35753/abstract/85\">",
"     85",
"    </a>",
"    ]. Offspring of mothers with blood levels in the lower group had a higher median IQ at ages 3 to 27 years (108 versus 100) than those in the higher group. However, IQ in the offspring correlated better with maternal IQ than maternal phenylalanine concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatic phenylalanine hydroxylase (PAH) catalyzes the conversion of phenylalanine to tyrosine (",
"      <a class=\"graphic graphic_figure graphicRef59603 \" href=\"mobipreview.htm?33/35/34366\">",
"       figure 1",
"      </a>",
"      ). Deficiency of PAH results in elevated blood and urine concentrations of phenylalanine and its metabolites, phenylacetate and phenyllactate; tyrosine concentration is normal or nearly normal. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complete enzyme deficiency results in classic PKU (serum phenylalanine concentrations of &gt;20",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1200",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      and elevated urine phenylalanine. Residual enzyme activity causes mild PKU (phenylalanine concentration 10 to 20",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [600 to 1200",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      and hyperphenylalaninemia (HPA, phenylalanine concentration 2.5 to 10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [150 to 600",
"      <span class=\"nowrap\">",
"       micromol/L]).",
"      </span>",
"      Approximately 2 percent of patients with HPA have defects in tetrahydrobiopterin (BH4) metabolism; BHR is a cofactor required for PAH activity. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanism by which the elevated concentration of phenylalanine causes intellectual disability is unknown. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Mechanism of intellectual disability'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Classic PKU",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most cases of PKU are caused by PAH deficiency, which is an autosomal recessive disorder. The gene encoding PA has been mapped to human chromosome 12q24.1; more than 400 mutations have been identified. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Phenylalanine hydroxylase (PAH) deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Newborn infants are asymptomatic before the initiation of feeds containing phenylalanine (eg, breast milk or standard infant formula). If undetected by metabolic screening, PKU may not cause symptoms until early infancy. In untreated patients, the hallmark of the disease is intellectual disability; epilepsy occurs frequently. Other findings include abnormalities of gait, sitting posture, and stance. Light pigmentation is common, and patients may have an eczematous rash. The body and urine may have a \"mousy\" odor due to the increased concentration of phenylacetic acid. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of PKU is based upon the finding of an elevated serum concentration of phenylalanine (typically&gt;20",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1200",
"      <span class=\"nowrap\">",
"       micromol/L]",
"      </span>",
"      in patients with complete deficiency of PAH). Molecular analysis can be used to demonstrate PAH mutations in peripheral blood leukocytes and for carrier detection or prenatal diagnosis in families in whom the mutation is known. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mainstay of therapy in PKU is dietary restriction of phenylalanine. This requires the use of medical foods including phenylalanine-free protein substitutes. Dietary restriction should be initiated as soon as possible in infants with PKU and blood phenylalanine concentration &gt;10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (600",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      BH4 deficiency should be excluded before initiation of dietary restriction. Continuation of dietary restriction throughout life appears to be necessary for optimal outcomes. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Dietary restriction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacologic doses of BH4, may be an alternative treatment in patients with mild HPA phenotypes. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blood concentrations of phenylalanine and tyrosine should be monitored frequently, especially during infancy. The intervals can be extended with increasing age. The NIH Consensus Development Conference on PKU recommended testing at weekly intervals during the first year, twice monthly from 1 to 12 years of age, and monthly after 12 years of age. (See",
"      <a class=\"local\" href=\"#H3596819\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dietary treatment appears to reverse all signs of PKU except cognitive impairment that has already occurred. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     BH4 deficiency",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with defects in BH4 metabolism typically have HPA",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      progressive neurologic deterioration during infancy due to decreased production of the neurotransmitters, dopamine, epinephrine, norepinephrine, and serotonin. Untreated patients typically die before reaching one year of age. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Tetrahydrobiopterin (BH4) deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of BH4 deficiency is confirmed by elevated concentrations of biopterin or neopterin in blood, urine, or cerebrospinal fluid; neurotransmitter metabolites also are measured in the cerebrospinal fluid. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Diagnosis of BH4 deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is essential that treatment for BH4 deficiency is initiated as early as possible in the disease course. BH4 deficiency is treated with a diet low in phenylalanine, supplementation with BH4, and provision of the neurotransmitter precursors L-dopa,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/9/3221?source=see_link\">",
"       carbidopa",
"      </a>",
"      , and serotonin. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Treatment of BH4 deficiency'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Maternal PKU",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated serum phenylalanine concentration during early pregnancy in a mother with PKU or hyperphenylalaninemia (HPA) can result in phenylalanine embryopathy (whether the fetus has PKU). The embryopathic effects include intrauterine growth restriction, intellectual disability, microcephaly, and cardiac malformations. Phenylalanine embryopathy can be prevented by dietary restriction of phenylalanine in women with PKU or HPA before and during pregnancy. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Phenylalanine embryopathy (maternal PKU)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Maternal HPA",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Offspring do not appear to be affected by mild maternal HPA, a condition distinct from PKU. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Mild maternal hyperphenylalaninemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/1\">",
"      National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000. Pediatrics 2001; 108:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/2\">",
"      Hofman KJ, Steel G, Kazazian HH, Valle D. Phenylketonuria in U.S. blacks: molecular analysis of the phenylalanine hydroxylase gene. Am J Hum Genet 1991; 48:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/3\">",
"      Erlandsen H, Stevens RC. The structural basis of phenylketonuria. Mol Genet Metab 1999; 68:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/4\">",
"      F&ouml;lling A. &Uuml;ber Ausscheidung von Phenylbrenztraubens&auml;ure in den Harn als Stoffwechselanomalie in Verbindung mit Imbezillit&auml;t. Zschr Physiol Chem 1934; 227:169.",
"     </a>",
"    </li>",
"    <li>",
"     Scriver CR, Kaufman S. The hyperphenylalaninemias. Phenylalanine hydroxylase deficiency. In: The metabolic and molecular bases of inherited disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.1667.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/6\">",
"      Ushakova GA, Gubkina HA, Kachur VA, Lepekhin EA. Effect of experimental hyperphenylalaninemia on the postnatal rat brain. Int J Dev Neurosci 1997; 15:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/7\">",
"      Kienzle Hagen ME, Pederzolli CD, Sgaravatti AM, et al. Experimental hyperphenylalaninemia provokes oxidative stress in rat brain. Biochim Biophys Acta 2002; 1586:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/8\">",
"      Infante JP, Huszagh VA. Impaired arachidonic (20:4n-6) and docosahexaenoic (22:6n-3) acid synthesis by phenylalanine metabolites as etiological factors in the neuropathology of phenylketonuria. Mol Genet Metab 2001; 72:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/9\">",
"      Glushakov AV, Dennis DM, Morey TE, et al. Specific inhibition of N-methyl-D-aspartate receptor function in rat hippocampal neurons by L-phenylalanine at concentrations observed during phenylketonuria. Mol Psychiatry 2002; 7:359.",
"     </a>",
"    </li>",
"    <li>",
"     Wappner RS. Disorders of amino acid and organic acid metabolism. In: Oski's pediatrics. Principles and practice, 4th ed, McMillan JA, Feigin RD, DeAngelis C, Jones MD (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.2153.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/11\">",
"      Fusetti F, Erlandsen H, Flatmark T, Stevens RC. Structure of tetrameric human phenylalanine hydroxylase and its implications for phenylketonuria. J Biol Chem 1998; 273:16962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/12\">",
"      PAINE RS. The variability in manifestations of untreated patients with phenylketonuria (phenylpyruvic aciduria). Pediatrics 1957; 20:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/13\">",
"      Weglage J, Bick U, Schuierer G, et al. Progression of cerebral white matter abnormalities in early treated patients with phenylketonuria during adolescence. Neuropediatrics 1997; 28:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/14\">",
"      Leuzzi V, Trasimeni G, Gualdi GF, Antonozzi I. Biochemical, clinical and neuroradiological (MRI) correlations in late-detected PKU patients. J Inherit Metab Dis 1995; 18:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/15\">",
"      Bick U, Ullrich K, St&ouml;ber U, et al. White matter abnormalities in patients with treated hyperphenylalaninaemia: magnetic resonance relaxometry and proton spectroscopy findings. Eur J Pediatr 1993; 152:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/16\">",
"      Thompson AJ, Tillotson S, Smith I, et al. Brain MRI changes in phenylketonuria. Associations with dietary status. Brain 1993; 116 ( Pt 4):811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/17\">",
"      Bick U, Fahrendorf G, Ludolph AC, et al. Disturbed myelination in patients with treated hyperphenylalaninaemia: evaluation with magnetic resonance imaging. Eur J Pediatr 1991; 150:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/18\">",
"      Cleary MA, Walter JH, Wraith JE, et al. Magnetic resonance imaging of the brain in phenylketonuria. Lancet 1994; 344:87.",
"     </a>",
"    </li>",
"    <li>",
"     Bodamer OA. Screening for phenylketonuria. In: Phenylketonuria: Special Issue: Annales Nestle, English ed, Lentze MJ (Ed), S Karger Pub, 2010. Vol Vol 68, No 2, p.53.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/20\">",
"      Feillet F, van Spronsen FJ, MacDonald A, et al. Challenges and pitfalls in the management of phenylketonuria. Pediatrics 2010; 126:333.",
"     </a>",
"    </li>",
"    <li>",
"     MacLeod EL, Ney DM. Nutritional management of phenylketonuria. In: Phenylketonuria: Special issue: Annales Nestle, English ed, Lentze MJ (Ed), S Karger Pub, 2010. Vol Vol 68, No 2, p.58.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/22\">",
"      Recommendations on the dietary management of phenylketonuria. Report of Medical Research Council Working Party on Phenylketonuria. Arch Dis Child 1993; 68:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/23\">",
"      Burgard P, Bremer HJ, B&uuml;hrdel P, et al. Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997. Eur J Pediatr 1999; 158:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/24\">",
"      Abadie V, Berthelot J, Feillet F, et al. [Management of phenylketonuria and hyperphenylalaninemia: the French guidelines]. Arch Pediatr 2005; 12:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/25\">",
"      MacDonald A. Diet and compliance in phenylketonuria. Eur J Pediatr 2000; 159 Suppl 2:S136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/26\">",
"      Clemens PC, Heddrich-Ellerbrok M, Wachtel V, Link RM. Plasma amino acids in adolescents and adults with phenylketonuria on three different levels of protein intake. Acta Paediatr Scand 1991; 80:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/27\">",
"      Prince AP, McMurray MP, Buist NR. Treatment products and approaches for phenylketonuria: improved palatability and flexibility demonstrate safety, efficacy and acceptance in US clinical trials. J Inherit Metab Dis 1997; 20:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/28\">",
"      Acosta PB, Yannicelli S. Protein intake affects phenylalanine requirements and growth of infants with phenylketonuria. Acta Paediatr Suppl 1994; 407:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/29\">",
"      Kindt E, Motzfeldt K, Halvorsen S, Lie SO. Is phenylalanine requirement in infants and children related to protein intake? Br J Nutr 1984; 51:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/30\">",
"      Duran GP, Rohr FJ, Slonim A, et al. Necessity of complete intake of phenylalanine-free amino acid mixture for metabolic control of phenylketonuria. J Am Diet Assoc 1999; 99:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/31\">",
"      MacDonald A, Chakrapani A, Hendriksz C, et al. Protein substitute dosage in PKU: how much do young patients need? Arch Dis Child 2006; 91:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/32\">",
"      Koch R, Burton B, Hoganson G, et al. Phenylketonuria in adulthood: a collaborative study. J Inherit Metab Dis 2002; 25:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/33\">",
"      Bosch AM, Tybout W, van Spronsen FJ, et al. The course of life and quality of life of early and continuously treated Dutch patients with phenylketonuria. J Inherit Metab Dis 2007; 30:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/34\">",
"      Lou HC, G&uuml;ttler F, Lykkelund C, et al. Decreased vigilance and neurotransmitter synthesis after discontinuation of dietary treatment for phenylketonuria in adolescents. Eur J Pediatr 1985; 144:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/35\">",
"      Channon S, Goodman G, Zlotowitz S, et al. Effects of dietary management of phenylketonuria on long-term cognitive outcome. Arch Dis Child 2007; 92:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/36\">",
"      Rey F, Abadie V, Plainguet F, Rey J. Long-term follow up of patients with classical phenylketonuria after diet relaxation at 5 years of age. The Paris Study. Eur J Pediatr 1996; 155 Suppl 1:S39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/37\">",
"      Cerone R, Schiaffino MC, Di Stefano S, Veneselli E. Phenylketonuria: diet for life or not? Acta Paediatr 1999; 88:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/38\">",
"      ten Hoedt AE, de Sonneville LM, Francois B, et al. High phenylalanine levels directly affect mood and sustained attention in adults with phenylketonuria: a randomised, double-blind, placebo-controlled, crossover trial. J Inherit Metab Dis 2011; 34:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/39\">",
"      Blau N. Tetrahydrobiopterin control in phenylketonuria. Genet Med 2003; 5:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/40\">",
"      Bernegger C, Blau N. High frequency of tetrahydrobiopterin-responsiveness among hyperphenylalaninemias: a study of 1,919 patients observed from 1988 to 2002. Mol Genet Metab 2002; 77:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/41\">",
"      Muntau AC, R&ouml;schinger W, Habich M, et al. Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N Engl J Med 2002; 347:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/42\">",
"      Fiege B, Blau N. Assessment of tetrahydrobiopterin (BH4) responsiveness in phenylketonuria. J Pediatr 2007; 150:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/43\">",
"      The Pink Sheet\" FDC Reports. Chevy Chase, MD. 2007; 69(51):9.",
"     </a>",
"    </li>",
"    <li>",
"     Kuvan&trade; (sapropterin dihydrochloride) Tablets. Product label. BioMarin Pharmaceutical Inc, Novato, CA December 2007.",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration Center for Drug Evaluation and Research. Kuvan. www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails (Accessed on January 07, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/46\">",
"      Hennermann JB, B&uuml;hrer C, Blau N, et al. Long-term treatment with tetrahydrobiopterin increases phenylalanine tolerance in children with severe phenotype of phenylketonuria. Mol Genet Metab 2005; 86 Suppl 1:S86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/47\">",
"      Lambruschini N, P&eacute;rez-Due&ntilde;as B, Vilaseca MA, et al. Clinical and nutritional evaluation of phenylketonuric patients on tetrahydrobiopterin monotherapy. Mol Genet Metab 2005; 86 Suppl 1:S54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/48\">",
"      Trefz FK, Scheible D, Frauendienst-Egger G, et al. Long-term treatment of patients with mild and classical phenylketonuria by tetrahydrobiopterin. Mol Genet Metab 2005; 86 Suppl 1:S75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/49\">",
"      Trefz FK, Burton BK, Longo N, et al. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J Pediatr 2009; 154:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/50\">",
"      Somaraju UR, Merrin M. Sapropterin dihydrochloride for phenylketonuria. Cochrane Database Syst Rev 2012; 12:CD008005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/51\">",
"      Blau N, B&eacute;langer-Quintana A, Demirkol M, et al. Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria. Mol Genet Metab 2009; 96:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/52\">",
"      Levy HL, Milanowski A, Chakrapani A, et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet 2007; 370:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/53\">",
"      Giovannini M, Biasucci G, Agostoni C, et al. Lipid status and fatty acid metabolism in phenylketonuria. J Inherit Metab Dis 1995; 18:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/54\">",
"      Agostoni C, Massetto N, Biasucci G, et al. Effects of long-chain polyunsaturated fatty acid supplementation on fatty acid status and visual function in treated children with hyperphenylalaninemia. J Pediatr 2000; 137:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/55\">",
"      Agostoni C, Verduci E, Massetto N, et al. Long term effects of long chain polyunsaturated fats in hyperphenylalaninemic children. Arch Dis Child 2003; 88:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/56\">",
"      Beblo S, Reinhardt H, Demmelmair H, et al. Effect of fish oil supplementation on fatty acid status, coordination, and fine motor skills in children with phenylketonuria. J Pediatr 2007; 150:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/57\">",
"      Cunnane SC, Francescutti V, Brenna JT. Docosahexaenoate requirement and infant development. Nutrition 1999; 15:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/58\">",
"      Millward DJ, Fereday A, Gibson NR, Pacy PJ. Human adult amino acid requirements: [1-13C]leucine balance evaluation of the efficiency of utilization and apparent requirements for wheat protein and lysine compared with those for milk protein in healthy adults. Am J Clin Nutr 2000; 72:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/59\">",
"      Pietz J, Kreis R, Rupp A, et al. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest 1999; 103:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/60\">",
"      Matalon R, Michals-Matalon K, Bhatia G, et al. Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine. J Inherit Metab Dis 2007; 30:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/61\">",
"      Ney DM, Gleason ST, van Calcar SC, et al. Nutritional management of PKU with glycomacropeptide from cheese whey. J Inherit Metab Dis 2009; 32:32.",
"     </a>",
"    </li>",
"    <li>",
"     Acosta PB, Matalon KM. Nutrition management of patients with inherited disorders of aromatic amino acid metabolism. In: Nutrition management of patients with inherited metabolic disorders, Acosta PB (Ed), Jones and Bartlett Publishers, Boston 2010. p.119.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/63\">",
"      P&eacute;rez-Due&ntilde;as B, Cambra FJ, Vilaseca MA, et al. New approach to osteopenia in phenylketonuric patients. Acta Paediatr 2002; 91:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/64\">",
"      Zeman J, Bayer M, Step&aacute;n J. Bone mineral density in patients with phenylketonuria. Acta Paediatr 1999; 88:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/65\">",
"      Yannicelli S, Medeiros DM. Elevated plasma phenylalanine concentrations may adversely affect bone status of phenylketonuric mice. J Inherit Metab Dis 2002; 25:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/66\">",
"      Koch R, Azen C, Friedman EG, Williamson ML. Paired comparisons between early treated PKU children and their matched sibling controls on intelligence and school achievement test results at eight years of age. J Inherit Metab Dis 1984; 7:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/67\">",
"      Burgard P. Development of intelligence in early treated phenylketonuria. Eur J Pediatr 2000; 159 Suppl 2:S74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/68\">",
"      Waisbren SE, Noel K, Fahrbach K, et al. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol Genet Metab 2007; 92:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/69\">",
"      Smith I, Knowles J. Behaviour in early treated phenylketonuria: a systematic review. Eur J Pediatr 2000; 159 Suppl 2:S89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/70\">",
"      Jones SJ, Turano G, Kriss A, et al. Visual evoked potentials in phenylketonuria: association with brain MRI, dietary state, and IQ. J Neurol Neurosurg Psychiatry 1995; 59:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/71\">",
"      Leuzzi V, Rinalduzzi S, Chiarotti F, et al. Subclinical visual impairment in phenylketonuria. A neurophysiological study (VEP-P) with clinical, biochemical, and neuroradiological (MRI) correlations. J Inherit Metab Dis 1998; 21:351.",
"     </a>",
"    </li>",
"    <li>",
"     Blau N, Thony B, Cotton RGH, Hyland K. Disorders of tetrahydrobiopterin and related biogenic amines. In: The metabolic and molecular bases of inherited disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.1725.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/73\">",
"      Shintaku H. Disorders of tetrahydrobiopterin metabolism and their treatment. Curr Drug Metab 2002; 3:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/74\">",
"      Maternal phenylketonuria. Pediatrics. 2008; 122:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/75\">",
"      Prick BW, Hop WC, Duvekot JJ. Maternal phenylketonuria and hyperphenylalaninemia in pregnancy: pregnancy complications and neonatal sequelae in untreated and treated pregnancies. Am J Clin Nutr 2012; 95:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/76\">",
"      American College of Obstetricians and Gynecologists Committee on Genetics. ACOG Committee Opinion No. 449: Maternal phenylketonuria. Obstet Gynecol 2009; 114:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/77\">",
"      Schoonheyt WE, Clarke JT, Hanley WB, et al. Feto-maternal plasma phenylalanine concentration gradient from 19 weeks gestation to term. Clin Chim Acta 1994; 225:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/78\">",
"      Lenke RR, Levy HL. Maternal phenylketonuria and hyperphenylalaninemia. An international survey of the outcome of untreated and treated pregnancies. N Engl J Med 1980; 303:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/79\">",
"      Levy HL, Ghavami M. Maternal phenylketonuria: a metabolic teratogen. Teratology 1996; 53:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/80\">",
"      Koch R, Friedman E, Azen C, et al. The International Collaborative Study of Maternal Phenylketonuria: status report 1998. Eur J Pediatr 2000; 159 Suppl 2:S156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/81\">",
"      Levy HL, Guldberg P, G&uuml;ttler F, et al. Congenital heart disease in maternal phenylketonuria: report from the Maternal PKU Collaborative Study. Pediatr Res 2001; 49:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/82\">",
"      Rouse B, Azen C. Effect of high maternal blood phenylalanine on offspring congenital anomalies and developmental outcome at ages 4 and 6 years: the importance of strict dietary control preconception and throughout pregnancy. J Pediatr 2004; 144:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/83\">",
"      Lee PJ, Ridout D, Walter JH, Cockburn F. Maternal phenylketonuria: report from the United Kingdom Registry 1978-97. Arch Dis Child 2005; 90:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/84\">",
"      Rohr FJ, Lobbregt D, Levy HL. Tyrosine supplementation in the treatment of maternal phenylketonuria. Am J Clin Nutr 1998; 67:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/58/35753/abstract/85\">",
"      Levy HL, Waisbren SE, Lobbregt D, et al. Maternal mild hyperphenylalaninaemia: an international survey of offspring outcome. Lancet 1994; 344:1589.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2919 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-22FFA76FCA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_58_35753=[""].join("\n");
var outline_f34_58_35753=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mechanism of intellectual disability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHENYLALANINE HYDROXYLASE (PAH) DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Brain imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11759633\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Dietary restriction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Other therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3596819\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11759930\">",
"      Osteopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Cognitive outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Behavior problems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Visual abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Resources",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TETRAHYDROBIOPTERIN (BH4) DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Inheritance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Diagnosis of BH4 deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Treatment of BH4 deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PHENYLALANINE EMBRYOPATHY (MATERNAL PKU)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Clinical effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      MILD MATERNAL HYPERPHENYLALANINEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Classic PKU",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      BH4 deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Maternal PKU",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Maternal HPA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2919\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2919|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/35/34366\" title=\"figure 1\">",
"      Phe and tyr metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2919|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/6/10348\" title=\"table 1\">",
"      PKU diet guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/29/4572\" title=\"table 2\">",
"      Recommended phenylalanine limits in patients with PKU",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27047?source=related_link\">",
"      Inborn errors of metabolism: Classification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_58_35754="Doppler umbilical cord prolapse";
var content_f34_58_35754=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65216%7EOBGYN%2F79970%7EOBGYN%2F59220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65216%7EOBGYN%2F79970%7EOBGYN%2F59220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Transabdominal ultrasound using color flow doppler demonstrating the presence of the umbilical cord (funic presentation) just above the cervical canal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 360px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFoAdQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDF0/4e+HruXSoUjlMt3b300irfAmM25OAf3ffFV28EeGl8MxXzWt/9tl06PU0QXY2GMyiNhnZnIJHau10m+0iObw+YdatXmRdQsh5WnzFnebnJx0wG6mobhdAXwwbM+Jbdru2tItFVxZyhdol8wsF5JzsPOccVTvfQhK1ub5/e/wDgHhHxK0yHRtW1vTbcsYrS6MK7jngY74968+r074xusvivxNIjq6vfFgy9CCFORXmNVUVnYig+aCb/AK0CiiiszYKKKKACiiigAooooAKKKKACiiigAooooAK6rR/+QbD9D/OuVrqtH/5B0P0P86unuRU2LlWbH783/XF/5VWqxZEBpyeggf8AlWxhLZlf/Citefw1rcGkjUptJvEsDtAnaIhTu6c0a14Z1vQ4opdW0u6s4peI3mTaH78ULXYexkGitDTdG1LVILmbTrC5uorYAytFGWCZ9ar6dY3epXsNpp9vLc3UpIjijXLMfYUDtrYrmgVojQ9VOjyaoNPujp0blHuPLOxSDg5P14q7qHhDxFpunPqF/ot9b2abSZZIiFwehz+Io8geiuzBPNFa2leG9b1e3luNM0q8ureIZeSKIlR+NS6f4T1/UdPa+sdHvZ7NGZWmSI7Qy/eB9xQLYxO1B6cVo2WiarfR2z2WnXVwtyzpCY4yd5Q/MB9MjNM1jSr/AEa+NlqtpNaXO0P5cqlSVPfFAFHigUgZfUUv40AL36UlFGKBgRR/KijtQIsWjIouDLGZECKWQHGRvHFezvYxNrPh+/k0ZbKMeHZplRbbzCsiudvykfO+Mdea8WgJWO6IJUiMYI6j5hW9q+q+K7ebT5dTv9Vjcxie0MsrDah4ynoKhtxkpJmlKpyu1uv6WNjxzoU2qePprDRbRTNPbJMqBBET+63HKDhT14FdhfeBIdam8NyPZ3iSyy2VndrCgURxmAszHjg57mvPp/DvjS11W2vJdP1dNSuXPkT4bzZDjOQevSmQX3jFNdksIrvWhq7uDJAJH8wso4JHsKIRd3diSjy8qOiGmWcviT4dWNzBG1pLGY5Q4C+YBdOvzHjPArupithPb6tq3hySPU0jvYIrews4yWjWZVjcowIPy55xXjTaL4mvZJonsdTnk00YdWRibcE7se3JJqlJr2rm/S9k1S+N5EuxJjO29V9Aew9qqMIX5ZbFKcWr+v4mn8Q45I/GeqpLIsjCUEFYljwCoOCqgAEZwa5rvTppnmmeWeUySyEszOclie5NNHsaEktjCCaikwra8N6rc6PeWV1ZeSZPtQjIlhWQEMADwwIrFrR0qxvNTks7PS4ZZ72W5PlRxDLFguePypvYtaNHrusatf3esfEu0FnZvBpmnSpb+XYxjy8OMcheuC1VPGPhXTJdRsr029zB5cmmCXzIxHbzpIqgqhGDnua4HVk8WeHpbn+1TqmnyaqhM4lcqZ16Hd6jmqAutb8QKLM3N9qCwoZhEZC4RUH3gO2AKiFOLb5i4zi15r9L3PUvGlh9vuNElvdDtra5j1qa2McUZjDWiMoVmx1HPWqHxft7UafYyRQBGjvLmAFrVbc7FOFwB98ejVxcg8W3N1JayHVZblLTc6MzFlgxuyf9nHNVtQh8RappEWraiuo3enRLhLmbc6IOnU9KylCpaz0POVKpJKLa0d/6+4xG717d4btLCTRfBmp3Fvaq2jWkdxMr7QbgSuyrkbfm+YAV4genWtgya7FpNtdl75dOkItoZMkI2w7gg9cHnFaTXmelTlbTzX6/5na/FZp4dH0mNrSOK2GoX4DR26oXCyYUbgPTNVvFFlJeeB/CE1hoMlpkXSERxMxbBTDs2M88nn8K5vUE8UXt5baNqJ1Oa5Y+ZBaTMxOX5yFP97rVzWrjxp4fS0tdauNXslMZ8mGeVhhBxwM9McVXK1pY5qqc9u50msmeX4P2ZvtOjtbiGaARhrIQ5QhvmV+r5715j/EKtXer395aQWt3qFzPbQDEUUkpZUH+yD0qoDkg5zSjDkW7Y4R5ZN93/kZkI+VuP4jRRB91v940Vyy3Z79D+HH0Pav+Eo0ea4gvLjX4hd/bvtLvHp0ilFwo+TDcH5enSqz6zoOZZU8R5kFxuiDWEmDH+8zu5+9+8/SvJfPk9R+VL58nqPyrobTd2zyZc0nd/wBf1c0viHc2t5f6tcWMry20kymN2XaSoVRkj8K4GuqeQyIVcKynsRkV33ww8AaT4m0vVNU1yeW1sbRtqLawK7yEKXYDIx0FKpKLd2wpx5Y69DxeivcfiH4K8I6P4f8Atnh6bUZblJ4EkW8hjC7ZYi64wPSvMvLhPIhhIP8AsCpsh31aOborpPLi/wCeEP8A3wKPLi/54w/98CiyHqc3RXSeXF/zwh/74FHlxf8APGH/AL4FFkF2c3RXSeXF/wA8Yf8AvgUeXF/zxh/74FFkGpzdFdJ5cX/PGH/vgUeXF/zwh/74FFkGpzdFdJ5cX/PCH/vgVPZWcdzcKnkQ7f4sqBQlcNTlKK9PXQNMLqr2rIHH3toIBNXo/CulNHsW3XzgDuL8D8K29hITdjyKuq0jjTYfof513i+ENGh2iSGOXoxKnH1H1rQtfCmlKiMbUxWjYKtJMV4J9BVwoSWopXloef1YsiA0pIyBExI9uK9hsfCvgia0P2ixvI5mbYhW6Y7v9rB7V0Om/D3wOdPVjby/adwV918ykg/7NFu5HI+hyniKRp9R1jX7bxXYxaLcJB5NgZjIXxswjRdVAweareMtU0kvZXPie107WLlrid0i0m7MSiFgChYjOGz2PNetXnwL8HLA8iWV5HtCkH7YxD8U1fgf4OdYX+xXUeYsuDePjP1qPtKUXZdi1G19DynwT5dyb/UtDmg0uxt5Fa10q61VV8yYKQWYtgsBnpVH4N6lo+l+I5J9ZvktdSe6jSCUIGjVdxMnzZwoPTNeuXHwQ8JLqqrHZXRghUM2bxvmP17UwfBfwTcSyLbx3sRC7trzvtHHrUxi1K9xJST5/KxwEuoWY8ITTw+ILd7GDSruwawL7XknecsjBO/BHPtR4r8R2d34e8V6dZ/2fHdItopnExZrqLYu4LlsZDDsK6M/BnQEUyPMVtzhsmZvpV5vgj4baxxFNJ9p7GS4IXkcHNXGLvuRKnKS1f8AW55xpivq2g+Ef7L16y00aSGN9FLeGFs+du3Bf4sr6V2WiaxYTWsV9ZnRDZLrN7cuLm9McsUJK4ZEBG7OD1FaUvwY8P6Uscmp2zzwOv8ArIrthk+lVo/hH4daT7VLpOpRWfAUeaxznpzUzpuVrMuS5m7LT+v8jjo760FtFodjqttbST6PM0Fx5+xBPNPvIZx907QAa7DTh4XXWtNh1mexvb6HTURY7jUEuIh+8+YCRuOnPrSW3wq8MLqRt73TruL5g6qLphuX0ye9LB8HvD11eXBiSS1gUjHm3DEqDShRlF3bukSlJWS2/wCH/wAzmBPoCaVb2K2WhKsunalJLKQjSpIrt5Khs8Hpj1rx0f6tMjnaM/XFfQ118GdIFz5NjDJcKrMHkEr4XHetHTvgv4ZjjuFu457mWKMlmW5ZVDenrWiVkNptfL/M+aaSvpqL4O+FpEZorG6Y7ARi6faeueatXHwi8CWtvbRXVleJeSoGP+mttBPSgh6Hy2aK+jtS+GPgTTGujctK0wT5YUu26gdc5rjLvw54XkWT7FoeobU48z7Q5B45xzTUWwSb2PLLRmUTsjAOEUgnpnePWvWvFaXmPDl5JqGgX8sGleTeefcxykMJN+Ao5ztwOKz9Y8KaUtvZ3VhptxHbzoI7hTOXKsOfwziodH8EWHiDVIIbC2nt7V5ArzyOcKO5pyoye46abe2zOvj1e3mu2+36volprF9FeQ2s9jKRHGjxjy95/hO7PvUJ1COTxFcxprulKJNIOnLqAkG83fkBd2/rtzxnpmqvjnwV4N0Jbaw05JLm8LeW0/2hsZ9cdAK8g8S6edI1J4Ipo5ohyrLz+FRVpNe/HRDb97TRa/1+J9CW+vaNLby2NzrllNLaSWwu5zdNH5irBsd0YffIPavNPhna2t1d+LXMdhcmGyMlrJqS5jVvOwGJPTg15eZnz2/KrVlrF9ZQXkNrcNFFdxiKdVA+dQdwH5iso8sdd2apuLbtv+Z7Ppdx4YtdRvo0s9CuIJdUaMmdQQkYtyW2ZPC+YMCuA8eS2lxqdlc2VvY24m0+CSWOzGEWQg7hjselcaZ3OTxz7UefJ2x+VK0XPnFO8unb8rFyux+Fk8Nr4z0Ge5kjjhju5CzSttXHkt1NcF58nqPyp32qXywgIADbhx3xirck1YhRkmmj07RPEFnfXPiTUJ9O0m3eHR2S1ikJkUy7wMqHJ+Yj0q98FDY28XiC7ubqGG4dYrKLdaCQL5rYyOeh5BryHz39sfSjz5OeRg9aScdh04cnTpY+goNVOr/E/wAQG01bT7XSI7KW0ImKWoc+UyIvPXDVmTalZ23wulsZLzTmkj0gWZZZ905uFlztCDgrj+LFeIGdyRnH5Uec+c8flWntIrToJQdlfdf8H/Muv3wevevS5v7Rn+FOjOuq6a19baiZooWu4w8UbIEXK9ueeleT+fJjqPyo85vbP0rObjIaTvfzT+49b+KOj3Go+IrS9i1jSpsWVpFLPHfoW8wYRiMHPGc1fsb/AEzUfHGtRyy6ZK9lBHZaS2ouGt9qMA5Jzg5AY/jXigmYf3R+FL5z+2PpST1TuOCcXe3f8T3fTLjw5a6PIsll4auJ8ajLkqDyjAxKuTnB5wO4rzv4jLYr4zv/AOy0tVtG8plFrjywTGpYDHHXNcZ578AYH4UqzuCOn5U5cjm5oiUG3cgg+63+8f50UlufkP8AvGiuaW7PaoL93H0JKSuv8SeD7TStIku7DxFY6lNbXH2e6t0QxtG3I43feGQeRVSDwndSeCbvxLJKsVvFNHFHCy/NKGON49ga1WtvM8uPvXa6HOelddoXxD1/QdP0+x0mWGCytGd2hCZW4Z+vmf3uOK5EjHWiiy6oq9k0eh2nxa1q3utSn/s3Rpft/l+YkttuRNibF2AnjivPWcuxJCjJzgDApO9J60E6C0g60dqKACkNLS0DE/lRRS0CEozR3ooAUAkhRzmtrSLViU8twFOSxPFVNMtJJZ1ARgzA4OOldEmiXQEaxyiQsMjaO/vW1KDeoPQvW4ZYLaO4csHOVz2A71radb2lzqItluAs6/xF/kesKCR7eSNJlZp1JjaN+AOKVJYI32x/Lg/eY5INdqYluel6VEkVrIdsTTK+SjJnIz1Bo1Cyj3osdvIxJ5XphexGa5bTdSuNOdnjneSLGF2titiHXI5biIXEc0SM2c7uWX6/WqsFrias7xtZpZuoljbAY9hjoatafcxz+bLcs4m24IA7jnNWZFt0tvtFj+584hRls496ebO2/sWS4u5QszSFUk9R70NIS0TubWm+K9QtNGjuFvZJ2uZlhSNm4ULyxwfqBXW6L4zmbTYRqaRO7xMmYmAC4bjIrgvEOlL5kMe3ctlCm4RnaNx+Zj9elY9951tK4t1DJhX2oD696y5Iz1sQkm2z2i38ZaZLcPcQ3f2e4YrEwdfl6cevetEXqXMU7/2haTvuCukZ45HT26V4HDOZZ5DD8u5/mDdBxx+tbU0bR6dHaOgebzVLTI5IznNDopOyYcsu56wUWa5SycIqmNXjHJHXGM9Kv+VMRPDeMfs0ZTG1Qc46j6V4bK99aatFMZZ4bEkKCspAHP19a0X1PV0WN01veTJs2PJjgmlKm9gUp9j3DVXt3hiLwxSaeh+UeprDlivZLcSyM0cQbCQ5OwYOQa8xv9ZvlnijfUZYo/mXcDlTtHXFRX3iLVTp0bWeq3rbjsyy4AXHUUlSaViXKfRfiesww+ZfG4uzE9xhVzCuWAHtWjLaxl2ljEskbrgrtAAz0NeGRa7qlvardrfSrKwb/locvzjp07Uuoa5dl3C3N0yzrvLGc/Lx068UezZTcnorHtNwY42kgt7eVZWGXw2OT/8AqrNjjGZLp7K3ilEoJEk2M9hnHFeLxavcRWpkuJLyaRtokkMjEAdOtVbW9lS8IvZpA0Y3Nliw9h1p+xfcn2cm9Wez6tq1yHhRL+yhfkMsYyAM81kXFvp1zLdXHiDXZLjCArGqYKr7V5dbzSyXqbZ2RHcIGP8AF361X1C6kuLiVmkZlBaIneT34x+VVGlbQpQXQ7GSLwvE7vI8ziYgIZW+6CeM07UryyW8mt7a5ijjhTMaRLkP7GvP7y7Z4pVWUyYcBWlXIwvvTotQeMKJRDPLw6lM/dHXNbco0ju7KGCaIiS0MFlcNulO8fKQeCPSq+t6oX26dp8BsrW3TEpDgc9jxWFFfagNPg+1sI7DczSouOVatrbYanpUt1bT28lzFiNwF5KY+U/0rNJRleTE7p6vRGZOmn3GYo7aSRURnE0rH942Ox+tcRrFg81jHb3EESvOhII5ZSDXpVnpb3Nup8y4doW/dqRtQZ/nXJeOIkg1iWQAG4WP7i8IDV3Q5bnj1zC8E7xSjDqcGosV0OvA3iq4hVJIlwSv8XNc/wCxrzqsOV6FoSig9KO9ZDA+lFFFAxfeik+tL2oA1NQ0DUtP0yz1C7gRLS8GYXEyMWGO4ByPxArLxSYA7UvY0A/IPaijNBoAKDRmg0CEpe4pKXvQMbb/AHD/ALxootvuH/eNFZPc9aj/AA4nY+J9V8J3Ol3h0ix1A6nfXf2iWW8dcQjJbam08jJ71dn8d2d34BudAuNKhjnSGC3t5ombBCOWJYE4Byew+tb2u3MWn+PtAvNP0S2WKXRYJWh+x+esWVO59vcgY5Nd5caPp66m0MXh+xmtNUvZ47qb7L/qkW2VlK4+5ySa19rJyu9P+CeYofu21otdP8Oh81Mwye1NDKQCGBBr3TQfCGmaHpLx7JLu7F5pPnPcQKY/3j7iEPcYOCK07+x0jXdY024T7NKLLXXSQjTVtQsKIzspA4dfl6msXXjb3RypuOv9dP8AM+eNw5ORx1pTjvXtUt8YJdHt9I8LadqFjrWnS3d1i3DMHdnziT+HbgdKyvgL4ZTUdck1W9sUuYLWQWq2z7WG51b5mB64xVuajHmEqUnfTZP8DyntxS9xU95E8NzLHImx0kZSOOxNQCqW2pmHpRQOKO9MAo6Ud6SgYvatPQtOF7dBpQTAp5weprMUbiAMZ9637W5S3hiSQbfLHbpk1dOKb1Baam1HppgmRoBtZjhSW6Ct7StLu9Pmgnjl3NJzIjsMZz2rlP7YjjsuY0diMZBNUY9Yl81VmZwo/h64ru5oRWhPU7PxsunPM1zb/LOSWZeoziuRSdCgYg7hycDg03UtQju0TCFXJ4JPpVFY2jAZsHeSV5rOc9dBRVjqbS6gnt3jLCE5G0ZPHqa6nTlDpaFDBOFBUrvwSM15zlFfeQuHIOc8g46Vfsb0xGUziNCeEIHerjU6MDvXtxMS0CSRqSzpHG27aV6g1ueH3W/j06BgXhDtJMGBGEHJJFcRousyWPnLnfGGD4IGcketdLo1/dDSbjU7SQo1wy2UauAAufmc/kAKuUtAei0Og1W60d1la7d7aS4bcJYn3g5Pp24qqht0EsaXaOsr7UkZuce47VjRNC1p+8iQSwuT5u3IOKoR75ppLgjy5Au8krxz6D6U4w0JSUVY7FtPBCbbiIhCSw8xR8vY/nWnHAbmRmEHytHkncF+Za4BbKB9N+1T3XKvgYVgdvYGmvJdyj7Za3G2PAXAbHtmjluyrdDfupW8ueyc75JGBjXdnH1qy8O2a3M+lbraNgSI+uPXNc4DeXd632pleRBuWXnC+2a1LzUWsopPLUXczBcujZIx7elO1tA2RYun0i9XzrdLmBYiWdpW464OBVi7ureNxHBdTyWTRLkuoxnPIFctPqN5PfM9tZLvljwybMqoPf2qhNebb9t/lxR7AhBztyB2oYl5nYLYabLZvE7u0wcNGpdVAXqKgtEmWCTyEhkijRg5BDbOe9YUerPMIVjtoVmIBJ29QKmXUfOiuY2dobmYbAUT5Tn1oSHY2boPdzpbO8QSdFPlx89+ee1VbqPTIrqVlSJXj++ZXOSelcxFNf6fdyyzHzImYYOP4cVdgNvJPNGbMyead/mkkbRj0PvT3F1ujQSeO5tVgtLM70ldzh+VwKy9StYEkuvs8piUBGLMeQ3eori3NvCyqYYRIC293wx4qncamzMlrGsapja7OuSxxwaLoErlqOONt0M04Lbjs+YhcEckmpNqWyMBIGZRsQBcgrms5HENyEdVDbtjAn5cAdai1S8hupFayQWzIhSQnjP0pN22GzR+0X+qNLbB2jRVAUBQAyjqc10PgNTYas8r5FhIcOJOAy+vNefm/JgO6dnlQbFBGMVC+oyP5myScsqhACTjFQ5LqJpPQ+hdb8R2NvJ5UMpMOzCqSNh9G46ivFvEt1FcXpRZPPJZnLEY/AVFYag+paS1unmG+sFGxupaE5yPfB5qCzMEkhM/mTT+V8h6YFTByadzOCd9VsY2oDyhujIXcvCnrWDPC6je3Oetb9/J56RpMxLJlcH0rIKDy3J+bdwPasKsbmyKNJU11A1vIUfv0OOtQ1z2sMMUUUvakMSloHJooAPSiiigQUUGg0DCkqaK3mmhmmhhkkhgAMsiqSseem49vxrW0/wnr+o6O+q2OlXM+noSDMgGDggHAzk9R0FOztcDEoHWtjxB4Y1vw60C63ps9m04Ji34O/BwcYJ59qqarpV9pN0lvqdrJbTtEkwjfrsblT+NK4dLlC2+4f8AeNFFsQEP+8aKze561D+HH0PT/FbfELSGj1TUNfN1JYztYiSzu0la3duNjBRxn3rlItf8UwrqUEd7qoE53Xi4b5iRjLccZHeu3vPiTbzeOsG0sU8OjV3u5HtrfY1wOQkj9yRnPY1a8X+PLS4u9em0nWI1lu4bGFHgjlAkVHJk3bhnp19e1KU7y9m46HkwjzRUpdf8l+pxFlrPi2Swkthqd9DbWUaXMcM7FfuMNhQEc4J4q3d6p471ayvtUvr/AFKSHTEHnSTfKUWU7eBgZzzXfeIfHWhXfi1r6HWUlB01Ii7RymESiZW2hWG4Dauaq+OvHWjarp/i+zsdbnk+32lsYWKSGN5Ucl1Xdyowe/FONNXtFClVna7ff7zidLPjO18Dx3el6jcx6DPcnTfJjm/jPYr1AOazdT0nXfBPie4gy8Oo6cFkaW2O8IGXIOcY6Gux8C+KtE03wlb6dqsnmss95cmE7wFk2IYGyo5y64/nXV2vxG8PHTdYia6hF7cWsYd5opSLgiAKy/KOobP3uKqCtG1tDWrvzRf9af8ABPFF0XUJ9CuNb2D7FHOkLu5wxdwSMA9Rweay69f8feMdG1jwXf2dhqrTSXGoW9xb2Ztygt4lTBQHGDg/zryAnmrs1q2YRlfpb/hhBS9KBSYpFB3ooo7e1AC1IJC2QzEcYqKpkBSRCp689M00M3LW3SUwl4vNRkyUA5+oqhex7ZpR5cir2z1FbFhc+QsJnZ02jClRjOakvIZdRZLmMDaDtIbv+VdSgnEl7mFFAjFQ7bFC9Ryc1KpKwKofcQflPrVm4sXgkDxRhSM7gTUltp888kARQnmH5WJ+UH6VKi0x7lVDDNCceZGyntyCaVSI7kLJiRVYNzVx7GXTb5475GSRRyoXg+4pJoFljdYzGdihzkEEmnysVywLgJczlV227pjK/N9K6PUpza2OmaXIQi2kYnlQDJ82Q7uf+A4qj4X0mfUNStURESGRgZCTxtBy3B9gai13z7m7v9WmGRdTEqoPQA4H6AU5XbSMpu0lH5/1/XQUarEbuQQtIkbnaCThRnr0q2NbSMBFlLKQ25gvT8azbudJ4tPRIFAiXJKpjcc96hxGi+ZPEPlZg678Z+lb8zNDsNO1aGWykEs6CAHCl13Z471TsdVgaeNYYo1TGN+wqrH61y9zdRrayJbmWMPhmViMfQVnRajdCSNTIfKR8hW4FJ1FEdrs7v8AtUpdRRWqtLM+WI8zPHpViy1R0kiaZBCrkxsm3OPeuJtb4W140yGPvgbeMU19UE0rSlc5OMjOB9KftExJHfardSQXVrIu5ECkSSKvDDtxVCW/FzdRPcbGtl3NtRQck1mW/iB4bdR5krRhdoRmHSs86rbxzvMIW8rZjaWPX1qnNWDZnWtaJqOoQT6V5iiOPDbiAMfWpLiFbreVvbWCaIjCxg5Pbk1xNvq8SSF18xF2ldgPB461DNq8ckpkjRVYJzg96nnjYGjo7u+8iK4t1nW5VcKjb8Z55qCS9iS3MT3PlvJzhBkr7VyguRc4YgBY8scdaQ325YSI1JXI6c1HttB27m+0st5FOsvzNGm1ecE4pIb4R2+G8p5s4yOvTisP+05kDMFyMk5bjtiq3n7f3mcAgHGKl1VuI2dQuTNdSqrLuJAKq2SPU1G9++9mKokWQOfasoFBLkbm3ICSD3oupd+8cH5f4RUuo27gjVe73eXkMFPJbii6dF81gkhyAwOetZNnNvURyMSFX5R61OxP2YAuVbHCk9qSnfcp6FvS9VuNN1KO8hz5S/fBHDg8EVf1q1FrfiWzZvsVwnmQy5z8vdfqDxXPwSJykik+gHc12/hrT31/Thpaq32iMGe3YA7c5+ZDRFJvmbJlfe+iOXsdNlvb3am8x53Ftvb6118XhFY7W2nkhwksmF9frUraV/YztE9yhYASOVOQB6YqG48QPdB1gJaJRlHZsEAe1bxgt5BzJrQ5zxTA8cIhdVIjkOHHX6VyjcHB4/Ct7Wb6bUJkjXOxGwMdz61Xu7AvaGWCGTfECZD2x2rnr2lLToKOiuzIpaTiiuY0CiijvQBq6hbaRFptlLYancXF8/8Ax8wPamNYjjs2fmrLooxx70LawktRaT+VHbFHagDqfDXjS60Hw5rGkQ2lpMmoBf3kkSkx4POcj5v6VueBvE/h/RfDVwL6+1A6kySRfZkh3RjLKQVbPy9DxXDaGqSa3pqSoskb3USsjDIYFwCDX198VfAfhPTPA9xc2HhzS4JhLCd6W6g8uo6/QmqnUcqfsnstS5x5+WT3dl+K/wAzxHxr428Kare6beWk93dNYzvdrBJbmNZWaQEoTnjgda5X4o+JdO8UeIrXUNMilRfsUUUm9icOMkjn0zjNfT1z4I8IRXMyjw1pJAbjNsK+c/jnpthpXxCuLXSrOCztRawOIoU2qGIOTivLoYylWl7OCaaN50JUacU9v+HPOLc/If8AeNFEHCn6miuyT1O2h/Dj6HsHi7wvoF34tsvDWiW2kaa8t7Oj3MN1NcSIsYJxIhHBx2Ga574d6Ho9942vLK/NvqumwWtzKjuzwI5RcqxI5ApsWneNU8ftfJotwPEE7zXYhaDrkfOQuegB/Csgpr/gjU5Vu7GSxu7i2kgK3MWcxyDDY9+etaWPHp2STlu1+J6JqPw007X/ABFpun6JNY6VcPYRzzxW7S3UO5ydrByOhFZtt8L01P8A4Ryz0y9jF3Nb3Mt/KwYgeXLsyB7Hiqun6z8QfDehW+pppjxadDAkAubiyD/IjZU5PIx61h6X478QpeWUVt9muJkeVIoWtw/mec+5kZf4gW5ANOrF8l47m75HJJbf8OaXg7wpYwfE690DxKq3lrZR3SymIkBjHGWDDHPpxXRR/C5JvDVtpqW3k+JTqX7yaTICWrBipxnnKrmuN0P/AISjUPFuqTaLpQm1d451uoIIABGrjZJ8uflxnHtV3XPFXjLw/q7W+qRLZXq+RMVlgA3LHH5aZ55XbkEd6n3pLT+tDNuPLG/ZfndnQ6J8JhZeNLa08QX9nLp7Xf2eOIb1a5/d+YQMdMA968nvY1iu50T7iyOqj2DECuxtfij4gttRku7X+zY3aQSqi2ibI327SVH8JI4OOtcXPK80ryPjc7Fjgdycn+dTTU0/eM4uWz2I6KSitShfWpVjKAGRPkYcGowM98VMkxEYiIJU/pVJAXLSyiaRxI6kKoYAdTV+PStrScFSh+UtT9MvIigSZBIdu1crXo+naYl7Zyfaoo0LINjKMcjoc1006aauD01PPzZyuYzbyMUPK8dx2rf0m0kbdHKv2e4WPzAW434rRg0OaK4EN4yOUbzNm3P61q6oVbTrZWjEckwIi8s/dHua3jET1V0R2+m2up6PHFdNDbTuu5Jt2d3t7Vw2pq2mSmNpZGCOQxU8H0Iq7q0F1bWs0MTxnB3qQeR7VzdxLd/aCl5I4GzGCetEpWWu5PW6Ne9v7+9t0tpV80phgxIzj61HYTRR3aRNGY5CCr+Z0Y+lY0QngaKdDJ5bdCR1rT877RIGuNxdXBORjAxWUZX3KSR2XhPWp9H0/V7xrVDAoS3t0bDB3kPzY/4Dmsa+vY7qQJbq8TGQkp/AB6AVX11vs2k6VpSOgd5PtkjdMGThB+AH61atfDurLayXNt5c8VvIpbDAk59qvmV9DGmuaTm9tiyukrqFtaWtvDL57NtkZlwBgZ4qe50RILRIw6DA3kSDHPcZqNfEmq28uyQJbgsdpAGRkVRm8Yz30JtL7ZIiHABOM+tXolc0euiMm+swb1YQoyq/MVycYrLaE+WC5O0kkADrWv8A2kJ5HmgjWMZPGecelYd7HLFmVPMChsDPbNYTXVDWmgyRlMv7xTgDAIOOntSI6MwTLbM8nPrVZZnUHkHJzzzSqwDGXPOemKx5hlxLlNzOpJ2cfN6VAkjqZWAyuO7dqgLqM5x8xyeOlSkIiuFKtu5BNPmbAkmcqqknCn+E9ajt1eXbDEilpZFA9znAFPsbWS/njgidfNl4RWOMn0q94RRf+EosfPUeXbu08gPpGpY/qKhyXUcbXsyvq1rJp97dWpkRvJkaIlBjJFVUkYzAtjb3IFNvLp7q4kuJHYtM7SNn1JzUAOO5olJX93YSTtqT7shkyWjxwRSGQFUWQ5UDsKjDfL2+tM96TY7EwYLkKflI6HvSPIMnYMZ9Kj42YxznrQODkDtRcCVXKFCO1aEKC+HzsI1QY3HvWUSW9a0dPCHiU7hjoRwKcXqBp6dBGUYKu7B+Vsda7zw74hn0fS5otOjjiuGICzdx61yUesMYYra1t4kKdTjsPerkInj01pTEhLE4ZjxXZTSRMtU10H+KporryrqAymC6j5x2lHLqf5/jXM3EqLAqxPsz97nk+1bOnObqSXSpQFinUsrjgJNj5SD79Kw47ZzcyWzRbZoSyvuGcNWUpTk25GdNNXjayKqTvCwkUA5PGe1dJodzNJHcBU3lhtbPGQfaq1hZ7YnllXfIowoI4p8GHuDtLq5OWPQYpxTW5r5GBrFp9mvJBGCYt2AcdD6VQxzXS3scVwrKm9488bf73rXPXELwStHIpVl9awqU+V6bCT7kYoHHWkoPoKyKFozzSCjtQAvaigYooGX9B/5D2l/9fkP/AKGK+4PjN/yT25/66Qf+jFr4e0A/8T7S/wDr8h/9DFfcHxnP/FvLr/rpD/6MWpls/Q0W0P8AEvzRWv5v9Mn5H3jXzF8fX3/Em4P/AE52/wDI19EX0/8Apkx/2jXzf8cW3/EK4P8A06wfyNfO5cv9ol/XU9rMafLRg/62PO4fun6miiH7p/3jRXuS3OWj/Die+vIYtYi02XX9IuIDp+oJFfyamjNLNKoyXbPyc9BXDeLpoNM8N+F9Gu9QtNU1Cymlmnltp/OVY2ZSEDd+hPFcHLbzQxo01vNHG/3S8ZUN9MjmkWN3DtHG7hF3OVUkKM4yfQV0+71R53Mk07bfo2/1PYtYu7aPXvFXiV9f0670XULOdLaxW7ZpMsgCKYsfLtIre1Obw9oWp6bcXMeiW1zbzac9v5aYlBKKZWk/2cHNeCLYXckDSpZXTQbSTKsLFMdzuxip9Rl1TU72Oa/F3cXM6qI98bbnVVAG0Y5wABxRCWnvamLg+ZOLta2h7C2s29jrHia9v30G7tGsrz7OlvMqm4zOCFYqQckcjvitfT9U8J6lrmoXNxFpEiNp9ulnbzzoqJD5bb03SZ+cOfrXz0UdQdyOoDFTlSMHuPrSwwyzyhIIpJZMcLGhZsD2HNRNc10nYXJdW8rHpnxQOjjwx4bj0pdJguBGRPBZtHIwwo+Z3XnJPY15iad5Eot/PEMgt95j8zYdu70z0zTKaVhqLTd3u7hR3p0aPLIscSNJI3ARQST9AKlW2keIMFYkHaRjpTWpY23l8qZGIyoODn0rorSzFzaySW4WR0+5tHNZlhpMlxci3kDRSuPl3Dg10Gm6XqGkztGN8bdeehHtXRSi+q0EzI03UJbFZYp7RZQD91l5WujstSW8t/LjllSMcbCThafqOlzXsT6jHDIrYw2Ezu965dJdR0p3by2VW6bxjcK31p+hN76M3ftNy1z5yTMoZTzv54qa1v2uljTe0dxGMLgEjNcvcXdy/lPGmwjP3RxVu11G5gLF2DlxzxS9qr3Q0uh018lze2N2boeZJZYPmr3Brn9Rgt4rlCryyjALmQZHI7V03hq+ntJri2lt5J/tKEMu3fxjisF4ndb2Ka1lDo2QyrjA96uS5lcT91mY0g2pHtkV4yWAB4H4VfsNLvdX1G0jMoeO7lVHIIyq5yxIHtmsqNJXuxlNp9XBGa9A8A6dZ3EeoXH2lLWaBPs6OwyBLKMD8hk1jBOTswm7RckcN4juVvPEF5OvMDTFIcHoi8L+gqexmu2QJFOyO3O3OM11mpeFbHSo4VubmCQF9xZG5IHtS+GNIs9Qu5djQrH5bMiz/wAWDxg1SpNO6JpLlhymPLDcW+X1ONZJAwCHGV59apeI9IWza1nS7s5Y5TnbE2SpPqKu6xJdxiW1dECq3JGSRWLcQqsaMp3LgZBA61U9FYa1KfVEEkiDy3BOBz1q1eFbqFhHJJtQkndwDVOENHMyMud/bPI962yrRx3EKy72KDriso3ZT2OVbOcHgikUHng8U6QnccnNNBbqDXO9GNG54et7S6URz2zyNktvOcewroZfD9jsIS2CsRgEZOKzfDep26W8Nod3nY9OCa6iJi6n17VwVasoy0PoMHhqVSn71mcRcaLc2V1afZpyZd+5GbjaRzmusPhuRtO1PWbZo1We3FvIwPyQyMw3N7ZFXlg3HMmB9az9W0qC8t2hWYxx5DlUOASO59+1XTxklpoTWyqCi5RVzjL9tOt4GtrRDcT5Aa5ckAY6hR6e9ZZNWNQt/st7LCDkKeD7VWrqvfVHhOLi2mFOGB1AIrY8KaGuvahcRT3Ys7O1tnuri4MZfYi46KOpya2b7wdaT+IdCsPDetw6nbauo2SmMo8TZwwdO2MZp9bCvrb+v60ON/lQCBnNdfrHhbS00G71Hw9rj6mbCREvY3tTDs3MVDKSeRkYrf8ABfwytPEGhaTfy6lqMU+oCfakVgZIY/LYjLyZ+UUPR8r3G9E5dP6Z5iODkitXSn8zfEYPMU4zg81ueFvC2k6h4e1TVtd1ufT4LG5S1zDaedvLZwTyMDitG10MaBrtzBdSh7ZI0mhuFXb5qOu5Tz0yK0pRc3oNLS5grFF9pZVDoVJATuPrXU6NaXVzYOphDBU4kk+6tYF40V5dSG3jKfMTuzy1d1Yw3g0FUit9pdcl2BwK7IRtLQz+zc4eayvb9ppohsEJAUxnpg8Gurn0uO80sapAspvZEC3eONsn97HuKuaBYKkKLd7t5YkxJ8oPuxqifEb2Wq3NgvlizumMU8iciMYODn2NDpw5uefQipe1kzmbpWN1FHHc5SMfNu45qjNaSSK3lzs4OSXJwAKZqtrLaX32e8l+eMkMV/i9/oabE5+yOA2Is4BPU1m5qT02HGSlHmTKHmyptWJ2AQ4+XpViTTpbi1eWRszjlf8AapXEHlQqp3DOSauW94z3UZ8plgX5VP8AeqEu5b7HMkdu4pK6DxbYQwXSXEEkWJhlo0/h4rn6xnDldhpmrqGp2d1plnbW+jWdnPBxJdRM5efjqwJx+VZdIKKz8xt31F9qBSZo+lAGhoH/ACH9K/6/If8A0MV9tfGeQf8ACubznpJD/wCjFr4k0D/kP6V/1+Q/+hivsz4yTZ+Hmpc9JYf/AEaKVrqXoaLRQ/xL80c5d3Y+0y8/xGvn/wCMT+Z47nYf8+0I/Q17Hd3R+0S9PvGvE/ilJ5njOYn/AJ4RfyNeJgYWrSPpM1X+zQ/rocdB90/7xopIBlTx/EaK9WW55dH+Gj3i/wBO8TardPYeNGi/sC41f/RFuWUO4G4qIiOikBRxWffaPa6VoviSWCwbS7u88ONLc2DSF/IcXKKvXnkAHmsOX4Zat9msJb2/nS3M14jM4LLbrbgnePm/ixxiqur+D7fT/CcWtXPiHUZLq8tI5xCLGRo2DHhGmzj86uOibm7v+tjymm4K39aWLenavf6Z8I7kXGoXBg1HUVsbeB5D5aRIQ8px0GSQK9C8Xa1daCP7Q1iJbiL+1fK0lImQN9leDBKY7A4rxC+0Z7fwdpusveM8F3dT24tyDiMoAS3XHOf0p/8AwjHiWeCwlOmahJDcAJas2cNxkBcnjgZ7U+SMUnc0nJ810tU1+Fv8vxZ6j460SDX/AA9qWoQztavYPPNJCoBHm4jLBjwTkMB07Vx/wRuXsfiDHcoATBZXTkN0wIz1rldR0jW9KtA2oW15bW1w+Mu/yyMAD0zycEHn1rLSSSJy0cjo2MZRipweo4osmtBRm1LVI+kbDw1YjRB4ZRLfUbUX8WoBSZIlLSxu4U9WOAF6Vly/D3w5Hqeuxw6E12IrqxRES5dPISWMmQ8nJAIzzXg63d0WULcXBJIxiVs8cDv2rYi1fUrXw7caYrsYLi4SeV2JMm5FKqA2emCeKtxvDlW5XPBWbX9afodn8LrKWx+K32bQ4Evo4rp4/NMfmFIQxG4HoOO9c9d2d1pOs3cd5aus0U7iSGRCCQST/I1iaA91aXhezaaKZV6xsVJHpxXf2UMt9brfWxY3Y/1kb5YkjvzWmHpa8zM5W0a6G7oFlpesSxKzmF9uEd/4D6Guj0bwte6nBdWivHcXNtkrG38Q/wBk1zNlrG29jmj01F8xNs6fwt7j0NdV4Rim0+WDVoxK0TPn/WdB6A132dhWTOc1K9vrG5jtYoWt/s523KGPotU9YSz1q0tIWhDRhj++4wa9V8Z6/pOoi1u1gAmkUqxaLcXPoSK4/XbnSpNPSCG3ggfgDy+GB9cUJ33M+lpHI6VDpcFpNZ70acPt5TP0IqnqNlcy3n2K5s4Io8Y80x7cntWppFppLT3kVzciG4YAq5yVP+FUr282z3NhFe/amAAROu4j0NVyod9Sfwioh10xoI2jhGXLHrT/ABNpVxZa9fuvmPp9ygfMJLday9JguFupb5ZFiy4V1fPAPXiu4kv0tbGcWtxu8vj5V+VwfrRq9thyWibOE07w5Pqd0ttBFItwi/IrvtZvQ811eraGmk6PZRXFncWs0u69nfjG4DYB+WTXbS6Ha65pen3DaqiX6sI1eIjcvsQKzPHsj3VpKEaOaIDyVDNhwq8ZGfXFQmkyKn8p55p+kQ67cpYw/vHf51mbOAD2r0J/hWILSyvraKRbgLsdIpsjI9u1U/hU8VnqZtlVissfIKZKH0ya9eGrTtHG2m2gDxN++3LwQeM5qJSaZs42SSPDB4ik0N54LrT4pGVtrb1DE4P+Fcz4nNprFtLqFpp8dn5DEGNRgtnvivR/ih4cSC8ubiXeZ7jbI7QkMEJPavK7m9WO4CyGSXcdu36HAzWujVzL4t9zndOtTFdSTqNzCMbkYdc56VqNLMtqtmtvbxOvJLj5sEV02hOLi4SG+0628rdksASSB71zHjPUbBdVuZLCMJJu2AKcg46U6Uacb8w5NqyMSbRVKbmmO/HOMYq1DoltDF5rO7tjGCBiobHVd8mJ7RivZlFdMkKXVqPJJBPY12U6GHn70UJtpGIunRyoHtoiko6EcYra0NpizW96f9IjUMT2Iqe2iFrF+8ByKzp86jqLwQgxyCPJlU9FJxXNmOCpVKTls0dmBxM6NVKOt+h0MpwAKo3V3HZQvNJnAGTkVf8As5jto1BMjqMEnvWT4iQNpU6hPnKEcfSvkYRTlyn1leUo03NbnBaxeLfX8k0YIQgAZql6Uo5UUGvVirKx8fUk5SbZteEtbj0S+u2urVruyvLV7S4hWTy2ZG9G7HIrYn8W6bYeIdCv/C+iLYQaSAVSWTfJM2SW3sBz1x0rjKKHFMh628v6/VnY6r4m0YaFfaf4d0e6sG1GRHvHnuvNDbWLAKMDAye/NXPDvxAOj2Wg2gtp3trKG7gu4llwLhZ2zwOgI465rgqBTt0ZDhe67/5W/I7Lwp4h0Ox8N6noms6Vf3tve3UVwv2a5WIrsBABJBz1ro5tXOust8bbyrf5IY4S+7YiLtUZ+grzrS7OS4uQsYUkYOC2K9k8O6Lc22xordRaKo3oeWzjqK6aEdeZFcumrOYWMw4aFQ3PIKYwM16Jpf2iaMxM7SMyfuUK8AAdhXPak0bawsbXLRxAiRyqgkDHIrutN1SMRxSaStqVIws0/wDrMYrqemwt4nKXGlXEFpdzFGndRnylUjBx3rzadHEZeaMJCwIKN1zmvXNWnltIriWSVwZAd+Du5rx26e4vrpkh3gBiSW9KHtchK7Jr9hrGkrd26k3en/ubntujOArfh0rCmidV2tuwoxwM8mulsZI9KuopZy3ltlZkHSRO4NV7nR5P7QIDn7F/rkfsyHkf4VzyjUlK8thQTUrJaGHBp8zEyYG0EAAVowQmOCQ3L5Cjaq9hUl1dIs7BJRtC5CrUFlG8uZrmXCjnaapRUdOppe5HdSCFMRW4cMMO7f0rnpUKN0wp6Vr6lfG4lIziFT0HeqzRPcAfLjjI9BWNVczEu5nZoFWbmwvLaCGe4s7mKCbmOWSJlVx/skjB/CqxHrWBVxaKQ0UDLuhnGu6WT2u4f/QxX118XLjd8PtXGekkR/8AIor5D0g41nTj6XUP/oYr6n+LErDwBrHzIQZEHB9JRVRV1L0KlJKML/zL80cRdXQ8+T/ePevKPiA4fxVK3/TGP+tdpcXp81/m71wHi2Tzdekfr+7QfzrzMNT5Ztn0mZVVLDRX9bGJAfkPAPzGikg+6f8AeNFdUtzzaP8ADR6vqfxXivbrxdItuFTVbBba2AiQGKTGHY88Zy3SuR8T+LH1PTdKsLa7u4rC0sYLeSFpcRmRM5O0HHevYPEd9ok/i2z0meXSr3Ux4lRbaK1sfKNtCGwySHAD9vWtJ59Nvta8Mv8A6Pe+Zrt0PM/syKFYUjRwYyB97nB59Kagk3p/X9I8+MOeCfTT+vxPHtM1zwtc+BrLRPEH9src2lzc3KPZLGUPmKAM7jnt2ro4filplrLBd21tfi7kktDcq5QoiQAD5B6sPWuX8ca/DrevadJaSpqcEKIFX+zktPMYtkoVTr6Zr0M6rY6frFvfazoZXVrS0mkMGmWSMsYbaI0YMCCVGeSDR7J1tIpsaT+L1OI+Jfj+DxhbaXHBEIBbPOxURoituYbMBT1CAA1wJYFiARn0r6KFgRdBX0i0v4tVv5oryZ7NQ0MAtw6fdACEEnkY5Fc/4106JPA+qWY0S2trLT7XT5rK7SEq7ySj94C/8XU/lVQkrWirGUouOv8AXn/XU8ct0y4y4Rj90n1rrNAjh1W3aOKRI76L/lmx4cVd+GVpa3E2uRarlbMaVMWlWISNHgr8yg969Ok8I+HLv+zk8rUzDaaQs8V1AiRbxvYDeMH5icd63hNwewTXKr/11/yPKdTsZ9KVbpIm2k84GdprtNCkFxpvnWsiR3JXdj1IqDTY51tZYLiVZSRlY5cB/pmptIjRo5hJF5ark/J8rrj+dd8EnqiL6Grpli97dSYAk8xdxReGDd6s6LHe2Vte2/kTS2rEsI2baVIqjbpb/aHnFxOIyg/eo3KEe1aWn6gdNDtNc/aoGUsk2M49jVvyC+hZ0+S2JjuEWOPyjlkZslT9DVPW7JtavCsUcMTuMoYsDJHesDVWF9bySxom/wAwEvA/ysue47VJqSX2lQ21xbxzOsfKsh5waLC00ubMHhC6gm894bdiyBCZDxnNaEXw/OqXgkaeK0vUbG6IhuMV5xe+M9Ujcu8jqknysrH09RVaLxy1rsMytM5fduD9MVEpeYLzPUj4BuoNRdryc3dsnWeID5T/ALQpdT8PfYtMZ7cSTxbcLIvzLn3FN+GHxJ017iZ7yR7F3UDcTuR/94Gu68QeKtFDWpht1lNyNrtbONhB74qVUdxyjZJHm/gO5vdIku7ufyFWOPcyOg/1h4XFSX2raZqFvEHVo52yT5ikjd7V3ur2uhXemwJpZEVxKROQybt23gZ/HNeW+KpYoryWS+iePZGRG0ScBh3pxak7ozveT8iO1vZIdYMsVxAkbRjdmXOcex6V61pevWfiHSoEs9Xs7GaMASxM4XzABXy1fXL3aZRtwjYEP0PPrXQ+H7KO6jbz5ioUYOCeT9aJWbsjVP3bHqXjbQf7Q09tSm1W1junG2NFlyWAPtXDaX4ehu5t8EZmkh+eTDdeeeK5dUvZ7jD3UsdqsmxdhJNdLpc01hEUW6RNn3vO+UsP5VUbvQmKsrkut3K6VdSG1WRVYEqIztOO/WvMdXlt2uJHjlkaTcW+cA8n3rU8R6vLIziX5gxIjKvwB+Fc3HBPc7UhieRvRRkms61RLRbhBNl2z1KcADyDIo4yo710dndTSAKqn8BVDSrC40+NDqEUlvuzjzIyAa31QxIJIpEwfSvUwnM4JyYpWK8q3BPO7n1NVbKOSLXgrkpuhPTvg1pSXI8su5yazYEm1O83wSeXsIG8dcdxSx6ToSUnY1wl/bRsrnWQ71jG0qT71R1SMvGxlYH2FTRM8EIXdvYdzxmq12ZJFbIr4aGkj7Wq06djzCUBZZABwGIA/Gm1LcoUuZlP8LsD+dRV6y2PjJ/ExyxuyllUlR1NMFLkgEZOD1FJiqJHAgIRxSxKWcYGaTBzitbw/ot9qV8iWkRZv6U0rgldnXeBdCins5ry5aIqvGN3P5da9RguF0mxI8iQS3C7BJIpx06gVqfC/wAJ20aCO4tpmMp2FHwAMD1rb8WafBNdSwCIp9m/iYEhcDoK7qdl7oVHbRHAWGnQLDKXV2mkBDMUySP6Vvy/YNNhs1h3GZE+SIr941saRZPKYDG4ZTGA4AILHOT+laGsf2DpcrywW6z6iQVQfeCGqcr6ES0Wh4x4g1i9ub0m9Plkk4jUYqlo8NlbzSXNxKgjUZKnlmNVfFdtqE2pyNNhpOThP1rEiWW4tp3RZCCcZLAAVTl0Jjtcu6rdpe3O/ZHHECVSJBlm9zWjLBNqHh8WSlPtFmuYkDctEScg+461zU84jhEMERiVByxOWc0zSrm9g1CK+QZWFt2SeCOhH5VjOz1krg4KSs3YrQLGl2Uk2Mu3O5eareaZpWigVyM49q2vFNjai8RtHyLKdBJHIen+0ufUGsBgVRRBvJxyRxWbv2sOMlJXRFKsgPl4UepqaBJ5YwsQyGOB6n6U6y065nbbGm6R/XtXYw6fa6BpzSXGZLxlx04WpjByZTslqYWsw3suhW0dxqM8v2XiO1eRmCg9cDOBXKnrXaTOxt12bVZhjOOea5fVLM2k+NwbPJwelOtTUUrCWjZTopKDXMUWdLONWsD2FzEf/HxX0T8Uro/8IJrJHOCh/wDHxXzrpxxqVkf+niP/ANCFe5/EOfzPB+qJ6lP/AEMVvQjdtBU/hq3dfoeQyeILoyN+5Tk981l39y95cmaVQrEAYHtXQPane3A6msPVU2XrLj+Fa2q5cqMPaXLlipzSjJmfB9w/7xopIPunj+I0V5ctz0qP8NHpGo+DdcsvFULDxJo9z4hkvpCfs9yTLHMoLFm+Xg8VzFnqfiG0WFrSfUEEtw9xEY0PzSkEM445JBNdjqPjwal8TUv76+VtGtby6e2dbcKQjqQucLuPbrW5B8QNGt5tOuI76SWM3FqyWLwNsskRdspB6Hdkn5fWutJO+mx5KfuRt1X+R5An2/TZYLpI7q2ljYNFIY2U7hyMZH0r0jWLfx+tt/al54qSfUdOQzNapeg3MCFQWO0D0xxVX4reN7PxLbaKmlxxIto0ryRoG+8GCpy3qiip9Q1zwzHqOt+KrXVZpdTv7aWJNONoy+W8iBTlycEDnFQk+ZJbsfPdcr8/+B95y2n6h4rlvzZW15qSTazKscm4souGfgFiR6H8qXWW8RR2qaDqNzdtb2czJFBIzeVuVtpK5HIBr1LX/Fllos2mwXuoXM0sZ0t0txF8tqI1VpHB7llOPWuA8a6vbXuuxXdprs1/AbuaQRvG6+SjS7gPm68elaey9n70dzRJxlGCfu3s/kdPb+CPEml6jq2ixtbxXUOnm4nkRj5ckRGducd8fpWhpHiLxGNIt4be7vrYTQBIjHkbgOw4rqX8caDc3d1JBMryTyzxtKwcFoTF+7GDxy5Iq8niewlXTYreYRKlu0G5I3LWrFFAPPBGQfu+tdFNJr3lcmzkvu/U5CbwzfahqVnpU08UuoSwiYO7bSMruGT61PZaHqmnW0E9w0P2eZ3hZJH+ckDJI9q6q9urR/GkOoRXDsY1h2O425KjBHNVPHWs6XJqdtausrWcGdszDBDucn/CqcpRfKloYy0fq/1My+0qOHSi4dRJt+WTOMj3rEht722b5bdJLdlw5jfIIPfFb2pBEki/06CexIH7qQY/WsDxBDosMyrb3EsDbSdiudv4Gtl0G3rqQWT6fawzxNHcecBnIA5FUby9lcxyW0s0fy/3iB+Iqxpl0stqyWYld1/1bFg3PpVi60YXdrJdX3+jTr/c6fiKegPTU4fXRLqt2nlmHfgnJPUisa68P6lbBHaAvvzjy/mBFaFzfzadmA26uob5Hwc4rQ8NeIILW5jl1OKS4tkO3aoIK59K55qMnqOOuxgJbzwxqXR4cHaQwwDWtpf2+S7SO1ctIxEcahs4JOK6fXPEGl3STwQOjwPyFmjwyfjWP4agt4dSm1WPef7Nhec5+6xxhBn/AHiKTi4rRic7JyZ6Kni2W3uLiztgskcCeQkigfL5YxnI9TmpbXWtPuLMC/lWWSZSro2QCa8dDzxNuikIl7nPUnrWxJ4tSPT4rW606GRh8pk24bPrkV1Kh7OCkyYPmWu501x4Xjt5VFu4BuF3bUAZTXQ6N4Xa5WOHyjE/Vzn730FeeW3iSaxuIpLeN2VFDDLdR6V0t18TZ7yGBEsl85WUhh8p+mR1rLmj0NLW0O3sPA2nxf6LbfaYpHbzJHnHC8djXK+OtN0+1s5B9oFxtG13BzjFYWsePtSmcJJLIsbjlQ+AK5LVdYe4uBBDLIscn3weQaanyrchpsxb9rVmCW4YKDnOc10HhVdLSaOS7nngY9Gjfp9RWLJbrvUwFWLrk8YwB1qVoiLhRwyngAA1zxXNPU0joej6raf8JAVih1mPy1XjzxjJHvWhongC41HTVlTV9Fj2ZDq85yMfhXm0S+ZIIyWAGVIDHitdtPW1tw8U9zyMkKa9VU61NWiZvlsXta017Rp7NZrO4kQ7S0Lkj88UzTbVLSJVyAcZOO5rIs7147gwzI+GOEbbyT71rmVVUM7gL7mvCzTEV5v2U1ZHvZZRoxXtE7stOy7Pl5rD8Qalc2VvmAR5Jx8wzWgdrx+ZHL077uK5HxHI5ZFe980E4KADAA+leXRp3lqd2NxDhTfKYs0rzSNJIRuY7mwMDNMqSVUXHlsWyOc00KNuWbH4V6Vj5htyd2Nx3pVBPTrSEDPByM1JGjMMqDycAAU7AWrCzNxJhjyD34zXsnw58D3IkFzc3aWseA64l+8R2rlfBfhC4uMzSErMoUoCPl6817n4f8NQm8iN3cREkCRdoJA49K6KcbaspaHWWUX9k+GjK53TSzrtkAwq5IAGRzTdVluJbxIrYwlYW3yYX5Tx3J61b1q/S706W3tdN8yC0IZnJwoYDg4Fc7pWiakWtZdSu5fsMrF2bd1HXFXHuzNu7Ny20uO4ubWdwAsufMMZwv1xVD4iXWkadpnl2tuu7/ZTBHuSa1INRjsdFZbK1zcHcE84578GvO7uCbVLq4N5PH5ob95u5+gFOMW3dkyV9EcJexWn2cTTQyF5GIysmDtNcrPa2k8Bj0sOjrIVOW4rc8bWcaXREU7scc7Rn9B0rN0iQxxi1WBuB9912j3PvWwLUzobLNv9pvkfy4OoQZ8w1mXk91K37uHyonHyxntXRs8iRyvI5ltkJ2Rg4DGs97hp4A4SOMKf4jyfpScQE0u1lu9KOj3BRbk5mtcdd3dPxFV9N0Ke4gkwPJC/flc9PatHR7LfOt5dSPvRw6RxjJyOhrovEb27W0F9AnlwXHy7T/DL1Ix+tTZvWT0RLcoy20Zl6JbWuleZPcy4RRncRyfpWZqOpLrV0RGpS2U5DN1NWZd17ayrKGESDG8gncazbW0ZXEYVxGxCqyrVvRe6afE9S/Z6YVQuw5c4V3PQe1Tf8Igi6bcz3JL+bkKWHT3Feq6X4LsRaWE2oX9nDAE3lJZcMx9DxXKeLNUE7yRp5ZgiJjiSI/KQOM5qVyy91inpp1PD761ezuXhcglTgEd6rV2OtwR3trswFuoySu307g1yDDBIIwa4qtPkfkEJdGSWPF/an0mQ/wDjwr2HxnOZPDl4mc7nQf8Aj4rx20OLy3P/AE1T+Yr03xBOZNLmTP3pE/8AQxWmG3bLlrFLz/yKb2n7xvl71yHiWPytXdcfwJXpz2p8x/rXnfjePy/EEi/9Mo/616uLf7gwXxI5uD7p/wB40UQD5Tz3NFfNy3Z7dH+HElFJSiitjyxOtLgdxmkp4wFwevamBKcyPmV3YYxuY5I9OTWpY6ek2IpH2O3KOehNZSy4BXse1XNPkuTHtQ741OcVcFFMSR0UeLYiK9jIPQkdjXo/hCzsdQtzDLcCKfH7qQHg/WvNhObkoHIY4xz1qXTpbmwgk8tn4bIBPSu1O2i2Envc7rVHurK/a0u2R4s4DZ6e/tTbnTtRmgEkhgu4gMZ35yK5WLU21AkXnMgHc9a19MnMFiWsnWWMH95byHkD1FaLXYm2mpfsy0dmBqNh5kedqup5Apx0xSz3Voq3SoMNCy5O2tzQWs9StZRbLIMfeizyD6gGr9rd2VhaTqLmA3SdVlXawo02GzL0fR9G/tSACB4hJhsEMhRv6iu9i8I6LezSiWVIpGHXcSGxWBb3VlcTx+ZNtYIGyoygNYl3cE61OrMyOBiORWIBzUtMHroQaj4Pvr67v4LeSzvI7dvkix82PY15zfaFfae7yCxkjR2yOSACOor2zw/fLayRl7BX3fLK27kH1B61pXkby29ytqkUlrncYpSGINS1foKzifNl8VnnhMMTI7DbJ3BNdbY2DW/hdxJlP7Qm3KpGD5cfGPxY/pXeab4TtdahmWS0CTKTtCJtP4EVB4p8MJZXUCOZJ7G2gS3jVJAHUjlvrzWVSDa9zcTceZQnszyW5t2tWAb5h2YUBQ6YIrsItP0+4W62yLG8ZYpHcOASCK4q8Y212I3Xy1zjcpyDz2r0cPifc5a25pUjBS/dvQ1re9OUtZrdZFboTwVB4P8AjT77R1LI0SlSmCAvQ1HHZTrPFcwSrKipnD/KR+FdBA0txbpIiIGdtirvH514+PpyhU5sOtD1sFOjWp8uIauYFloyPas5ny+/DRMMsRnsK2Y/C0l9CGWzh2WwOXyUZvwNO1Cy1K3KGRUjfaWEiOOCPcV0mjC8urPfNE6scMsrSZRgR0IqqblUjyzTTOWpCnRlzQakjjJtFCxAQ2cjMwO3ahY+/StmDQ7LR4YP7WGJTGJUCMNyegIrudNaW7uBaJdWsDWwOGHy5Jo1nwpFdsl1O1xNcgKkkkRABPQdacKU6TuncmpWhWsuXl8zyPU9OSZrq9F2QJnLDfHt4Ndb4c1Xwjp+kQDUtE/tC5QBXkW4ZAffGaz9d8Ha7HdwRXFtbJsj8uONZxuYAk5INcbqcklkXSSEq6EqQRjBFez704WnKxw8yi3GJ0Wv+IdMuLpGttDgs4kJ/wBU7Pnngkn2rl9V12G4XZZ27RPyOfWqja/KIigiXB64NZNxKsrlwpVicnmuatWio+7JMautBZ2uBgTNIBtAwTjgdKgAA9qViWOSSfrzS8MT0HFeS9Xc15pNasQ+1KCdhHbrSoGGNo5PSnoC5IPB7k0WJHxRM6BUUMSeg64r0LwBoEt8BdTWkLxREAbmwR7471zGj6TNK1vKxR1m3qArgFQpXJP13V9BaF4be2hjS1/dhVXKnBLmt6UUylpqdJp1l9g0WQyW8ZnmTbFt4UDHUitq30uySKwTyxdEx/vY4zggY4wc1Ut4r6wtZrm6vopdrACJ0wAo7VtSX80unreLJbQ3LKQkcP3tnrirk7uxLa1Zz+sWEkELaVpgntFmXzpSz8Ek8Cl1W5uLfULW2e6V7VYVRlD/ACoRVebVBcXUkZnZpHAAZhk8fWsLUZdXF8ba2tYJC6eYN3PAPU1dtCUtjoL25lm1KyBEL2pyuHlxgAday5rE21zdNapbRPI3mHc+4sPQDtWeVaOB9Qu7RGuSxjQCQ8n2FP03RJbyG61HU7kRyOPuBslVFUlZhayOD1m0uJdSkYXX+kH/AJZRAYA965vWPthuSl200e8bQcdq6m8eK1jmg06eRHOSZOKwZY7m+tiZZZp3zuJJwBWpK2sYsiLaXItwPMES53bs8ntUFsj3EwLqscfYYyaszWf+kJHMqwqcneDnPvWz4b0qeaWKO1tXuGZvlyMZ54qLdC4q5o6dBfzSLY6PAkQkXDTMMt+FeneEvhVM1lKuuSFrVysio3VXH8Qrsvh/4T/4R3T2vtTija7KlsAZ2j0qDxd41jsbSSTzCGZMRxoOc/WsZy9p7q2JrKNrPc878faTFDF/ZmmCC0tbd83ErHlvasazEFukHneWI0+4AMs3vUPjHWpL7RYr65VYhv23IHzHcT8rH61wE/iV4beXEpZWOF4w2K2V1H3tDOnO911R1njLxZHJehI2eZgAFiU4VfcmuE1PXZJ9yIV3D+72rDmuJp5S+1sNy3PSoVmjhbhST1JrGVXsaKPc1rDKrukPJ5ZielZWspC9w01sCIzx9felmnkukA3BYwc/WmqyfdA3djUSldWKtcpW5xcQn0kX+dd1qE2+2256yx/+hiuHKeVdIAQRuB4+tdRNNvMS+s0f/oYpUXy3Key9T1B4T5j8d68r+IybPFEo/wCmMX8jXszRfvH6da8h+KS7fFko/wCmEX8jXfip/urHl0K/PV5TioBlD9TRTrf7h/3jRXhSWp9TQX7uPoPoo7UVqeSFSQRGZ9i/ePSo60tFlFtdQtcKRFIcBiOKqKu7DQg0yZDkKQw5AI4NXbKPypMoTDIfvKRwa77TFs7lPIuABxlJF5xVXVLGztspdbSTzHItdioJaoV7M5C5Mwu0eN03EYIA61fur6TyBHPBJFcAcHHDfQ1vT6Pa6lpS3FrIsdzH3I+VqrTWN3PZKsoAliHybuQw9jV8rTuiXpoYdhaTThZo5V3r1U8E11OnyQwsk8oIwNr7V/nXLW4lCzJ91wenpSWs9/Ax8svj6ZFKL5RnV3WoQx3cU2nXJhlQ87G+8K1rq7muoDLe3CjK4DGLlvxrA8Nz2D3ayapaqQ3V1HA+orq9XuYba1BsGhktk5Mcg5A9jWidxNWRZ026t5vD/ki4AnQY8wIc4/CpP7ckEaQNDAzxKAWwSXH0rCh1i+aJ4reS1WMrnbswSK0raWGTTjcsFifqsqE8H3FPlBvqbnh/V7Q6WZgkkymXbIgBV0PsTS+IPE50y8jTThJtk+UmRcHn1rno9R1CxeSFDBcw3AEgfZyD9aM2erQeddCdLuN8BcZBNJxQbs9C8N6tqkMsEqxedDBG0srLGBkAcD86zte8RWqys1+beN7jojJypNSpcHT/AA6bJ5WWW+bYhdSCFUZPT3Irm7K3t7q3U6/ot5dSQjCTwn0PUip5dbmduao32K+sSabHIks8UDA9HH8Q/GuXn0iHVWjhmeGJN5KME5I7Cu0vRBcsLb7DbSvtIj3kqVHbIrmNSsJJbmKOxuQt0hyI0ORV6W1LVriadpNuz3iSmTzoxhOM8fQ11Xh+DQJNLjh1JplukJ2nGw/qKxI9F1mK4R5IG2zEKZGfBU+tb93YSRxtBqDGVlTAVYdxyehyKLdEN7HP32kwSBooZrh5t2I45ehH16V0Wi6FfL5VraQm3XALq5yG+mKZ4X8K3SxLc3DyTOrfKkjbdo+hrt5Unis45RaSLcQkGMoQQ3OO1S30Ha25y93o8qX2ycFJGO4COM4bB6Zrt7TT47Kx817R3eQAESEkgetNkn1C5VTe2ckO0/K0aZz+BrW0qG+1OxK3Y8gxtwCpBI+lZyfcForHDeJ9FsxbxXctvdXLs2I5lk5XJrlNe+Hf9sXSx6bHdhXU+Y+wNg17ALOKYMr2c0kNsOUddqN7jFbGjwkWgk060lgypHlj7pPY5PNJzEoLc+NvEHw/1bSr2a2MMzFCNg8s5fNZsngbxIkau2kXe0858s19sQaTftqVtfXMYM8a4dCAQ30NWvEOuXtlYSFNMJdgQN7Aj8qxlGLfuhey1Pgw6HqKyeW9rIjZAwRjFINKuo51i8sF27V9L3WjanqMwvrPS4WWUAyfKGO72HauB1nw1rbaqrppslvIxKDIxn3ArRUF3BN3szzvRfCmqanc+XarGrrx8zYFdd4M+E+r6rrr2st1BZtEysZnw469h3rp9O+HXim1sR5dvMEch2lJAJP413PhDwferZXFxdSvFdQHcSZeuPYUOnFIuOjuYt98LDpN3qsmq6jMsDhEjuREoEpJXICjkYwewr0CDQotJg+3RSvdRIFbLLtwAO1LqUmp3Oml7iRXiicbXUAtjHvVRtdI0xLOUE3lwf3R5c498cCkotbi5pWtfUvw3M+s3D3TxAWEWAsMpG2QntWnBfW0erPb6hbxWuFxGsa8FfQmsI6k6XNjbyAs6PkxkELwOvFOvdUuryWQJBEqrnmNck/1qnqHoZWuX2nwa5I9su6WMYComAB6+9VXuLKBo7pLpoWkUqzMjZY+wrVm0i8cxxwXkUKyKXkdowWC+ma52HS9OjEklzqsgZZM7yP0UVorEJdBr2V7p1rHd3Zl+zli0bynavPfHWmRapLqOmXa3Am/s+PAaZBgN61uXt895DDbeX58RJIeY87f6Vz+t67bXFodPhtkSJWAdY8ndTB9ipNZ2Mdo89jZoQVwjOvP19K4HUhN5ckMUjiPdmQ7gAfYYrpNR1JryR7NUnFy/EcW35UUetUtfsppLRYHdcquFVBhVPqT3q1fZieupgWunNJeCCeQhWA27eTz2r0fwNdPpOtGGCHgKAHPzMP6CuE0q8htb+NbhnbyiA7hcD8K6a68VfYoXuoUjeI/KBwDRJXRopcp6r4w8XT6Nocm2Qz3EuFRR/Dnua8Y1/xMdyRSytc3cnJA6LWpC15r1stxc7YrcDIV++PavPvEiM80kyO6bW2qFGO9TGKSujNrXUlm1tE1FYdSYizuR5Uyjog7H6g1zWt2xs9RktNqh0xhuu4EZBH1qlqdrj7rSOy/eJNaPnjVNCjlwzX+mjbN6vCeFP4HisKtRv4nZE+8mmtupleZNvMUhCKOcL/Wq88sbLsQfVjWnqUmgmxszZQaimoEZummlVo2OP4ABkfjWPMd8gWOPCjoKx5rq6NU76EbDA4zigs+3HIBqWSNowrMw3dlHaoGZmJyc1DGCf6xT7jmtuGXfdWy56zx/wDoQrDq7psrPqlivY3Ef/oQoi7AfSZh/eP/ALxrxj4vJs8YSDj/AI94un0Ne9i3ZpJMITg+leG/GpCnjWUEEH7NDkH6GuqvO8bHyOV4jnxbiedQfcP+8aKLf7h+porzZbn6JQ/hx9CQUUlLWp5QGtyyIl0YRuN6jPB6jntWHVuyvDANpGVParg7PUXQ6rwXqsdvfJHdL5kPQg9QPau28UaVbpZreWpE9o3zKR1U15bavbyODGdsynIzwa6vTPEX+jvZXgYKwxntmuylO24p6rTck069SC1mMTMpPZhkfSrtvrUdraBZo1uLWTrEByh9q5CW/uLWeS2VVZH5G7v9KuRXclxaqlxGFkX7sidR9avnWwt0SajYJJO9xY3TBWOdjjBHtUNiJludzOU9CGqN7iYPtnVmbHEi9DT4z5iDEZEo7hf5ip0uNabGxApmuQiyCN8clBwa0TDKHhWG7R42O2RWwQfasK0ZrdxLswe4VuhpJZJ5WlMZWJwdzI56j1FaJqwmej2tzptlaiK6EbykHy1VefwNOsriKS3d5LYx28qn96BjH17VwMF2BEtzGkpkUZVuflNdZ4Y1ZJrIQ37zpJkkEYww+lF9R2vc1oUleyt2hkjSBQfnTkH0yO1R6fo80gjvFkWMglt23gmseYeVeSGym/dk/wCr6DP0rufC9xLcz2sdwYGiiBeXymyAFGeQffFNuwulyXWYdSa5t/Mukb7JAIxGq53MRlj+dTLcWTWQf7fJ5qna0TAqymtLTJTPJMt1Hb+eSXEikjOT3FYPiLTpjI7W4jMr/Mf3h5xUR1IXux9TH1mxnef7TbzvhQVJzuJFUNGhDXcq37gxIAFGwq4H4VpfaI/7GRY5ngfner85PtVkxtJb296suyWAAgsQN49Oaq/cpKx2Fvo+j3Gm2ouGubiBuj7h8h9+c1Xk037BLMzgyw9YSCWIHvjNczZ6s9ysizYiJOU8sZB+tb+hvanVzfSz3iKITGEYFRu9fcVGqK6lyOxnu3t5JjiA/f2N09MgCuh06xeGP7PNJNFlyY51xswemQar3F7Bp+mQ7vM84twfLKq+e2a1GmkfT7f+0bNYOcq27cGH4VDbGiRdNitdqzatLdDdmRNm4c/TpXSadBDDIy2ymNCM7d5bP4GuMttUja5keDTLbykOWZJijP74NdVpF5b6gomhtzDnu7ZP6VjNOwGuzKmFwMnjFV5LowyJGLeQlv7mCB7msHVJYI1Sdb1oNj5AQEkn6GprLWLO8RBd+YJU6OV25/KocNARtZIMq+eC3UHglaxr/Uba5k8lAJyiHduO0ZqS6vbe4hfylAYHBbgZH1zXCxW1jNrDrbakFaN9zQGU5PtVwh1Yt3Y6l0t/syrY3UVpLuB2xsDjnvisfxTdm/dbaIRPcxkESP8AKGA6gGk2WazTRtbyJLKvBiwSDVJ71hqIg1CB4l24SRlAb61qkD1M7VLzUbmSC2sbaN/LI8xI5mPFb2kWQTU3m1GO5T5AMxucfTAqnDaaPbSf2iNSuUMo5CyKM02GGIxXFx5+pMDkgLKAcfSqeqsCdtTdEkFzPdPYOtuoGGa4Utk/SsnTNWNjZzMLeG7u4SVhYkLk+1czdXi6b5/mfa3ikUEEuS2ff0q1p+oPPHBFYaaRcYJaZhnbS5bbgtdjft55Btm1BoEv3O7y1+fHtzWK91PfandLbabMHVgolUbcnvwKyddeeTVIBaW8qTwyB7ieQbQfXGasxLFah72DULqCbJfcgJVj7DvT5RK27NbVbO8aF47eR5L4kBgJMbF+mK4gSXK6mFv4Q6pIRl5AMn0AHNdLp+pW9/JI5ubiW4mA3vLmNQKg0vwxbJrMl5C6PKr7lMj/AHD9KqLsCvfU0oGivJGjm823ZI/ljwe9chfWkju/2UR5WUKSxO4itTxlfaxqELC28+La23zYwFEmOwrzy/kOmpJNPeSGcgHylG7HuapIm+tzU8RKiaor2chBRf3r54A9M1zVxrFzdXCrZwym2H/LTORkd+aqXEhv2CiOTYedu77/ANatWOoW2kR4uYJppWHyxIPlGO1NvsNeZDNeT3Vy8Ny7kZHyrhd1XobaAzkXMbLbKvAY5G72qhOJNZ1C1uvs8gQscpEdpHsa1Ps8u7fdZhto8ogJyS2M007h0NfTLlrSzUp++uHJ2gchR2zXP69pMtzIHnuApHzkZ4FbWiaU76J9rlm+yWoYnzZG+ZvYCuc1q8N5M1rpsMksfVpX7/SjRA9zj9Ykjhd0gm80g8nHeqOl3cmnajHcFtyv8k6Ho8ZPKmty+ijsIg90oXPOAOTXMXMyzzllQAH+VcdaN9wsno9S/rtmmnXwEbB4ZVE0DDoUYnFU4Z1VWZvwrTsQNX0h9OZT9vtMyW7EZJiAJZPqOoFdx8QdN8PWXwx8JP4cdZ0mmka4nIxI8mwZDemPSsHKS2joTKpGmuVeh5ZI5duD1qNhg4BzTmHzkAfSkbIyKHruali306/uoWmtbG7mhThpIoWZV+pAwK6PQPA2pazobarZXunIyFmFu9xtmwrAbsemT6isfT/EWt6bZS2em6vfWlpLkyQwTFUfIwcj6V0fhPxlpmgeH57X+xZJtSlDobgXJVGVmU8rjrx6iplpG8dwl5B4u8NeJPC01lFcaqt0927RRi0umfDq2ChzjnJrF8YaLqeg6wlnrM6zXjW8c5IkL4VwcKSe4wa6/wAU/Eiw1e4sr210OaC6tJGuLdprgSIJTIGbI28rxjFc14/8V/8ACW6zbX5s47Zo7SO3cIB8zLkk8duelRedk2hQo01FOyUv+HOVg+4f940Utvyh/wB40VEnqevQX7uPoPpKWitjygqaLYylZMg9mqGpkLLEuQGQ/pTW4hpBjcZ5HYir9vdRqcSM2D681RVlJKNkKeh9KGBA5GR2YVadgLmoNHKVIlyB0NW7OSaKNX5kj74Oaxy4fqoz61bsr3yZVLqWUcHbVqWtwRvvMrBWtnXn+Fqtw35s13SqMnt3FYN3e2csitGrRyA9V70x55Xcb5AyDpurb2iTEjoZNULXCq9p50cg4KjBqxY30en30T3ds3kyfLk8lKw757ny4ZYJCqrzuB5FaOms+oXSiZ0kDY5PrV819wXkbtzcxi9iubQhrXGCoXH6VqwanZakkUU8H2a6TiOTbjd+VZlzpMkSCFmww+ZQpxmmW9nLNc7Ht3jEXLgngj1Fa7C30NXT5HS9ktb+NQ7DcpY7d1aV9cXNho15qVtbMZZmW2RYHydqnLn+QrKtdLWW9BhuvtMe07N4LbfbmuvksNNs47Ww1GSTdbRDd5R6u3zMcfkKG+4nqlcwdMS6aFLu6iu1gmGfmYhlrRvorBtLEn2uaOaPJTznP881rXtnFqNgsehXZeTGDHKuCa5iTwxPetPBNIsNyozhiQtF0EuyK3htprqznjuHeRN2A2QcA1BqGnXxmgs7V5pGBLKsTAkj6VRGkahb3Bjt2t18ojP7z7w9q2bDVbjTbwzW1skrAdNmWU+zChdh6PUku7aPSLKFppJFkJ5V0KOv6VtaReahPaK9lqCzY+6jenvXI674n1DV7gfbFukghIJQICx/Gul8P2MGqaoItMuruKJYt8iyHB/A0ntqCTZ1VqdZ1Szka5ni2I4xG2HUEegretJLyBbcXMghKuNpBIVvYg8VPb+GmGn250J4ZFRw0v7zeT65Fat7qM/2UWl1pc08eeAkfII+tYuXYrYhuEmluUFqm6VRljAFYH60/StYigv/ACNT3ovQI6BOfwrk726uL68Q22mvZSrIFZWYozAH1FbuuzPa2kKxxQRsxyzSIJGB9jRJX0EnbU3dTimJ8xdP/wBE6jBLA+5rIsr28ia4W3toZbQDO4jJX2HNcfqj6tp9qJm1SaWF3Hy7yMA9sZrVsfFOiQQpYi3nnnl+Ukj5c+5oUWkCN7Q0t2FwYrVXdhuZpmAAPtzXJyWmnm5eFtQiguBIzgLg7vbIq5qV+tha5LQGBmw0YbO0fhXK6tfaJqMyrpzRN5RyfK3K2frVRQm9SxPqczawpmZ5TCCpMecD0ORWtZaxDJLLFCrXdywwGum3rH+BrP0LxQ7P9ktF8lOQ7mHc35mtLU9Ys7e3MZsLiad/+WjRKF/Gmw2RuWdp4ev4YYp3jN5Cdw2RbBmrTX1tMk1tBp1xJj5S6MMH8ua4iyv11CN7eVYLS5ZiqIFILKPSt7RLR42K219DAh4YPIynNS1Ydrk/9ltpsQnt4YmL/MQcjafcmq1w97PuntD5ZjPLxNya1dbtdPhgjW41ESEc7WcsG/OsGw1W0kE0cuAV4BVAMD2oTuLrYsa5qKnTVt5WuvtUw+/LhFz/AFrBv/tFrZw25uQYcAAxSc59hWhq0Zu4EZITFCjY824lGSPYVQMsMzxNabLcwNjOzO7FUtBbmv4cvZIPD2ojS5ZLrUY5oxtC7mVD17V0GnW903imKRm8tso80cUZPOOcnpmvPLy6uYLye6tZ0HmYBdJdvP0FWLK9v0tXMmtXUUuTIUUk7vy5pOm+nUvm6h8Y765kFqqw6iBh/LM3yDPcjFXtT1SP/hHb3T3lvJLiHRLcm3YJ5WHHLjjJIrlH1TUZYJbyaeKZG+WPzyXKDvwc1zGta5e3lyDfXkcUfl+XuQcsv9047e1KdOTS5ehn9lx7/wCR13hKzs9dtbXy5cpoV99rnIIXMDLk8d/mUdfWn+ArI6z42tNeVpInnvPOWPgnDMePpiuFN0Le3lfSZLgJOhjkKpsRwex9q0vD9+dOtmuBMxljHylXK4PtSVJuVyoaScn/AF3/ACRq3OrXWneJr2G0h82/a+YRDGSX3nitz4l3gtLazXTYIXt5pWMzrlgtzj5gfwzXFNcTG4/tMyJFPI+5DnLlvUe9GnWl7ezPJfyXC2/meYFZz87euPWnONS6cCWm4qK6HWeHPCmo+Jo47jV5ylpGMrCg2r+VZ/jfW9M8OwPaWEcXm9Mjn8zW7d69qSWcWnWUaWkRXOFOWx6k15v4thtrKF5Wge5nYZDv0/CrV92Ob6LY4HV9Rlvp2d2LAnpWeygHOSverd7JIJAzEBjzgDGKqyMWbc4HTpXHUbb1KirIfa3M1hcxXdvvWRDlSVIDDuPfIrU8Q2wQQ3Nk7DTLwm4hjBOEfowx65qtda3qV7p9rY3d7NLa23+pjc5WMY6AVb0B1vIbjRZTue4w9ozdElHJHtn2qOZr7VkTPn+z0MPaQMng03vTzG+9lYFSpwwPY019vRfz9am91dFp3PS/h/YeH7jwLqM+o2+jTagJ51ka+umiljiEOUMYHU7vY102nReCVgsIbnSNAZtunxySmdgx86NvOY/NjKkD6GvCyAecDNBUHqB+VENGmytHv5Ht+iL4de4sPD11/ZdxaWelSSLPc3OI1mkkLEggjJCgDH868XmVFkYR7NgYgbTxjPaoCo7AUo4wB0pztKV1sZRpqL5r/wBXGwfcP+8aKLf7h4/iNFYPc9mj/DiPpRR2orU8oKUEgfKcZ7UlOP3FyB9RTQhEBLcEZqzJiNQBuGfyqoP1qVZWxtJyPeqi7AL5fOVPPpipEXCblIZe69xUG5h/9al8xiQeCRRdAPjk2uC6hkz361OrRm4EcjFom9+lViyscbQM/pThAQAw59qdwN23hZEaJJAyEdH71PHCsYSVXVGU4ZVPP4VkW90UcLIXZT2I6VpWsX2pggCkbgw3jH610QaYHR2niTdAls6LIg4/eH5h9K1P7QZ7NY9rNJnhlGeKrWOiaXexK0sn2e4Ud2BU06OSSxuilvtfYMZHNdEb9RaXPRPAmp6bcaolo2nsNimUucAgKMmuhuozrt0JJfKiDMSG4z7A1xWmXl1p+h3l9qUUM8E7LaoR1AbluRz0FdJDeeXoYutAhLk43JIu8Csm7zsiL3ld9C1daVp9pIf9HuI7+IbhKhJVh+Fcb4o1EC3kn0/zRMxwxIz/ADqPxF4t1GMhLmKByehjyrAemKz7TxMGtzbiyik80YCS5DA/WtUrbj1Zf0TT7nUlbzGGGX5QxAJOKcsus6RIYkilIQYO4Kf1rL1CDW45I7i002SGFRnKy/KcV3XhXxFDf2y/b1Tz+m1j1PpmhuxVr7GVpu66WaSUnfLH+9VVUkVzUs+pWd8s9jeSLh9q4O3K9hg17FFbWEsvmS+HtStpWx/pNsSQ/wCFYniSz0e2If7FOWBGfMhbNZSXOrXsXTqezkpWuct4d8R+KtLlmLfuEK7w7RfNIc9sV1GlfEDVZYXfWLgjHCD7rVqaJouk60E/srU5Ip1PKkg4PptNaHiPwNBJ5Utw5laMfN8h5/KphFR0k7sdWak7pWOKsvHt4+oSxXLiaEv8oljycema2Rr0kV9G9tDbxWzdQ6F2B/Gs7+zbRNU2COU2sRyyMCv5Gu2stK0m9U3cWUgCAFAxLZq20jNbJmFeMlxfKbya5w/SM24VPzrmvE1jJoatcSXEX2R2ym1ssCfpXWXwluL+FbW7uRaocFZvmI+mRWb4lk0+SeK31CeS5ReRuGwDH0pxZL20PNNb8UPbWUgtIcsB80jxkZ/OsODXpAjvHZ2h3g5yCDnHrmvSBrnhmNJYtRRpGDYVCgZQPeue8TXfhe8VIdJ061S4H8aIAPxxXRTlBaTQPTVGX4LnjubuYXWrWejxKQcyFjnPpXa3OraNZlLOLxLBfRSHLOhJYH2yK4eLSLS6tY0ivLa0uDncskGQPoahHhIx3i+Tq1vK/wDdSLk05Qpybadh3d9T0688WadFan+zNRnkkHXHb8hVXQL3+1biRWe6uFHzM3EYH41xFnpE1k6KLhYQT1dclvwrbRIY7hIp7lBHn52TKswrBpDW9zd8RXlsUIjitIViHzO8m56h0DWtJ+wKLXTrq91OUfMqH5V/E1X8VWnhwaVGml2dzcXTMASZs1ygtL62kYzXyWgHSKJsHH0HWjlvqSna6Opnu7ldZkiulEEbr8ked+361XjSG+1mWzu9RKrFHv2x/wAXtWp4du9LtNOkFxdFZ2H33G92+grCu52+3eZFC0KHgMVVXkpoezsJa2kVzfMm6ZLWPkAjjirwuoLRLmeSIthSsaxnBP1rnJzcy3bozx2kZ++S+Cadc30EEKwI0iKBy6AHPv61SE9UVrua7udGP2KVId5J2yNub8q5u3EdgnEpubktlj5fyg/U1oS3jwsZIGb7M3yngBjWVNbS3l0WtI5VhUcZP9KmWwddC7q+sXctgPO81Yh02qF/IVnaZFJezKGuDBbnlgTkn8K19UtIxpscH2oPOwH7oLk/jXS+A7Kz0XT2luLQ3d0xyN4Cqv51LvoVG2pDpFtNNqVtbaVapK4IHmSdR717NpPguGxtBeawRdXOMrEvCJ7msfwaLW1lkvrk2tszncWcgsB6AVn/ABB8cteM1npBcxp1mdsA/QUat2QSfKkupf1y1sr0hjGI0Q/MQ+OPSvJ/HF9a3UhitwFgj4z61HqOq6tNZtuuVhiPU9zXBa5cSggCUsvqTTk+RXZna7Kd7cRvcExR5C55NUGcsxY80rMQvUfSo64JyuzVKw4kY96RHeORZI2KSIdysDggik/Cjvk8VD1A3deC3dnb6vCAEnPkzqBjbKq8n6GsKuq0Oxew028bWyltYXtsxiSU/vGkH3GVev4nFcuccYPapUtbWsRHli+SKEx2oNJS80ywoFHGKQUDG22dh/3jRS23+rP+8aKze561D+HEfRRR3rQ8kSlzxSUtABSA5PFKenFJ60xDtrEAjmkwfpShiBihcsQGoGAU8jFWba48sAMpNSRWjycbuf4cVIkEfmiK6Bj/ANsDpWiTQjSht47jZIpYAH5lYV01lZQJAxhMU2RkqTyKwNKikF15aSLOnbacEitaSMQo0ltCzHHzKRzXXTWlwb0JDZWUz/JP5UinlA+CfzpuoziFd8M28ovPGGxUFtJZ3MIF7C8EqnIlHI/EVqWPh6bU9TtY7O4hkglb946EcIOWJH0FXzW1REtEQ67eT2+n6RZiZ45UtzdygnH7xzwD2+7iq2neIdWsbyI/bZo4WdQzbjgD8Kra9ctqGo3N0648x8qufugcAfkBWTIJGBXzXCnqueK6qFGXLe17mNCXu8z3ep0XiXXzctkyCdtxBbAqlp+ozWjx3VskcueMNnIrEeNMYkB5Oc1cs7mS0j2xhWXtkZxSqYWpf3djaLSO807xzNp1myX1p9pjc9iRtq3p/jZZn8q2061VgchnGD+dYvh9rDVrSRLpQjE4PlsFYfga0Lbw7cXMzQ6TeAsnASaIbvzFczi46Ms6pvi1qX2UW7QuGjJVWjkAH1q9o3xUvY9MkF1JHJMW4Eo3H9a5uH4b+JChmFqJUzuJi7/hWmfAW6KMtDdW0gzuWReSfauNuon8KaOpRoNayaZZk8dpeeReXVpbRKrctEm1uvXIr0az+JkMkCRWUMMzBQWBf2rylfAk1xG/lXNuWA+ZXiOSfwqNPBOs27xNaI5kBIYCBiuM+9P2nPpKDQSoQivdmmevjx14XvR/xM7SNbkHaUxn9aszw6HPaoui30dm8p3+WH4Nee+GvD9xf3pgksghLEO33P0xXsOi+HdP06wjjn0+3UxAnzCN345NXK0Njmtpc5fWPEbwW4086dLeTIoJb5QpH1HNZWq6muoWP2eDTbVJNuCX4I/E12eoSaGZ5PIuLYXG3HlhNxNcNrUmnC4DtIlldHhY8H56qFnqjN66M8X8W+H5bK5e4AVct2yw/Xise8uZlTHmKOMY6En617V4gsYJ7aJ9VdBap8xCtzJ+NcN4kg0e800fYLAQkHIG8ljW6dxbKxymmam9v/o7wySk843hsVuadqEO0C9QGU5CANsI/SrFtols0Ed2seDtwcD5qxdUtp2mzAC0KnILdfypxKb1sTPq6QTeVqMLHn5HJ3kCup0TRbnVU81HzBjK+YhrD1CJ4baxkuIJ5CRu2rGq8D3q5/b8gsPMtRdJEw6G4IC/lQ7hdJFbxZJ9jvIYbyaSOOM87I9oP49agsYFQpPpsyzQySZbeckD61gX0d3c+fdur3UZRsfNyp9ck81p6eJ5btZLyBbLcuZvNlypG0cgZ+lLd2ErJa7no0mmafqFok/nxRiEZLKQATXDa4qoGuDNJLKSRHhhgVYtbS8ucW2mTxQ2Zxhtu4P+BqDxTpL29uI7iUTyY4WP5DTV9hS7nGXS3skqy3MrIPeoILa8eKWWKWRIkzkscbq6b+yFNjBIGMl31SAtuIqtNo8/kyG688OOqLgKv1NS4vcrYyoHFtZpLqCyAPnYAOtW9FME5d5Z3RRnCCqUsu1F8zyrhUOAmelWIEku2M0kAFsBgIhxUoY7S2t4NYdonkPuWySa0tf1iWOKOG3jCKOoL5LH3rDsrC6bUW+wWbdcAg52+9dVpvge+1WWNbqSRVZuWK8k+1NPcVm0kWvBmi3GsncfOmc9VDEgfj0Fdnd+ELq2tHllso1iUffbJA/GvS/Cmlad4Q0GMPBGpVR987mY/QVyXxF8Xw3WnzRSXKx4GBGeMfhUxlJuyQVWlseQ+Ims0sfJEiueSxUYA/GvNtTuIpG8u3TgdT61t6vqMU7NhjIi8AA4BNYCTR7mcKu49vSprzvohRXVlNsjqMU2rthZXerXZjs4TK2NzsOFQerN0A+tabWukaRKv2yQ6pcqMmGE7YVbsC3Vh9MVxvuU5JEqeDNSfSrPUvP04WV10k+1KfL4/jA5B9uppn9oafo6ldIgW5vMbTeXADbT32L0H15P0rM1PVJ79gHKxwLwkMY2og9AO1UKNOhHvSd9kS3NxLczNLcSNLI3Vm5qKlpPxpNt7miVtgAozxS0lIBaBRQKBjLf7h/3jRS2+Chz/eNFZPc9ah/DiPFHekpa1PJCiiigQd6T1paTvQAuOBxUix5X5Dk+hqL2pRkcjINNAWI7mSB+CcitGXWRMqrcQpLx97GDWMWLYyc1KrMQMqGHritIza2CxtaU8Xn/ACM0Dk/Kc8VfvL26t5VDTAIf4hWJFNDHCF25B6kHkUS+aVHlOJE647itYzshM2HvGYiKeeKSInnI/rXVaIyWWg6rc2+N3li1hcdmk64PXhc155avbu5FyCrjvjGa7CQLa6DpNkjMrMrXsnPGXOEH4AfrW9C9WSRhiPg5V10M2WJ1GB0HFQuvHIxVotNk8gioJ94B2r+Fe7FWVkCVlYreYAQD0pN69BgZpkjEoWKkYx+tVd9y6MwgbYOAxUionWhDWTKSbJ18yFnYMSpXovHNdf4W8R2lhEzXEYnkIwCzYI/GvP5JrgDkFATkEVNuSKLEiHB715OIq03K8GaK6R9C+H/inb6bHAhF4hyMKXLJ+td+Pi9p32JZZLPzpP7sfNfKekOrRCNd5z0JBxW1aStpMvmB2APUfeH5VhyRnqU33PpqT4h+Gr2OJjb+XKxABdNpB+tW4viVoSSfY31DZc/whlDCvlyDXbq6vB9mEeFOeen5GtpvEEM0qC7trAsvBYHD/hin7GL0Qj6OXxsjXRjgSGbcpbzQu3H1FWbbWLGdg81wjbx8wD7Rmvny0nEge4sJpkyhHE4GB9Kg0PV7YX/kSG+kjyTIxkBz9KPYpAux674ilsbDWDeJqlsm4YVQdxP6VJLaW11aRag8ljdMuCV2FSfxrm7HXPCL2TQpY3NyydTKMbT9aR/EumpbLHbxReRnBUuTtp2YttDodYsoNQhhNnZ2lrtGSzy7h+RriNZsoY5jvlWVj8p8pBtA/OtG+1GIgGC4hMLD7hXgfjWalvAInaFoHkdsElxgVUdBW1KFpcqBJCLW5mgHCuhHWsS5sZbO8SZ1ZCThIZ5BnH0rptTiu2jW2gkgBQbh5Z6/jWFqmlTalCq3XnGRTydpB/OrQdbk2tsIraGZLYMw6lJDxWXfTWusQRpa+ZHIp/1QkwK6CHT47KxTyPseARvWZsk0z7LayyNLGIycfdggGPzNO4WKcWmx29kr6hZxTMB8ubgEj8Kl0XSrIvJLDpUad8u2SaLu3inaCOysZnmX5flxg1tHTmu4BazRNazOMEGQD+VTZXuU9TitZ8Q3djqF1H5ESIgxF5ZAIFcX/bUr3UkspkZm6s7nivTNR8MWmjyEwkLI42tNu3GuafTLCzuGeRFugDuYtwW/Ck1J7Ext1KmheK76zeQ2kURBHErRFj+FZs2u32qySpdTkEuQ5Ix+lbniHxTd3tqltZ2Mdpbqu1UReW+prKsPB+o36/a3U26H5mL8ZqG5Lbce7u9jOultogSN2ehx1pn2macJFZ27pH/tMST+FbkOgzvIy253sDgBVIH1JrvfDGn6PpEapfQyXeouMmOFc4os+g0jI8HWbWFnIZpHt3fnco/xr0vwx9hhCXGoX8hjjOVG4ZauM8Vw6rcKqwQNZWz8LGqfOf61jw2l3aRNFHFcSXRACh0JZifQVdtA5+p2PxC8fxz/AOjaUpGwEA54HufWvGLl2uRM93cOzt8xZgeTXRava6hGnlX7WumKwOZLhxvc+gRcnP5Vzt1PpGlRR+SZ9Uu9ow0+FhU+uwcn8T+FZ1Kkaa01MOeKdt2Zllp1zeSPFYQBoQC7zyEIiL6lmwBUjRaLpO3z1Oq3gXlY3KQKT6t1b8MD3purarNqeUuriRkxgJ0VQOwA4FYVyU3BY2JArnnyyV1c0jzPdWNLUNevrmJbfcsFoi7Ut4QFRR9B/n61lySlwOABUf1pKwXu7FRhGOyDNHrQaKCgpTSdaXpQAgpaKKBhQOtH1oHX8aBDLb7h5/iNFFt9w/7xorJ7nrUf4cSSikpa1PKENFLR2oAKQ9aWk7mgAPFKD70lHegQ5SPb8aVNwbKHB+tMoz2pjJA7ZOQDn1FTWhLyoqcN2PaqoPvUkStyYyQwppgbB0t7qJmZdswHGDw1WdP8S6jYx/ZL6OC7gSPylS6iDMqjoA4wwx2Gce1ZlpfSQ8eayn/a5FPmuhM2ZUyfUdK203i7NGcoKT1RtRazo99ITdQ3umFiAGgInRPcjg4+ma2X01LkxNpN5b38ePn8mUeYPcoQD+FcbtOVMYIz1HFXra38lg+1HB77sMv0NdEMVXv8RLp2XunRr4WuL0osU0aytg+VICjEV3OkWzaaBaSxLBG/DCRfMU/nXEWXiK80yNbe6nW6tnYYE4EoXHTGa9Fs/GtjfQJbXEcZc9RE21u3Zgf0xWk60ppcy1C7jpYx9X+H05sZZNNiW6WRty7O3tiuZ1L4e6tDAH/srUFQ9R5W4fpXuPhwWqzwpa3k8LFlIDpx+hr0uC/v7ZVW72OuMhwhxj3rCc12HzR7nwtdQz6VKscaTQyDrvUr/OtKG8vJ7YG5jUpj76cn9K+377RdJ1qAf2jp9pcZ67owT+dcjrHwm8GXUXlDTxaytyphkKk/hURqpPsVdtHyTFMtjOrRCRhjk0T3rG6Ev2ZJG9WOP5V7brXwZZDJ9gkvSo6ZG7+dec678OtT0zfKEkmUesZBFbXuvdFzdylYa0tipkn0uObeMYJNY1xqEr6hJLZWyQBuRGrEYqRPDl40e6e5ljBGQhQiqK+ZaSujEZwQGJocpWH1NvSNS1hYphBIIUPUY3Zp9pqlxHP5Nwflk7bOCaztJvriGJ0tdwkLZc561H57yXRku7eQlemAc009B9T2vw7c315pmxLfTwsYGGGAf1rYsNHS5LyXtoI5WIwHYBT+leY+G7VJbcG7nlhgcggRt8/5V39vc+H0UzHUtTuniHKyAkD8qbG97mprGnRQojO+nxbBk7XGVride1RpJEgs7u2uI34+QN1p3inWkeZv7FilkhMZ3MtuTk8ccj3rN060vms2aaPaQNwUoRmnFojldrsrypfXK+XLGkJY4AL44rqdD0GVflt5rZeCpMjBgcjtXJ6XpUdzdyLNJHFcj5sTScAf7vWteHQppEe5sr0XcecbbcfKGHWnLsho6QeHjpMRZ76Ektuw7hBn271mm6t7e/Ae3a4uGGVeOQBFrCurC9juEu7qyHlwjgzyAD8s1t2l+mo2yuLtJgpx5FvGAPzpWsCO58P6Np97ZrJcmAyNy73B4X6etXdQ8D+GLyBpIbsSSL94Q4xXBXNzc3IjhnmmS0BwyIpz9OK6O1kFvYGDT2eyhVSfMmXZuP1aoad9GJuNrkOqW/gbQrffLp0t5NAN2JfkDH2x1qPw142ttUvvLi8NwlTxHbx8AD3JrKlgW1SW61fULedCwICL5j7fqcAVYt9Xivr6EaHowyinM0rAH24BA/PNJpW7iVT5nb2S61qVxdiw0fTbO3yF35DMM9R0rorbQdC0lTNclWn2/NKcLXnlrruqNNLbBpLdVIZzFtVAax/EviDShF5Oo3F3cSZ6ebtBqeWT8iXKVtFY7DxFr3hvSpzd75ZAVCgxgHH0Y15J4u8ezXFw66fFNbxSNuVI+GI/2m7/AE6Vk6hdW+oM8yRt5CHgGQgD865LUp7i/unkBiht0GF5x/8ArrTlUY66k+zu1zO5Br2pvczlTbkseWOc81z0z4fcUwe2KvzTwrMRJMz4/ujANULqfe+UTao6E1z1H1NoxS2IZJmZcbcA0wNs5A5prkk8nNBUr1rC7ZQhOeT1opRntSUgNG+/sc2Fr9g/tD7d/wAvHnhPLzj+DBzj61nmkopALSUGigYtJS0nSgQuaF60hpR1oGMt/uH/AHjRRb/cP1NFZS3PVofw4klFSm3kW0S5IHku5RWyOoGT/Oou9anlCUtApKACjvS49ASfQck1ta/4U1zw/ZQXer2D29vOF8tywPLDIBx0JHY0roLMxKD9K6+T4c+JkNkGs7fdesqwr9ri3MSM8jdkcetY3iLw9qPh28Frq0cMc7J5oEU6Sjb6kqSKYno7MyaO9IHX1HTNLkHpTsA7IK42/N606JtpHX3qP60A9eBQgLf2fzUykoJ/ukU2CB5dybG49BSKY/LB2sjDuDkVZsNRe0kBLErz2zWit1GTE7oEVAuVHOQRTLOUrIwkVygJGU5qxLc293JmRljjPUqK3ItFsWtRJYaijnqU6E1qo3egvMzwu9lNpdbkPJVlAK11fh24EupKst9bhlTB8yMH9axNN0uKS4KyThZB90suRTZ4m0S5eUrGwboyGtkmtWK6R6xafb7WdGsdVtnTIOxsYrp4fHt5ZXEcL4STpiVCyN9K8GTX47hFW43KfVVqRL2KKZXM7yr1CsW4qmoyF5M+g4/iSI7va6oZRyURSFNdxpfiiwv7aK5MjwsO33se2a+Shr8b3Q8h1hYcFmy4H511nhrxhdaZKkcNxayxyHnYSp/KolSi9hKEX0PpX/hI7RWIF8m0dS2Cal/tCAWks4lju4j82wgE/hXgHiHV726dGMZ+f+NI+ldR4Zv0lgMQv4ROq4Kyhk/lUuikSqd07M6/VLPTtVd5EtZIQUJ2LGDz+Fc9qPgHw+8KvdzPEHH3WiXr9aw9R128s78RLLEuG5eLcRj3qS/8RTX86ReXJN24OUP9atRktLkqErblZ/hZYwS+ba6xAbVz2UZWnN8MIbdmkOq2c8bY2qz4NaNjcQx7YYovJkY8gMcfkau3w0/KG4Mcsy8g4IwfwovIfLNbMybbwp4e0+MzaiztJ0A80KtQapY6QbTbZ/ZYFYcsbkdMVia7e3cmoKLeSNYkOSx+bis25a51RkEFtBNBn5jHkGrSYv3kuxoQ2drBavBa6zDs67F3f4UXV3pNjCFvdZurjYASscbYH54zXOa3DBDqNsWtZrNT97aCSagvJYdRZ4LgSJAmCjbAC34mjlfcdpv7Rq6lq+l3rQzWF3c71VldPL2t0+U5Oal03W9Hhsmjuv7QlSM8HeEUnHJyozWPPc/6O8ahUJwFywycfSsW61bVvLaKERrB0CFRVcqSu9yrO1rndW+u6VPAFtLaylUkEi4ldyD/AJ7Vi6pqd7ZXiHTZLW0jYf8ALCAbs56jNZlpaW0Nsv22K7M74I8lQP1qG8vbaGVB9iuSqDqzZJqVFbsl0lfU6Sy1zW45Y47a/kdyMM0mFH5LUt9rCaBaPPcLa6jqMznqjMRmsPT/ABAUciyht4R0+ddz1XlvHuJ2lu3SaQdFAwB+VNRXQfs4rZF2CS3v5jd6tJEXbgW4zgfgKtnxFNZM0GnWsccXdwuOKzYNQsLu3kSSMGVM4CisG+vL0277ZRDEG4BcZYfSjRLUryR6E+qSXmmAXEi7MfcRhHk+/c1xt3BH80t0+0jlQrZxVKyc3VukspKxrzycE1T1XUXuwogjWOMHGWJyaOZWuNrUntUa9ugjPcMCeMj5a0dW8Ny29iJVjMgHOXG0YrI0nVrq3uh5bKCO/X+daWo+Kri4JhlffgYPpUJxe4NaaHJXaxmRV2+VIOOBxn61BdW86qu58jsK03kivp8ySAbTnaq1FqFzHHhYV56FzWEop6h0MlIsHDg57KKjkB344J9KnlcBSQxBP5mqv49axasUOHAwWH0FNbHOKTrSd6hgHelpu5c43DPpmlBGKQBjvQaKKACloooGJSjrR70UAMt87Dz3NFFt9w/7xorJrU9Wiv3cTWfU91kF2gXLbkc7F2bNoAwOxzWb6VrmyjFo8n2OXzBbq+0yfdz/AB/T2rIPWuiUOVI8aM+ZtdhPwpaKKgsACxCq4Qk43n+H3r1TxJb6e/h61sbPxjpFzErpc3MkkkjyyTKnHBXGBjaBmvKxtyNxIXuR1xXY+ObLRoPDXhK70G0kiN7BP5jSNl5mSQKCRnA/Cs5JNpMa0abfVf5/od3J4vsmmt72fxHpU2rTXG63uUsOLKIwlGV1x6kdM1LaeIPDSTyLHrGkRausUC3OpPZborpVVvMVVx1JK9hVG++Fqpo/hvTIbeRdWmvJVvrrY33BCJMAeg6cd6h8VfD3SpPEV7JBdJoOjRQ2kcXmRO5aeWItz352nNaKftZ2WqFyxneTWmq+7+vmX9K8WaJZ6Bp0H2jSPNhsLYZe2UsJvtR39uojJP0ryrxbLaTeJ9Yk01o2sXvJWgMYwpQscEe2K7TSfhdb32k2V7N4ntrfz7aK5eNrdjsV5TEDkdfmA/OuB1vTX0nWL7T5ZFke1neAsowCVJGaaq7030HNJyv11/Qo0LncMUD2pVbawYYOKQicRCQbldQf7tOW3Mg+UISOwODVdX2nI6+lSm5DY3IAfVeK00AWVk8vbsCsKt2KqiGRd/06VBErxL5sarKD1DDNWDdkLuVFQewqo7gXLfVUiUg+YpHfPNQTXa3UuDcM+4/dkFZc87SMd2CPpSLvOCucjvVOq9gsarvNACAqhffpU4Miqj+Zz/s1nmeQDbcA47MOatpGkwj/AHzbc4ximn2AmaOZ8yRbv9oPxn8as2FtE80Z+z5cHvJVpohbQqXaRlI9ccVny3AUfumznsRyK0tbViudFqepyW6pBA80Mw6fMWFa+jSas8sV3eXCvGnRQ+K4qGMyOoaf5uuJBj9a2NIS9jm3SxCSNDlSj1opXBabnqdit3ql1HIsskNt1OULZ/MV1M15FaIsKY83HD+RtNedWviXUY4Mss6QoOAM1G95f67PGynySvKl5Cc1bjcH2Rvahr2vW99JtjEsPbcgGKs6Fcy6gzrd6jLDnoiqPyyaxtXu9TgWOJUtFkIxuHNGm3KC6NvezRh26G3Q/qaGhIu+LLP7BsexliSVuryLvLflXPnW1ZfKkvpIpQOfIXH6Vs3hBu1CpbpD/wA9Z5SSfpXParp8lszTaW8NwG+9/Fj8TTSJ2K8uo2sEpe4F1qDdjKcUy/XRJYkMdt9lkbu0xPP0rI2Xl5dBLmExR9Mr8v611tn4M0+8gUy3kcPqXn/pSuVbQxXtbG4kgxepD5fdVzuqHVNLjDq/mPcIOcH5cflXS3Hg3SLaMkXtvcuv3QhJOa5loTBcz/b3uFi+7Gy8jFPdaibHI+mqqPNbXjvjAAm+Ws+7uikxjtLRo1bqc7iKZMsO0pFcsB2ZjisRp2juZFS5J39wamUuVD3Zq6VpbXN8SLn7MrHLNI+M11sGjaHZPma+iu3xkpDKf1ri7BnWQE7CB/z1bj8q3rLM1wcwwsm3B8tdopRsxsoeIfspDtYwraoOpDZJrmrW6tluVLEyNnk9a3NatrczYEUjn0B+UVm26pCG/cgE/wCxmoqXvZCiar66phNtZooYDBL44/KsmdZZPmcxkD0FWba3gVX3qE3dWPBqtPb26o2y4GD2BzQ22tQKEsgWYbdmcdqjErSzBN2F7kCkeKBUw7nd2qJEVMs78emKwbZRrmOBYMKSo7nPWs+YROxLOojXoAc1DvjkGZHYL2XNRSrGQRBGze9DlpoIhlYM5K9KZTtjdx0pO9YMYlFBpaQzqNL8aXGnW8EC6J4dnWJdokn05Hkb3LHqa5u4mM88srJEhdi5WNNqjJzgDsKjooE9XdiGl70Ud6AA0UGigBKUUn4UuOaBjLb7h/3jRRb/AHD/ALxorJ7nrUP4cSTLZzk5xjOe1GaKK1PJCkPSiloAT8vxFdTc+OtZuNPs7GVdONtZoY7cfYYsxgjnB2556/WuXpP50B5HRzeN/Es1pDbyazeFYZWmRxIQ4Zl2n5uuMcYq0vxE8TrdSXJ1HfK8aRnzIlcfIpVWAIwGAJ+brzXJUCnF8uqA6OHxrrkdtHAtzH5aQx24BiU/JHJ5qjp/f5rG1K+uNS1C5vbxw9zcytNIwGAWY5Jx2qr3oocm9WLzA0qKWYKvJNJ1oBIORwaQyVoSu0ONrHjnoauWUMaN/pCHafVciqJkZsB2yB61di1AImx1OP8AZNaR5bgW7n7PbqWtWXB7GsqeUsx6D6GnTyrIOGJ56EVXpzl2JDJpy/NwSBTaUMQexrNFDwwBwckfWporh4pFKF9npVXv/SpA+VCscAVSkBrG8MqBgxOB3plndNJJkHB74UGqMVwkakFSfxqayu0hnJESEH1rTnb3FY6G2mmjAkJMwHYLz/Kug0/WIoZkH9nPIW4yQVxXJW168kpHmeSPatWzuh56rc3rmPOfu5IrphLsB6TbWcUlsL2SOW3xy29GcEVNpl1pV7l4XtFKHBYAofyxXLzeKzY2ywwXU7JjH3f6Vhvqdtcu00MzCbqQw25rT1ZN9dD2RYo71oksUtpsY3MXVf5iuglsfDsFt/p1sonxz5bjOfqK8Rs/FEkcIjckkD+BgDTY/EM/2gYaZI267vnNK3mD7HpkcGiyXLebaOsKnKBnDZ/Ony674dgje3FhFuA4AjDH+debXtxbXCEy3Mzk/wALrt/rXJyEJeZt7UAA8sJe350PTUN9DuLu4s5ruRlt5HjySIWIXmtrSm0k2rM8dtFNj/V5LEGuCspTeXiiMKir1ZyF5rc+z3wDPY3dlv8AYZNVuGyK2oXsqX7BGeKInjy81n6tcowEbTsGP8UgFW3u9TZZA77mHoMVhz2tzJOJdskmfvfIAB+NEnZaCS6FeRoYeftyyyDkBRmoBLDLOpnikbHTYuKmubaSB/NjEar3XIJqrLIkibmkZW9OlYt9xlm6uwq4toQh9XbNVorqZXBnndt38MZwKp/ZS7b3uNq56Zqa1uvIlPlIG7Anmp52NG4SPKJUSMCOjsax727mDBI48Z96tw3N1cHZuVM9l5NJdW8MOPNkYyt/eNW3daCasZkdw0cgE4yMZIA3GrQuFlP7uJIh/t9T+FVJLUxSB0uVyx+6DzVmKJIJw8kgJPUkgmslfYe5kXplEmWbr6DFRq5KhUHJ71oavcQtxFtJ9etZJboRwaynowRM8bxsCWBf0xmrsTfuv3pIGOg4rNEjDvSFmPUmpUkhktxIGYhAFX2qCilqW7gFJSj3oqQEo78Vo3uiapY2Nre3un3MFndDME0iYWUY/hPes+gA4o70UdaBgKKPYUUCE5pe/NFA60DGW5+Q/wC8aKLf7h/3jRWT3PWofw4klFH8qStTyRfpRigmgUCEoo70dzQMKKOKKACjvRmigAxR3pfWkoADR9aDRxQIKPpQetFABR1zRRQMXv0oI6Hg0maKYh6Pxt2qQfan7I8cyDPpio1dl6Ej6UhZmPzEmmmBetnZW2g/L6k4rQhuLhWAE0YXH8RBrB3tjGTigMQcgkVcalgOgl1CaZjDIkTekiimIAiYuVZh/smsUzy9PMbH1ppkdhhnYj0zVe1vuFjZeWKyYSWYl3HruPFaUOutHCMh/MI6g1yplcrtLtge9Kk0qfckYY9DQq1noFjannluJvMnlZwegJximqEa7BLfKOcVjvNLJgySO31NM3NnO45odW4JWOygvhBKGDKU6fMorZstemjO2C5jhB77K818xx/Gfzp63MykFJpAR0OatYiwWOy1TV7+RmXfJcqeAQ2B+VUoLm/gjJkjmjQ+pJBrnjqF42N11McdPmpGvbpvvXMp+rE0OumxJWNmeW+mUt9wdu1Uht3f6SuSO6nNUGuZ2HM0h/GmF3J5ZqzlVuO1jWUtISbe3byx/E7darkPJOBJIsYz/DzVPz5du3zH2+maYHcdGPHvSc0wOoiFnp8W5Z7mSRupAwKr3Jsz+8nuDknOB8xrDe5ndAjzOV9Cai/E1XtVayQWNG5uoA48hCwHdjzVOacynJUVEaTtWbm2FhTSUY54/GlqBgOaSlFIKBC+xooooAKKKCaBkjzSvGkbyyMifdVmJC/Qdqj60ZxR9KADnvRRRxQIO9J3paD1oGFA6ij9KKAGQfcP1NFJB9w/U0VjLc9Wj/DRL2pKKK2PKA0tFFAgxSeuaKKBh70UUUAGKKKKBBR34oooADR2oooAKKKKBh6UHrRRQAUUUUCCloooASiiigYGg9KKKADijtRRQIOlFFFAwwKBRRQIPxo96KKBhR3oooAPajiiigQUnNFFAxRRRRQAetBoooEFAoooAMcUUUUDDpQQaKKBBRRRQMKKKKBBRRRQAY9aO4FFFAEcA+U/U0UUVhLc9Wj/AA0f/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Transabdominal ultrasound using colorflow doppler demonstrating the presence of the umbilical cord (funic presentation) just above the cervical canal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Transabdominal ultrasound using colorflow doppler demonstrating the presence of the umbilical cord (funic presentation) just above the cervical canal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_58_35754=[""].join("\n");
var outline_f34_58_35754=null;
var title_f34_58_35755="Rx fibromyalgia chronic fatigue";
var content_f34_58_35755=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F53766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F53766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Therapeutic plan for fibromyalgia or chronic fatigue syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Step one: patient and family education",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Validate the diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Educate about prognosis, pathophysiology, treatment principles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Step two: medication trial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tricyclic antidepressant or similar medications: low-dose at bedtime.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If no response, consider adding a serotonin-receptor inhibitor in the morning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If repetitive limb movement is suspected, trial with low dose benzodiazepine at bedtime",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Analgesics, NSAIDs may be useful to decrease pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Step three: nonmedicinal treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Physical therapy, massage, myofascial release",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiovascular fitness training",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trigger point or tender point injections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Step four: specialized evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sleep center, if suspect sleep apnea or nocturnal myoclonus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mental health professional, if suspect major depression or panic disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain or rehabilitation clinic",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_58_35755=[""].join("\n");
var outline_f34_58_35755=null;
var title_f34_58_35756="CHD likelihood with chest pain";
var content_f34_58_35756=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F51033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F51033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Likelihood of acute coronary syndrome secondary to coronary heart disease in patients without ST-segment elevation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        High likelihood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Any of the following features:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Primary symptom is pain or discomfort in chest or left arm",
"        <strong>",
"         AND",
"        </strong>",
"        current pain  is similar to pain of prior documented angina/MI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Patient has known CHD",
"        <strong>",
"         OR",
"        </strong>",
"        MI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Transient mitral regurgitation",
"        <strong>",
"         OR",
"        </strong>",
"        hypotension",
"        <strong>",
"         OR",
"        </strong>",
"        diaphoresis",
"        <strong>",
"         OR",
"        </strong>",
"        pulmonary edema",
"        <strong>",
"         OR",
"        </strong>",
"        rales",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        New (or presumably new) transient ST deviation (&ge;1 mm)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        New T-wave inversion in multiple precordial leads",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Elevated cardiac troponin or CK-MB levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intermediate likelihood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Absence of high likelihood features and presence of any of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Primary symptom is pain or discomfort in chest or left arm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Older than 70 years of age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Male",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Extracardiac vascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fixed Q waves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        ST depression 0.5 to 1 mm or T-wave inversion &gt;1 mm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Normal cardiac troponin or CK-MB levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Low likelihood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Absence of high or intermediate likelihood features. May have any of the following and still be low likelihood:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        History of symptoms that are probably ischemic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Recent use of cocaine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T-wave flattening or inversion &lt;1 mm",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: T-wave inversion refers to a T-wave with opposite polarity to the dominant QRS in that lead.",
"    <div class=\"footnotes\">",
"     CK-MB: creatine kinase MB fraction; MI: myocardial infarction; CHD: coronary heart disease.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Anderson J, Adams C, Antman E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_58_35756=[""].join("\n");
var outline_f34_58_35756=null;
var title_f34_58_35757="Overview hip imaging children older than 10 years";
var content_f34_58_35757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Overview of the use of various imaging modalities in the evaluation and management of common hip problems in children older than 10 years*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Plain radiograph",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ultrasonography",
"       </td>",
"       <td class=\"subtitle1\">",
"        Computed tomography",
"       </td>",
"       <td class=\"subtitle1\">",
"        Magnetic resonance imaging",
"       </td>",
"       <td class=\"subtitle1\">",
"        Radionuclide bone scan",
"       </td>",
"       <td class=\"subtitle1\">",
"        Arthrography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Slipped capital femoral epiphysis",
"        </strong>",
"       </td>",
"       <td>",
"        Diagnosis:",
"        <ul>",
"         <li>",
"          Stable: widening and irregularity of the capital femoral physis, osteopenia, increased density of metaphysis",
"         </li>",
"         <li>",
"          Unstable: displacement of the capital femoral epiphysis",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Treatment planning in advanced disease",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Early diagnosis (demonstrates physeal widening before apparent on plain films)",
"        </p>",
"        <p>",
"         Detection of complications (eg, avascular necrosis)",
"        </p>",
"       </td>",
"       <td>",
"        Detection of complications (eg, avascular necrosis)",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Pelvic apophyseal avulsions",
"        </strong>",
"       </td>",
"       <td>",
"        Displacement of the apophyseal center from its normal position, callus formation, bony reaction",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        <p>",
"         Useful in suspected avulsion injuries with negative radiographs",
"        </p>",
"        <p>",
"         Demonstrates bone marrow edema and soft tissue injuries at the site of avulsion; also may demonstrate physeal widening",
"        </p>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Iliopsoas tendinosis and bursitis",
"        </strong>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        <p>",
"         Demonstrates enlarged bursa",
"        </p>",
"        <p>",
"         May guide bursal aspiration",
"        </p>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Thickening with increased signal in the iliopsoas tendon with increased synovial fluid or hypertrophy of the bursa",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Snapping hip syndrome",
"        </strong>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        <p>",
"         Dynamic sonography can confirm the diagnosis",
"        </p>",
"        <p>",
"         In external snapping hip, the posterior iliotibial band or anterior portion of the gluteus maximus muscle catches over the greater trochanter",
"        </p>",
"        <p>",
"         In internal snapping hip the iliopsoas tendon moves over the lesser trochanter",
"        </p>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Athletic pubalgia",
"        </strong>",
"       </td>",
"       <td>",
"        Symmetric sclerosis of the pubic symphysis",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        <p>",
"         Edema of the pubic body",
"        </p>",
"        <p>",
"         Injury to the insertion of the rectus abdominus muscle",
"        </p>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Stress fractures",
"        </strong>",
"       </td>",
"       <td>",
"        Chronic stress reaction (may be normal in the early stage)",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Early detection (demonstrates bone marrow edema)",
"       </td>",
"       <td>",
"        Early detection (demonstrates increased uptake)",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Acetabular labral tear",
"        </strong>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        MR arthrography shows the labral tear",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Demonstrates the labral tear; however, conventional arthrography has been replaced by MR arthrography",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Femoroacetabular impingement",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Cam-type: demonstrates a non-spherical femoral head or lack of femoral head-neck offset",
"        </p>",
"        <p>",
"         Pincer type: acetabular over-coverage",
"        </p>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Facilitates diagnosis of the type (cam or pincer) and demonstrates abnormalities of the femoral head, neck, and acetabulum",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Idiopathic chondrolysis of the hip",
"        </strong>",
"       </td>",
"       <td>",
"        Joint space narrowing and osteopenia, protrusion acetabuli, osteophyte formation, premature physeal fusion",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Early detection (shows cartilage loss, geometric abnormal signal in the proximal femoral epiphysis, acetabular bone marrow edema, synovial hypertrophy or enhancement, and minimal joint fluid)",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NA: not applicable.",
"     <br>",
"      * This age range is approximate; these problems may occur in children outside this age group.",
"      <br>",
"       &Delta; Use of computed tomography is limited because of the risk of radiation exposure.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_58_35757=[""].join("\n");
var outline_f34_58_35757=null;
var title_f34_58_35758="Accessory paths in Mahaim tachy";
var content_f34_58_35758=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    AV connections in Mahaim fiber tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 175px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two types of accessory atrioventricular (AV) pathways are associated with a Mahaim fiber tachycardia. The most common is an atriofascicular tract (AFT) that arises at the AV annulus and inserts in the apical portion of the right ventricle. The second is an atrioventricular tract (AVT) that arises from the same location, but inserts into the proximal right ventricle, near the annulus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_58_35758=[""].join("\n");
var outline_f34_58_35758=null;
var title_f34_58_35759="J curve systolic HTN";
var content_f34_58_35759=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F80901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F80901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Lack of true J-shaped curve in systolic pressure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 449px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Age- and sex-adjusted mortality rates (per 1000 patient years, bars show the 95 percent confidence intervals) according to achieved systolic pressure in active treatment and control groups in a meta-analysis of seven randomized clinical trials of hypertensive patients. The number of events is shown below each bar. Among treated patients, cardiovascular mortality initially falls at achieved systolic pressures below 180 mmHg and then rises again at low systolic pressures (upper right panel). However, a similar relationship is seen with noncardiovascular mortality (bottom right panel) and in the control groups (left panels). Thus, the increase in mortality at low diastolic pressures probably reflects underlying poor health rather than an adverse effect of antihypertensive therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Boutitie, F, Gueyffier, F, Pocock, S, et al, Ann Intern Med 2002; 136:438.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_58_35759=[""].join("\n");
var outline_f34_58_35759=null;
